

Schultz, J.
101673063 Page 1
Seq ID 3

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 10:20:44 ; Search time 1762 Seconds
(without alignments)
1210.005 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943
Perfect score: 44
Sequence: 1 gcgggtccgcgtcctctcta.....ccggtcgcggtattagaagaa 44

Scoring table: IDENTITY NUC
Gapop 10_0 , Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues
Total number of hits satisfying chosen parameters: 1839042

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database :
1: gb_ha:*
2: gb_hcg:*
3: gb_in:*
4: gb_on:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sbs:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	16.2	36.8	32	6	AX468571 Sequence
C 2	16	36.4	27	6	AX338903 Sequence
C 3	16	36.4	27	6	AX338904 Sequence
C 4	16	36.4	38	6	A09534 Sequence
C 5	16	36.4	38	6	A09567 Sequence
C 6	16	36.4	50	12	SYNNA3C Sequence
C 7	15.8	35.9	38	6	AX515653 Sequence
C 8	15.8	35.9	41	6	AX515653 Sequence
C 9	15.8	35.9	41	6	AX515653 Sequence
C 10	15.8	35.9	50	3	DROPRM1 Sequence
C 11	15.2	34.5	33	6	AR365669 Sequence
C 12	15.2	34.5	37	6	AX147162 Sequence
C 13	15.2	34.5	47	6	AX081593 Sequence
C 14	15.2	34.5	47	6	AX374774 Sequence
C 15	15	34.1	31	6	AX248444 Sequence
C 16	15	34.1	50	10	MMU41925 Sequence
C 17	14.8	33.6	31	6	AX582316 Sequence
C 18	14.8	33.6	33	6	IO3806 Sequence
C 19	14.8	33.6	36	6	AR429930 Sequence

C 20	14.8	33.6	36	6	AX099684 Sequence
C 21	14.8	33.6	37	6	IO3802 Sequence
C 22	14.8	33.6	47	6	AR288505 Sequence
C 23	14.8	33.6	47	6	AR289990 Sequence
C 24	14.8	33.6	50	6	AR032973 Sequence
C 25	14.8	33.6	50	6	IO29713 Sequence
C 26	14.8	33.6	50	6	IO1387 Sequence
C 27	14.8	33.6	50	6	AR209637 Sequence
C 28	14.6	33.2	32	6	CQ68809 Sequence
C 29	14.6	33.2	33	6	AR365650 Sequence
C 30	14.6	33.2	34	6	AR365637 Sequence
C 31	14.6	33.2	35	6	AX739899 Sequence
C 32	14.6	33.2	39	6	AR365666 Sequence
C 33	14.6	33.2	45	6	AX642259 Sequence
C 34	14.6	33.2	46	6	IO13724 Sequence
C 35	14.6	33.2	47	6	AX291680 Sequence
C 36	14.4	32.7	20	6	AX462584 Sequence
C 37	14.4	32.7	32	6	BD061913 Sequence
C 38	14.4	32.7	34	6	AX574343 Sequence
C 39	14.4	32.7	40	6	BD235752 Sequence
C 40	14.4	32.7	40	6	BD235803 Sequence
C 41	14.4	32.7	47	6	AR291235 Sequence
C 42	14.4	32.7	50	5	XELRG73 Sequence
C 43	14.4	32.7	50	6	AX057065 Sequence
C 44	14.2	32.3	20	6	AR316182 Sequence
C 45	14.2	32.3	20	6	AR337058 Sequence
C 46	14.2	32.3	21	6	AR529926 Sequence
C 47	14.2	32.3	21	6	AX095951 Sequence
C 48	14.2	32.3	25	6	AX304716 Sequence
C 49	14.2	32.3	25	6	AX615111 Sequence
C 50	14.2	32.3	33	6	AX280063 Sequence
C 51	14.2	32.3	36	6	IO18300 Sequence
C 52	14.2	32.3	38	6	AR089801 Sequence
C 53	14.2	32.3	48	8	AR835268 Sequence
C 54	14.2	32.3	48	8	AR835276 Sequence
C 55	14.2	32.3	49	6	AR239848 Sequence
C 56	14.2	32.3	49	6	AX279650 Sequence
C 57	14.2	32.3	50	6	AX190235 Sequence
C 58	14.2	32.3	50	10	MMU41975 Sequence
C 59	14	31.8	24	6	AX1608 Sequence
C 60	14	31.8	24	6	AX5670 Sequence
C 61	14	31.8	24	6	AX5712 Sequence
C 62	14	31.8	24	6	AX5754 Sequence
C 63	14	31.8	24	6	AX5796 Sequence
C 64	14	31.8	24	6	AR116287 Sequence
C 65	14	31.8	32	6	AR534294 Sequence
C 66	14	31.8	32	6	AR544580 Sequence
C 67	14	31.8	35	6	AR534275 Sequence
C 68	14	31.8	35	6	AR544561 Sequence
C 69	14	31.8	38	6	AB6752 Sequence
C 70	14	31.8	38	6	BD062648 Sequence
C 71	14	31.8	41	6	AR305163 Sequence
C 72	14	31.8	41	6	AR309267 Sequence
C 73	14	31.8	41	6	BD106074 Sequence
C 74	14	31.8	45	6	AR763470 Sequence
C 75	14	31.8	47	6	AR032638 Sequence
C 76	14	31.8	47	6	IO29378 Sequence
C 77	14	31.8	47	6	IO1052 Sequence
C 78	14	31.8	47	6	AR209302 Sequence
C 79	14	31.8	47	6	AR289255 Sequence
C 80	13.8	31.4	24	6	AX445527 Sequence
C 81	13.8	31.4	25	6	AX115688 Sequence
C 82	13.8	31.4	26	6	IO1917 Sequence
C 83	13.8	31.4	26	6	AX134798 Sequence
C 84	13.8	31.4	26	6	AX137764 Sequence
C 85	13.8	31.4	29	6	AR160337 Sequence
C 86	13.8	31.4	34	6	AR157567 Sequence
C 87	13.8	31.4	34	6	AR212616 Sequence
C 88	13.8	31.4	34	6	AR430014 Sequence
C 89	13.8	31.4	34	6	AR533433 Sequence
C 90	13.8	31.4	35	6	IO3808 Sequence
C 91	13.8	31.4	37	6	AX800567 Sequence
C 92	13.8	31.4	38	6	AR272268 Sequence

C 93 13.8 31.4 42 6 CQ767048 Sequence
94 13.8 31.4 45 6 E05105
95 13.8 31.4 45 11 AL834120
C 96 13.8 31.4 47 6 AR382719 Sequence
97 13.8 31.4 48 6 BD263286
98 13.8 31.4 48 6 BD263298
99 13.8 31.4 48 6 BD263303
100 13.8 31.4 48 6 BD263304

ALIGNMENTS

RESULT 1
AX468571/c 32 bp DNA linear PAT 16-JUL-2002
LOCUS Sequence 12 from Patent W00238745.
DEFINITION AX468571
ACCESSION AX468571
VERSION AX468571.1 GI:21901398
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Mesikene, I., Hirt, H. and Jonak, C.
TITLE Regulation of mitogen-activated protein kinase (mapk)
JOURNAL Patent: WO 0238745-A 12 16-MAY-2002;
Oesterreichisches Forschungszentrum Selbstdorf GmbH (AT)
FEATURES
source
1. .32
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

ORIGIN

Query Match 36.8%; Score 16.2; DB 6; Length 32;
Best Local Similarity 85.7%; Pred. No. 8e+04; 3; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 23 AACCGTGGCGGTTATTAGA 43
Db 31 AACATGTCGGGTTATGAGA 11

RESULT 2
AX338903/c 27 bp DNA linear PAT 09-JAN-2002
LOCUS Sequence 8 from Patent W00185971.
DEFINITION AX338903
ACCESSION AX338903
VERSION AX338903.1 GI:18129070
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Alberte, R.S. and Smith, R.D.
TITLE Transgenic plants incorporating traits of Zostera marina
JOURNAL Patent: WO 0185971-A 8 15-NOV-2001;
Phycogen, Inc. (US)
FEATURES
source
1. .27
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

ORIGIN

Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 9.9e+04; 5; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Qy 20 AATAACCGGTGGCGTTATTAGA 43

Db 25 AATACTTGTCGGGTTATCAGA 2

RESULT 3
AX338904 27 bp DNA linear PAT 09-JAN-2002
LOCUS Sequence 9 from Patent W00185971.
DEFINITION AX338904
ACCESSION AX338904
VERSION AX338904.1 GI:18129071
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Alberte, R.S. and Smith, R.D.
TITLE Transgenic plants incorporating traits of Zostera marina
JOURNAL Patent: WO 0185971-A 9 15-NOV-2001;
Phycogen, Inc. (US)
FEATURES
source
1. .27
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

ORIGIN

Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 9.9e+04; 5; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Qy 20 AATAACCGGTGGCGTTATTAGA 43
Db 3 AATACTTGTCGGGTTATCAGA 26

RESULT 4
A09534 38 bp DNA linear PAT 02-SEP-2002
LOCUS Oligonucleotide.
DEFINITION A09534
ACCESSION A09534
VERSION A09534.1 GI:411963
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 38)
AUTHORS Flier, R., Fukushima, H. and Yeh, P.
TITLE Method for the microbiological preparation of human serum albumin
JOURNAL Patent: EP 0361991-A 5 04-APR-1990;
RHONE-POULENC SANTE
FEATURES
source
1. .38
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

ORIGIN

Query Match 36.4%; Score 16; DB 6; Length 38;
Best Local Similarity 68.8%; Pred. No. 9.8e+04; 10; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
Qy 11 TTCCTTCTTATTAACCGGTGGCGTTATTAG 42
Db 7 TTCCTTCTGATTAAGCGCGCGGCTTTAG 38

RESULT 5
A09567 38 bp DNA linear PAT 02-SEP-2002
LOCUS A09567
DEFINITION Oligonucleotide.
ACCESSION A09567

VERSION	A09567.1	GI:411995
KEYWORDS		
SOURCE	synthetic construct	
ORGANISM	synthetic construct	
REFERENCE	other sequences; artificial sequences.	
AUTHORS	1 (bases 1 to 38)	
TITLE	Fleier R., Fukuhara, H. and Yeh, P.	
JOURNAL	Method for the microbiological preparation of human serum albumin and other heterologous proteins from a yeast	
FEATURES	Patent: EP 0361991-A 39 04-APR-1990; RHONE-POULENC SANTE	
SOURCE	Location/Qualifiers	
ORIGIN	1..38	
	/organism="synthetic construct"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:32630"	
Query Match	36.4%;	Score 16; DB 6; Length 38;
Best Local Similarity	68.8%;	Pred. No. 9.8e+04;
Matches	22; Conservative	0; Mismatches 10; Indels 0; Gaps 0;
Oy	11 TTCCCTTTAATACCGGCGGTTATTAG 42	
Db	7 TTCTTTCGATACGCGCGCTCTTATG 38,	
RESULT 6		
LOCUS	SYNRNA3C	50 bp ss-RNA linear SYN 27-APR-1995
DEFINITION	Synthetic Bromo mosaic virus (BMV) RNA 3' end/CAT gene from PB3CA42, partial cds.	
ACCESSION	M19550	
VERSION	M19550.1	GI:209273
KEYWORDS		
SOURCE	synthetic construct	
ORGANISM	synthetic construct	
REFERENCE	other sequences; artificial sequences.	
AUTHORS	1 (bases 1 to 50)	
TITLE	French, R., Janda, M. and Ahlquist, P. G.	
JOURNAL	Bacterial gene inserted in an engineered RNA virus: Efficient expression in monocotyledonous plant cells	
COMMENT	Science 231, 1294-1297 (1986)	
FEATURES	Original source text: Bromo mosaic virus and plasmid PB3CA42 RNA.	
SOURCE	Location/Qualifiers	
ORIGIN	1..50	
	/organism="synthetic construct"	
	/mol_type="genomic RNA"	
	/db_xref="taxon:32630"	
	10..>50	
	/note="coat protein"	
	/codon_start=1	
	/transl_table=11	
	/protein_id="AAA72637.1"	
	/db_xref="GI:554572"	
	/translation="MSTRFSGAKEXKM"	
CDS		
Query Match	36.4%;	Score 16; DB 12; Length 50;
Best Local Similarity	62.5%;	Pred. No. 9.8e+04;
Matches	25; Conservative	0; Mismatches 15; Indels 0; Gaps 0;
Oy	4 GGTCCGTTCTTATTAACCGTCCGGTTATTAGA 43	
Db	41 GCTTCCTAGCTCTGAAATCTCGACATTATTAATA 2	
RESULT 7		
LOCUS	A17381	38 bp DNA linear PAT 27-APR-1994
DEFINITION	Nucleotide sequence 6 from patent number EP0481502.	
ACCESSION	A17381	
VERSION	A17381.1	GI:513877

	KEYWORDS	. unidentified . unidentified unclassified.
SOURCE ORGANISM		1 (bases 1 to 38)
REFERENCE AUTHORS TITLE JOURNAL	Weidle,U.H. and Kaluzs,B. Process for the production of chimaeric antibodies Patent: EP 0481502-A 6 22-APR-1992; BOEHRINGER MANNHEIM GMBH	
FEATURES source	Location/Qualifiers 1..38 /organism="unidentified" /mol_type="unasigned DNA" /db_xref="taxon:32644"	
ORIGIN		
Query Match	35.9%; Score 15.8; DB 6;	Length 38;
Best Local Similarity	65.7%; Pred.No.1.2e+05;	
Matches	23; Conservative 0; Mismatches 12;	Indels 0; Gaps 0;
Oy	1 GCGGGCCCCGTTCCTTTAATAACCGGC CGGT 35 36 GCCTC CAGGCTTATTATTTAA GCGGCCCGCT 2	
RESULT 8 AX515653 LOCUS DEFINITION ACCESSION VERSION KEYWORDS SOURCE ORGANISM	AX515653 Sequence 1851 from Patent WO02052044 . AX515653 AX515653.1 GI :23562954 Homo sapiens (human) Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	linear PAT 05-OCT-2002
REFERENCE AUTHORS TITLE JOURNAL	Nakamura,Y., Sekine,A., Iida,A. and Saito,S. Detection of genetic polymorphisms Patent: WO 02052044-A 1851 04-JUL-2002; Riken (JP)	
FEATURES source	Location/Qualifiers 1..41 /organism="Homo sapiens" /mol_type="unasigned DNA" /db_xref="taxon:9606"	
ORIGIN		
Query Match	35.9%; Score 15.8; DB 6;	Length 41;
Best Local Similarity	81.0%; Pred.No.1.2e+05;	
Matches	17; Conservative 1; Mismatches 3;	Indels 0; Gaps 0;
Oy	5 GTCCCGTTCCTTTTAATAAAC 25 : : 16 GTCCCRTTCCTTCATYATAC 36	
DB		
RESULT 9 AX518248 LOCUS DEFINITION ACCESSION VERSION KEYWORDS SOURCE ORGANISM	AX518248 Sequence 4446 from Patent WO02052044 . AX518248 AX518248.1 GI :23567646 Homo sapiens (human) Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	linear PAT 05-OCT-2002
REFERENCE AUTHORS TITLE JOURNAL	Nakamura,Y., Sekine,A., Iida,A. and Saito,S. Detection of genetic polymorphisms Patent: WO 02052044-A 4446 04-JUL-2002; Riken (JP)	

```

FEATURES
    source
        1. .41
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
    ORIGIN
        Query Match      35.9%; Score 15.8; DB 6; Length 41;
        Best Local Similarity 81.0%; Pred. No. 1.2e+05;
        Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy
    5 GTCCCGTTCCTTCTTAATAC 25
    |||:|||||:|||||
    16 GTCCCTTCCTCATATATAC 36

RESULT 10
LOCUS      DROPRDM1      50 bp      DNA      linear      INV 26-APR-1993
DEFINITION D.melanogaster paired (prd) gene with a 1.1 kb insertion in exon 2,
ACCESSION  K03518
KEYWORDS    K03518.1 GI:158175
SEGMENT     insertion sequence; segmentation gene.
SOURCE       1 of 2
              Drosophila melanogaster (fruit fly)
              Drosophila melanogaster
              Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
              Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
              Ephydroidea; Drosophilidae; Drosophila.
              1 (bases 1 to 50)
              Frigerio,G., Burri,M., Bopp,D., Baumgartner,S. and No1,M.
              TITLE
              Structure of the segmentation gene paired and the Drosophila PRD
              gene set as part of a gene network
              JOURNAL
              Cell 47 (5), 735-746 (1986)
              MEDLINE
              87051745
              PUBMED
              2877746
              COMMENT
              Original source text: D.melanogaster (X-ray induced mutant strain
              PRD-2.45.17) DNA, library of C.Nueslein-Volhard.
              The insert in mutant Drosophila exon 2, described in [1], causes
              the prd mRNA to increase in size by 1.1 kb. The process also
              deletes five base pairs from the wild-type prd gene, starting at
              position 1065.
              Location/Qualifiers
              1. .50
              /organism="Drosophila melanogaster"
              /mol_type="genomic DNA"
              /db_xref="taxon:7227"
              <1. .>50
              /note="pseudoprd cds"
              /pseudo
              /codon_start=1
              ORIGIN
              Chromosome 2 band 33C1.2.

Query Match      35.9%; Score 15.8; DB 3; Length 50;
Best Local Similarity 74.1%; Pred. No. 1.2e+05;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy
    12 TCCTTCTTAATACCGTCCGCGTTAT 38
    |||:|||||:|||||
    17 TCGATCCGATACCGGTCCGCTCAT 43

RESULT 11
LOCUS      AR365669
DEFINITION Sequence 36 from patent US 5519127.
ACCESSION  AR365669
VERSION     AR365669.1 GI:34429581
KEYWORDS
SOURCE      Unknown.
            Unclasiified.
ORGANISM

```

```

REFERENCE      1 (bases 1 to 33)
AUTHORS       Shah,J., Bunarhin,A. and Iane,D.J.
TITLE         Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL       Patent: US 5519127-A 36 21-MAY-1996;
FEATURES
    source
        1. .33
        /organism="unknown"
        /mol_type="genomic DNA"
    ORIGIN
        Query Match      34.5%; Score 15.2; DB 6; Length 33;
        Best Local Similarity 77.3%; Pred. No. 2.2e+05;
        Matches 17; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy
    8 CCGTTCCTTCTTAATACCGGT 29
    :|:|||||:|||||
    3 YCCTTCCTTCGATACCGGT 24

RESULT 12
LOCUS      AX147162      37 bp      DNA      linear      PAT 08-JUN-2001
DEFINITION Sequence 4 from Patent WO0136457.
ACCESSION  AX147162
VERSION     AX147162.1 GI:14346333
KEYWORDS
SOURCE      synthetic construct
            other sequences; artificial sequences.
REFERENCE
    1 Mardin,A.D., Oomen,R.P., Wang,J. and Dunn,P.
      Chlamydia antigens and corresponding dna fragments and uses thereof
      Patent: WO 0136457-A 4 25-MAY-2001;
      Aventis Pasteur Limited (CA)
FEATURES
    source
        1. .37
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="3' PCR primer"
    ORIGIN
        Query Match      34.5%; Score 15.2; DB 6; Length 37;
        Best Local Similarity 71.4%; Pred. No. 2.2e+05;
        Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy
    2 CGGATCCGCTTCCTTAAATACCGGT 29
    |||:|||||:|||||
    5 CGGATCCGCTTCCTTAAATACCGGT 32

RESULT 13
LOCUS      AX081593/c      47 bp      DNA      linear      PAT 27-FEB-2001
DEFINITION Sequence 98 from Patent WO0109350.
ACCESSION  AX081593
VERSION     AX081593.1 GI:13170418
KEYWORDS
SOURCE      synthetic construct
            other sequences; artificial sequences.
REFERENCE
    1 Berthet,F.X., Dalemans,W.L., Denoel,P., Dequeane,G.S., Feron,C.S.,
      Lobet,Y.S., Poolman,J.S., Thiry,G.S., Ihonnard,J.S. and Voet,P.S.
      Genetically engineered blib vaccine
      Patent: WO 0109350-A 98 08-FEB-2001;
      SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE)
FEATURES
    source
        1. .47
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="PNS4 primer"

```


ORIGIN

Query Match 34.5%; Score 15.2; DB 6; Length 47;
Best Local Similarity 71.4%; Pred. No. 2.2e+05;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Db 17 CTTAATACCGGTCGGTATTAAAGA 44
41 CATATTTCCGACGCGTTAATTAAGA 14

RESULT 14

AX374774/c

LOCUS AX374774 47 bp DNA linear PAT 01-MAR-2002
DEFINITION Sequence 98 from Patent WO209746.
ACCESSION AX374774
VERSION AX374774.1 GI:19169676
KEYWORDS

SOURCE

ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE

1 Berthel, J.G., Dalemans, W.G., Denoel, P.G., Dequesne, G.G.,
Reron, C.G., Garcon, N.G., Lobet, Y.G., Poolman, J.G., Thiry, G.G.,
Thomard, J.G. and Voet, P.G.
Vaccine composition
Patent: WO 0209746-A 98 07-FEB-2002;
SMITHKLINE BEECHAM BIOLOGICALS S.A. (BB)

TITLE

JOURNAL
SMITHKLINE BEECHAM BIOLOGICALS S.A. (BB)

FEATURES

SOURCE location/Qualifiers
1..47
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PMS4 primer"

ORIGIN

Query Match 34.5%; Score 15.2; DB 6; Length 47;
Best Local Similarity 71.4%; Pred. No. 2.2e+05;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Db 17 CTTAATACCGGTCGGTATTAAAGA 44
41 CATATTTCCGACGCGTTAATTAAGA 14

RESULT 15

AX248444/c

LOCUS AX248444 31 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 523 from Patent WO0166800.
ACCESSION AX248444
VERSION AX248444.1 GI:15863067
KEYWORDS

SOURCE

ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

1 Cargill, M., Ireland, J.S. and Lander, E.S.
Human single nucleotide polymorphisms
Patent: WO 0166800-A 523 13-SEP-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)

FEATURES

SOURCE location/Qualifiers
1..31
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 34.1%; Score 15; DB 6; Length 31;
Best Local Similarity 76.3%; Pred. No. 2.7e+05;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Db 12 TCCTTCTTAATACCGGTCGGG 34

Db 29 TCTTCTTAATGACCTGCGGG 7

RESULT 16

MMU41925

LOCUS MMU41925 50 bp DNA linear ROD 05-JAN-1996
DEFINITION Mus musculus recombination between immunoglobulin heavy chain and
c-myc.
ACCESSION U41925
VERSION U41925.1 GI:1147659
KEYWORDS

SOURCE

ORGANISM Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 Muller, J.R.
Direct Submission
Submitted (05-DEC-1995) Jurgen R. Muller, Lab of Genetics, NIH/NCI,
Bldg. 37, Room 2B09, 37 Convent Dr., Bethesda, MD 20892-4255, USA

FEATURES

SOURCE location/Qualifiers
1..50
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="BALB/cAn"
/db_xref="taxon:10090"
/chromosome="12(15)"
/map="1(12F1,15d2)"
/tissue_type="Oil granuloma 7 days post pristane"
/dev_stage="7 days post pristane"

ORIGIN

Query Match 34.1%; Score 15; DB 10; Length 50;
Best Local Similarity 67.7%; Pred. No. 2.7e+05;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Db 4 GGTCCGTCCTTCTTAATACCGGTCGGG 34
11 GGACGAGCTCTTCTGACTTACGAGTCTCTG 41

RESULT 17

AX582316/c

LOCUS AX582316 31 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 4154 from Patent WO0211674.
ACCESSION AX582316
VERSION AX582316.1 GI:27654126
KEYWORDS

SOURCE

ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE

1 Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)

TITLE

JOURNAL
Patent: WO 0211674-A 4154 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)

FEATURES

SOURCE location/Qualifiers
1..31
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Enzymatic Nucleic Acid"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 31;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Db 5 GTCCGTCCTTCTTAATACCGGTC 30

|||||
Db 30 GTCCGTTCTGTTAGTACGCCGCTC 5

RESULT 18
103806/c 103806 33 bp DNA linear PAT 02-DEC-1994

LOCUS Sequence 9 from Patent EP 0055942.
ACCESSION 103806
VERSION 103806.1 GI:592012

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 33)
AUTHORS Inouye,M. and Nakamura,K.
TITLE Plasmid cloning vehicles
JOURNAL Patent: EP 0055942-A2 9 14-JUL-1982;
FEATURES Location/Qualifiers
1..33
source /organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 33;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 6 TCCGCTTCTTATTAACCGGTCG 31
Db 29 TCCTTTCATTATTAATACCTCTAG 4

RESULT 19
AR429930 36 bp DNA linear PAT 18-DEC-2003

LOCUS Sequence 40 from patent US 6645765.
ACCESSION AR429930
VERSION AR429930.1 GI:40190357

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 36)
AUTHORS Anderson,H.M., Chay,C.A., Chen,G. and Conner,T.W.
TITLE Plant regulatory sequences for control of gene expression
JOURNAL Patent: US 6645765-A 40 11-NOV-2003;
FEATURES Location/Qualifiers
1..36
source /organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 36;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTATTAACCGGTCG 34
Db 6 CTTTCTTCTACTCAGCGGTTCGG 31

RESULT 20
AX099684 36 bp DNA linear PAT 02-APR-2001

LOCUS Sequence 40 from Patent WO0119976.
ACCESSION AX099684
VERSION AX099684.1 GI:13538738

KEYWORDS

SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.

AUTHORS Anderson,H.M., Chay,C.A., Chen,G. and Conner,T.W.
TITLE Plant regulatory sequences for control of gene expression
JOURNAL Patent: WO 0119976-A 40 22-MAR-2001;
FEATURES Location/Qualifiers
1..36
source /organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 36;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTATTAACCGGTCG 34
Db 6 CTTTCTTCTACTCAGCGGTTCGG 31

RESULT 21
103802/c 103802 37 bp DNA linear PAT 02-DEC-1994

LOCUS Sequence 5 from Patent EP 0055942.
ACCESSION 103802
VERSION 103802.1 GI:592010

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 37)
AUTHORS Inouye,M. and Nakamura,K.
TITLE Plasmid cloning vehicles
JOURNAL Patent: EP 0055942-A2 5 14-JUL-1982;
FEATURES Location/Qualifiers
1..37
source /organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 37;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 6 TCCGCTTCTTCTTATTAACCGGTCG 31
Db 29 TCCTTTCATTATTAATACCTCTAG 4

RESULT 22
AR288505/c 47 bp DNA linear PAT 12-JUN-2003

LOCUS Sequence 240 from patent US 6537751.
ACCESSION AR288505
VERSION AR288505.1 GI:31675789

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 47)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 240 25-MAR-2003;
FEATURES Location/Qualifiers
1..47
source /organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 47;
Best Local Similarity 61.1%; Pred. No. 3.3e+05;

Matches 22; Conservative 1; Mismatches 13; Indels 0; Gaps 0;

Qy 9 CGTTCCTTTAATAACCGGTCGGTTATTATAGAA 44
Db 46 CATTTAATTTAATACATGCTCCTGTTTGAAGAAA 11

RESULT 23
LOCUS AR289990 47 bp DNA
DEFINITION Sequence 1725 from patent US 6537751.
ACCESSION AR289990
VERSION AR289990.1 GI:31677274
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 47)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 1725 25-MAR-2003;
Location/Qualifiers
source 1..47
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 47;
Best Local Similarity 59.5%; Pred. No. 3.3e+05;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 3 GGGTCCCGCTCTCTTATATAACCGGTCGGTTATTATAGAA 44
Db 46 GGTCCCATCTCTCTTATATAACCGGTCGGTTATTATAGAA 5

RESULT 24
LOCUS AR032973 50 bp DNA
DEFINITION Sequence 585 from patent US 5869241.
ACCESSION AR032973
VERSION AR032973.1 GI:5948578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 50)
AUTHORS Edwards,C.A., Cantor,C.R., Andrews,B.M., Turin,L.M. and Fry,K.E.
TITLE Method of determining DNA sequence preference of a DNA-binding
JOURNAL molecule
FEATURES Patent: US 5869241-A 585 09-FEB-1999;
Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTTATATAACCGGTCGGGTT 36
Db 27 TGCCTTTATATAACCGGTCGGTT 2

RESULT 25
LOCUS 129713 50 bp DNA
DEFINITION Sequence 585 from patent US 5578444.
ACCESSION 129713
VERSION 129713.1 GI:1820504

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 50)
AUTHORS Edwards,C.A., Cantor,C.R., Andrews,B.M., Turin,L.M. and Fry,K.E.
TITLE Sequence-directed DNA-binding molecules compositions and methods
JOURNAL Patent: US 5578444-A 585 26-NOV-1996;
FEATURES Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTTATATAACCGGTCGGGTT 36
Db 27 TGCCTTTATATAACCGGTCGGTT 2

RESULT 26
LOCUS 191387 50 bp DNA
DEFINITION Sequence 585 from patent US 5726014.
ACCESSION 191387
VERSION 191387.1 GI:3935857
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 50)
AUTHORS Edwards,C.A., Cantor,C.R., Andrews,B.M. and Turin,L.M.
TITLE Screening assay for the detection of DNA-binding molecules
JOURNAL Patent: US 5726014-A 585 10-MAR-1998;
FEATURES Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTTATATAACCGGTCGGGTT 36
Db 27 TGCCTTTATATAACCGGTCGGTT 2

RESULT 27
LOCUS AR209637 50 bp DNA
DEFINITION Sequence 585 from patent US 6384208.
ACCESSION AR209637
VERSION AR209637.1 GI:21511114
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 50)
AUTHORS Edwards,C.A., Cantor,C.R., Andrews,B.M., Turin,L.M. and Fry,K.E.
TITLE Sequence directed DNA binding molecules compositions and methods
JOURNAL Patent: US 6384208-A 585 07-MAY-2002;
FEATURES Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;

Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCTCTTAATAACCGGTCCGGTT 36
27 TGCTTTATATAACCGGTTCGGTT 2

RESULT 28
LOCUS CO868809 32 bp DNA linear PAT 13-SEP-2004
DEFINITION Sequence 20 from Patent WO2004073728.
ACCESSION CO868809
VERSION CO868809.1 GI:51998743
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Westphal,O., Waelli,T., Gorczynski,R., Mueller,S., Mach,J.P.,
Hattmann,A., Bessler,W., Hofmann,P., Zaehringer,U., Alexander,C.,
vor dem Bache,U., Ulmer,A. and Verdini,A.
TITLE Compositions comprising fetal hemoglobin and bacterial endotoxin
and optionally additional fetal liver components
JOURNAL Patent: WO 2004073728-A 20 02-SEP-2004;
Clinique La Prairie Research SA (LU)
LOCATION/Qualifiers

FEATURES 1..32
source /organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

ORIGIN

Query Match 33.2%; Score 14.6; DB 6; Length 32;
Best Local Similarity 81.0%; Pred. No. 4.1e+05;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 19 TAATPACCGTCCGGTTAATT 39
1 TAATPACCGGTATGGTCATT 21

RESULT 29
LOCUS AR365650 33 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 17 from patent US 5519127.
ACCESSION AR365650
VERSION AR365650.1 GI:34429562
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 33)
AUTHORS Shah,J., Buharir,A. and Lane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 17 21-MAY-1996;
LOCATION/Qualifiers

FEATURES 1..33
source /organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 33.2%; Score 14.6; DB 6; Length 33;
Best Local Similarity 81.0%; Pred. No. 4.1e+05;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGT 29
4 CCTTCCTTCTGATTAACCGGT 24

RESULT 30
LOCUS AR365637/c

LOCUS AR365637 34 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 4 from patent US 5519127.
ACCESSION AR365637
VERSION AR365637.1 GI:34429549
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 34)
AUTHORS Shah,J., Buharir,A. and Lane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 4 21-MAY-1996;
LOCATION/Qualifiers

FEATURES 1..34
source /organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 33.2%; Score 14.6; DB 6; Length 34;
Best Local Similarity 81.0%; Pred. No. 4.1e+05;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGT 29
31 CCTTCCTTCTGATTAACCGGT 11

RESULT 31
LOCUS AX739899/c 35 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 7 from Patent WO03025016.
ACCESSION AX739899
VERSION AX739899.1 GI:30519182
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Dawbarn,D., Allen,S.J. and Robertson,A.G.
TITLE Polypeptide purification method
JOURNAL Patent: WO 03025016-A 7 27-MAR-2003;
The University of Bristol (GB)
LOCATION/Qualifiers

FEATURES 1..35
source /organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

ORIGIN

Query Match 33.2%; Score 14.6; DB 6; Length 35;
Best Local Similarity 73.9%; Pred. No. 4.1e+05;
Matches 17; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 21 ATAACCGGTCCGGTTATTAGA 43
32 AAACCGGTCCGGTTCATTATTA 10

RESULT 32
LOCUS AR365666 39 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 33 from patent US 5519127.
ACCESSION AR365666
VERSION AR365666.1 GI:34429578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 39)
AUTHORS Shah,J., Buharir,A. and Lane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 33 21-MAY-1996;
LOCATION/Qualifiers

ACCESSION	BD061913
VERSION	BD061913.1
KEYWORDS	JP 2001517091-A/247.
SOURCE	synthetic construct
ORGANISM	synthetic construct other sequences; artificial sequences. 1 (bases 1 to 32)
REFERENCE	Chow T.P., Fry K.E., Lim M.Y. and Mcatee C.P. Antigenic composition and method of detection for Helicobacter Patent: JP 2001517091-A 247 02-OCT-2001; GENELABS TECHNOLOGIES INC PN JP 2001517091-A/247
COMMENT	PD 02-OCT-2001 PR 25-APR-1998 JP 1998547263 P R 25-APR-1997 US 6,070,451 THERESA P CHOW, KIRK E FRY, MOON Y LIM, C P MCATEE PC C12N15/31,C07K14/205,C07K16/12,A61K39/106 CC Strandedness: Single; Topology: Linear; FH Key Location/Qualifiers.
FEATURES	Location/Qualifiers source .1..32 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"
ORIGIN	Query Match 32.7%; Score 14.4; DB 6; Length 32; Best Local Similarity 75.0%; Pred.No. 5e+05; Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Oy	1 GC GG GT CC CG CT TC TT TA AT AA 24 Db 4 GC GA TT CC CAT TC CA CT TA AT AA 27
-RESULT 38	
LOCUS	AX574343 34 bp DNA linear PAT 07-JAN-2003
DEFINITION	Sequence 7 from Patent WO0250545.
ACCESSION	AX574343
VERSION	AX574343.1
KEYWORDS	G1:27551693
SOURCE	. synthetic construct synthetic construct other sequences; artificial sequences. 1 Pelletier,J., Gros,P. and Dubow,M. Compositions and methods involving staphylococcus aureus protein stau-r9 Patent: WO 0250545-A 7 27-JUN-2002; Phagotech Inc. (CA) Location/Qualifiers .1..34 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="Synthetic oligonucleotide"
FEATURES	Location/Qualifiers source .1..34 /organism="synthetic construct" /mol_type="unassigned DNA" /db_xref="taxon:32630" /note="Synthetic oligonucleotide"
ORIGIN	Query Match 32.7%; Score 14.4; DB 6; Length 34; Best Local Similarity 75.0%; Pred.No. 5e+05; Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Oy	1 GC GG GT CC CG CT TC TT TA AT AA 24 Db 2 GC GA TT CC CAT TC TT TA AT AA 25
RESULT 39	
LOCUS	BD235752 40 bp DNA linear PAT 17-JUL-2003
DEFINITION	Strengthened functional expression of heterogenous G

Accession	Version	Keywords	Source	Organism	Reference Authors	Title	Journal	Comment
BD235752	1	GI:33045522	JP 2002523090-A/5.	Synthetic construct	Pausch,M.H., Lai,M., Silverman,S., Biran,C., Baumbauch,W., Tseng,E., Kajakowski,E.M. and Ozemberger,B.A.. Strengthened functional expression of heterogenous G protein-coupled receptor	Patent: JP 2002523090-A 5 30-JUL-2002;	BASF AG	OS Artificial Sequence PN JP 2002523090-A/5 PD 30-JUL-2002 PF 01-SEP-1999 JP 2000567691 PR 01-SEP-1998 US 60/098704 PI MARK HENRY PAUSCH,MARGARET LAI,SANFORD SILVERMAN,CAMELIA PI BIRAN, WILLIAM BAUMBAUCH,EUGENE TSENG,EILEEN MARIE KAJKOWSKI, PI BRADLEY ALTON OZEMBERGER PC C12N1/19,C07K14/72,C12N15/09,C12P21/02,C12Q1/02,G01N33/15, PC G01N33/50, G01N33/566//C12N1/19,C12R1:865),(C12P21/02,C12R1:865),C12N15/PC 00 CC Description of Artificial Sequence:Oligonucleotide FH Key Location/Qualifiers FT source 1..40 /organism='Artificial Sequence'. FT location/Qualifiers 1..40 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"
Query Match	32.7%	Score 14.4;	DB 6;	Length 40;				
Best Local Similarity	65.6%	Pred. No. 5e+05;						
Matches 21; Conservative	0;	Mismatches 11;	Indels 0;	Gaps 0;				
Cy	9	CGTTCCTTTAATACCGGTGGCGGTATTAA	40					
Dp	5	CGTGCCCTTACTTACCGGTCAACCATCAATGA	36					
RESULT 40								
BD235803								
LOCUS	BD235803	40 bp	DNA	linear	PAT 17-JUL-2003			
DEFINITION	Method of modifying function of heterogenous G protein-coupled receptor.							
ACCESSION	BD235803							
VERSION	BD235803.1	GI:33045573						
KEYWORDS	JP 2002523091-A/5.							
SOURCE	Synthetic construct							
ORGANISM	Synthetic construct							
REFERENCE	other sequences; artificial sequences.							
AUTHORS	1 (bases 1 to 40)							
TITLE	Pausch,M.H. and Wess,J.							
JOURNAL	Method of modifying function of heterogenous G protein-coupled							
COMMENT	Basf AG Patent: JP 2002523091-A 5 30-JUL-2002;							
	BASF AG							
	OS Artificial Sequence							
	PN JP 2002523091-A/5							
	PD 30-JUL-2002							
	PF 01-SEP-1999 JP 2000567692							
	PR 01-SEP-1998 US 60/098704							
	PI MARK HENRY PAUSCH,JURGEN WESS							
	PC C12N15/09,C07K14/72,C12N1/19,C12Q1/02,G01N33/15,G01N33/50, PC G01N33/566,							
	PC G01N33/68//C12N1/19,C12R1:865),C12N15/00							
	CC Description of Artificial Sequence:oligonucleotide FH Key							

FEATURES	source
FT	location/Qualifiers
FT	1..40 /organism='Artificial Sequence'
	location/Qualifiers
	1..40
	/organism='synthetic construct'
	/mol_type='genomic DNA'
	/db_xref='taxon:32630'

Query Match	32.7%	Score	14.4	DB	6	Length	40
Best Local Similarity	65.6%	Pred	No	5e+05			
Matches	21	Conservative	0	Mismatches	11	Indels	0
						Gaps	0

Oy 9 CGTTCCTTTAATAACGGTGCGGTTATTA 40
 || | | | | | | | | |
Db 5 CGGTGCCTTTACTTACCAGGTCACCATC ATGA 36

Search completed: May 24, 2005, 12:43:56
Job time : 1770 secs

This Page Blank (usps)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 08:29:04 ; Search time 258 Seconds
(without alignment)
1009.568 Million cell updates/sec

Title: us-10-673-063-3_COPY_900_943

Perfect score: 1 gcgggtccgcgttcctctta.....ccggtcgcgttattaaagaa 44

Sequence: 1 gcgggtccgcgttcctctta.....ccggtcgcgttattaaagaa 44

Scoring table: IDENTITY NUC
Gapop 10'-0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 4167226

Minimum DB seq length: 0
Maximum DB seq length: 50Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 100 summaries

Database : N_Geneseq_16Dec04:*

1: geneseq19608:*\n2: geneseq19908:*\n3: geneseq20008:*\n4: geneseq20018:*\n5: geneseq20018:*\n6: geneseq20028:*\n7: geneseq20028:*\n8: geneseq20038:*\n9: geneseq20038:*\n10: geneseq20038:*\n11: geneseq20038:*\n12: geneseq20048:*\n13: geneseq20048:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	17.4	39.5	39	13	AdS87007 PCR prime
2	16.2	36.8	32	6	AA143407 SIMK muta
3	16	36.4	27	6	AA520859 Gene-spec
4	16	36.4	27	6	AA520860 Gene-spec
5	16	36.4	30	12	AdB85746 BphA2 inv
6	16	36.4	33	12	AdL27336 Forward p
7	15.8	35.9	45	2	AAQ87806 Primer us
8	15.6	35.5	33	6	ABK89998 Human hea
9	15.4	35.0	34	2	AA527543 C. pneumo
10	15.2	34.5	37	5	AA527543 Staphyloc
11	15.2	34.5	38	9	AdB81046 LINE retr
12	15.2	34.5	47	3	AA265893 Human map
13	15.2	34.5	47	4	AA591472 N. mening
14	15.2	34.5	47	6	ABK37852 PCMK(+)-C
15	15.2	34.5	31	4	AA130035 Human sin
16	15	34.1	47	3	AA269059 Human map
17	15	34.1	50	6	AB202614 Human leu
18	15	34.1	50	6	AB207725 Human leu
19	14.8	33.6	31	6	ABK59783 Human CTC
20	14.8	33.6	36	4	AA581443 PCR prime

21	14.8	33.6	39	6	AA243960	AA243960 D1228 oli
22	14.8	33.6	47	3	AA267378	AA267378 Human map
23	14.8	33.6	50	2	AAQ69835	AAQ69835 Human pap
24	14.8	33.6	50	2	AA264297	AA264297 HPV type
25	14.8	33.6	50	2	AA117585	AA117585 Test sequ
26	14.8	33.6	50	6	ABK83076	ABK83076 DNA bindi
27	14.8	33.6	50	6	AB202818	AB202818 Human leu
28	14.8	33.6	50	12	AD80615	AD80615 Duplex ol
29	14.8	33.6	50	13	AD591869	AD591869 Nematode
30	14.6	33.2	25	9	AC197514	AC197514 Human mic
31	14.6	33.2	34	2	AAQ10823	AAQ10823 Pneumocys
32	14.6	33.2	34	2	AA242447	AA242447 Probe 148
33	14.6	33.2	35	10	AD135720	AD135720 Human tyr
34	14.6	33.2	38	2	AAV06323	AAV06323 Human Col
35	14.6	33.2	41	6	AB247662	AB247662 Human ATP
36	14.6	33.2	41	6	AB245067	AB245067 Human ATP
37	14.6	33.2	41	12	ADL60971	ADL60971 Human org
38	14.6	33.2	45	6	ABN84317	ABN84317 Rhinoviru
39	14.6	33.2	47	12	AD018016	AD018016 Primer of
40	14.6	33.2	47	12	AD018088	AD018088 Primer of
41	14.4	32.7	20	6	ABQ93060	ABQ93060 T. tausch
42	14.4	32.7	25	9	AC188894	AC188894 Human mic
43	14.4	32.7	29	10	ADK66726	ADK66726 Glucocina
44	14.4	32.7	29	10	ADL09096	ADL09096 Staphyloc
45	14.4	32.7	32	2	AAV90788	AAV90788 Primer Y1
46	14.4	32.7	34	6	ABK87091	ABK87091 S. aureus
47	14.4	32.7	40	3	AA294303	AA294303 Rat M3 mu
48	14.4	32.7	40	3	AA294354	AA294354 Rat musca
49	14.4	32.7	41	12	ADL60971	ADL60971 Human org
50	14.4	32.7	47	3	AA266643	AA266643 Human map
51	14.4	32.7	50	5	AA284632	AA284632 SIV gene
52	14.4	32.7	50	10	ADL11889	ADL11889 Butterfly
53	14.4	32.7	50	10	ADL11920	ADL11920 Human ret
54	14.2	32.3	20	8	AA297393	AA297393 Primer us
55	14.2	32.3	20	8	AB281133	AB281133 Dual spec
56	14.2	32.3	25	6	AB292866	AB292866 Human eos
57	14.2	32.3	25	6	ABV75348	ABV75348 Human BCP
58	14.2	32.3	31	6	AB222006	AB222006 Helicobac
59	14.2	32.3	31	6	AB222037	AB222037 Helicobac
60	14.2	32.3	31	6	AA518580	AA518580 Human tra
61	14.2	32.3	32	12	ADL70702	ADL70702 Becherich
62	14.2	32.3	33	6	AAH77221	AAH77221 PCR prime
63	14.2	32.3	33	13	AD573809	AD573809 E. coli n
64	14.2	32.3	34	2	AAV33572	AAV33572 Leukocyte
65	14.2	32.3	36	2	AAQ62183	AAQ62183 Tryptoph
66	14.2	32.3	36	2	AAQ81847	AAQ81847 PDI promo
67	14.2	32.3	38	3	AA243342	AA243342 Mutine ty
68	14.2	32.3	38	3	AA505327	AA505327 PCR prime
69	14.2	32.3	39	10	ADP54788	ADP54788 Influenza
70	14.2	32.3	41	6	ABL40260	ABL40260 Human pro
71	14.2	32.3	41	10	AD53158	AD53158 Thernus t
72	14.2	32.3	45	6	AA146572	AA146572 Human PAP
73	14.2	32.3	45	6	AA146580	AA146580 Human PAP
74	14.2	32.3	48	10	ACF04958	ACF04958 Hair papi
75	14.2	32.3	49	5	AB110693	AB110693 Tail adap
76	14.2	32.3	50	4	AAH90534	AAH90534 Human clo
77	14.2	32.3	50	6	AB204787	AB204787 Human leu
78	14.2	32.3	50	10	ADG33460	ADG33460 Human DNA
79	14.2	32.3	50	12	ADH74736	ADH74736 LIC cloni
80	14	31.8	24	4	AAQ24974	AAQ24974 PCR prime
81	14	31.8	24	4	AAQ09446	AAQ09446 Sense PCR
82	14	31.8	30	4	AAH84364	AAH84364 Human cel
83	14	31.8	32	3	AA236904	AA236904 PCR prime
84	14	31.8	35	3	AA236906	AA236906 PCR prime
85	14	31.8	38	2	AAV34694	AAV34694 TRK2 gene
86	14	31.8	38	2	AAZ31019	AAZ31019 Upstream
87	14	31.8	38	4	AA54760	AA54760 PCR prime
88	14	31.8	38	10	AA54760	AA54760 PCR prime
89	14	31.8	41	2	AAV85621	AAV85621 LRP5 exon
90	14	31.8	42	11	ADW79708	ADW79708 Group B S
91	14	31.8	45	10	ACCT8190	ACCT8190 DNA seque
92	14	31.8	47	2	AAQ69500	AAQ69500 Human nuc
93	14	31.8	47	2	AA263962	AA263962 Human nuc

94	14	31.8	47	2	AAx17250
95	14	31.8	47	6	ABK82741
96	14	31.8	47	12	ADe80280
c	97	13.8	31.4	24	ABQ07869
c	98	13.8	31.4	24	ABQ01975
c	99	13.8	31.4	24	ABQ07910
c	100	13.8	31.4	25	AAH38015

ALIGNMENTS

RESULT 1

ADs87007/c
ID ADs87007 standard; DNA; 39 BP.

AC ADs87007;

DT 18-NOV-2004 (first entry)

DE PCR primer 1 used to amplify murine TRP-2 cDNA.

KW vaccine; ubiquitin; Ub; T-cell target; melanoma; sarcoma;
KW Hodgkins lymphoma; non-Hodgkins; leukaemia; neuroblastoma; myeloma;
KW lung cancer; stomach; skin; thyroid; ovary; prostate; womb; pancreas;
KW colon; bladder; breast; oesophagus; kidney; brain; mouse; murine; ss;
KW PCR; primer; TRP-2.

OS Mus sp.

FN WO2004035085-A1.

PD 29-APR-2004.

PF 16-OCT-2003; 2003WO-JP013279.

PR 17-OCT-2002; 2002JP-00302816.

PA (KYUS-) KYUSHU TLO CO LTD.

PI Himeno K, Furue M, Maehara Y;

DR WPI; 2004-357144/33.

PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
or cytokine genes for prevention and treatment of cancer.

PS Example 6; SEQ ID NO 23; 266pp; Japanese.

CC The invention relates to a novel genetic vaccine containing the ubiquitin
CC gene together with a gene encoding an antigenic protein containing a T-
CC cell target sequence. The vaccine of the invention may be useful for
CC prevention and treatment of cancers including melanoma, sarcoma, lymphoma
CC (Hodgkins or non-Hodgkins), leukaemia, neuroblastoma, myeloma and cancer
CC of the lung, stomach, skin, thyroid, ovary, prostate, womb, pancreas,
CC colon, bladder, breast, oesophagus, kidney or brain. The current sequence
CC is that of a genetic vaccine/ubiquitin (Ub)-related PCR primer of the
CC invention.

XX Sequence 39 BP; 11 A; 10 C; 12 G; 6 T; 0 U; 0 Other;

Query Match 39.5%; Score 17.4; DB 13; Length 39;

Best Local Similarity 68.6%; Pred. No. 1.4e+03;

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 5 GTCCGCTTCCTTAAATACCGGTGCGGTTATT 39

DB 36 GGCCCATGCTCTTAATTGGCGCGCTTGATT 2

RESULT 2

AA143407/c
ID AA143407 standard; DNA; 32 BP.

XX AA143407;

AC 02-SEP-2002 (first entry)

DE SIMK mutagenic PCR primer (SIMKLOF).

KW Salt stress-induced mitogen activated-protein kinase kinase; SIMK; ss;
KW stress tolerance; salt tolerance; plant cell; PCR; primer; SIMK; SIMKLOF.

XX Unidentified.

OS Synthetic.

FN WO200238745-A2.

PD 16-MAY-2002.

PE 06-NOV-2001; 2001WO-EP012800.

PR 07-NOV-2000; 2000AT-00001880.

PA (OSTP) OESTERR FORSCH SEIBERSDORF.

PI Meekiene I, Hirt H, Jonak C;

DR WPI; 2002-490077/52.

PT Salt stress-induced mitogen-activated protein kinase, useful for
improving stress tolerance, especially salt tolerance in eukaryotic
cells, particularly in plant cells.

PS Example; Page 17; 42pp; English.

CC The invention comprises the amino acid and coding sequence of a salt
CC stress-induced mitogen-activated protein kinase kinase (SIMK). The SIMK
CC DNA and protein sequences of the invention are useful for improving
CC stress tolerance (i.e. salt tolerance) in eukaryotic cells - particularly
CC in plant cells. The present DNA sequence represents a stress-induced
CC mitogen-activated protein kinase (SIMK) mutagenic PCR primer

XX Sequence 32 BP; 8 A; 9 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 36.8%; Score 16.2; DB 6; Length 32;

Best Local Similarity 85.7%; Pred. No. 4.4e+03;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 23 AACCGTGGCGTATTAGA 43

DB 31 AACATGTCGCGGTTATGAGA 11

RESULT 3
AAS20859/c

ID AAS20859 standard; DNA; 27 BP.

AC AAS20859;

DT 09-APR-2002 (first entry)

DE Gene-specific PCR primer Z-ST-P18 for cloning Z. marina sulfotransferase.

KW Plant; transgenic; marine eelgrass; zosteric acid biosynthesis;
KW saline-resistance; anoxia-resistance; anti-fouling genetic trait;
KW marine vascular plant; sulphated phenolic compound; Zostera marina;
KW sulfotransferase; ST; enzyme; PCR; primer; ss.

OS Zostera marina.

FN WO200185971-A2.

PN 15-NOV-2001.

PF 10-MAY-2001; 2001WO-US015412.

```
XX PR 10-MAY-2000; 2000US-0202529P.
XX XX
XX PA (PHYC-) PHYCOGEN INC.
XX PI Alberte RS, Smith RD;
XX XX
XX DR WPI; 2002-121947/16.
XX XX
XX PT New transgenic plants comprising a zosteric acid biosynthetic gene, a
XX PT saline resistance gene or a hypoxia resistance gene derived from Zostera
XX PT marina, useful for producing plants with antifouling traits.
XX XX
XX PS Example; Fig 3; 117pp; English.
XX XX
XX CC The present invention relates to a new transgenic plant comprising a
XX CC heterologous gene derived from the marine eelgrass Zostera marina or at
XX CC least one heterologous nucleotide sequence encoding a zosteric acid
XX CC biosynthetic function, a saline-resistance function, or a anoxia-
XX CC resistance function. The invention describes the method of producing a
XX CC transgenic plant possessing an anti-fouling genetic trait by providing a
XX CC cDNA population derived from a marine vascular plant, isolating from the
XX CC cDNA population a nucleic acid species which hybridises to a nucleic acid
XX CC that encodes a sulfoltransferase (ST), an alcohol dehydrogenase (ADH), and
XX CC phenylalanine ammonia lyase (PAL) or a cinnamate-4-hydroxylase (CH), and
XX CC transforming a target host plant with the isolated nucleic acid. The
XX CC plant is useful in the genetic engineering of plant species having
XX CC desirable genetic traits such as antifouling traits, salt and anoxia
XX CC resistance, and pathogen defence strategy. The expression of such
XX CC biosynthetic enzymes are sufficient to support the production of zosteric
XX CC acid and other sulphated phenolic compounds in a target plant. AAS20856-
XX CC AAS20862 represent degenerate or gene-specific PCR primers for cloning Z.
XX CC marina sulfoltransferase
XX XX
SQ Sequence 27 BP; 8 A; 6 C; 5 G; 8 T; 0 U; 0 Other;
XX XX
Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.2e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
XX XX
CY 20 AATAACGGTGGCGTTATTAGA 43
DB 25 AATACTTGTGGGGTTATCAGA 2
XX XX
RESULT 4
AAS20860
ID AAS20860 standard; DNA; 27 BP.
XX XX
XX AAS20860;
XX AC
XX DT 09-APR-2002 (first entry)
XX XX
XX DE Gene-specific PCR primer Z-ST-P19 for cloning Z. marina sulfoltransferase.
XX XX
XX KW Plant; transgenic; marine eelgrass; zosteric acid biosynthesis;
XX KW saline-resistance; anoxia-resistance; anti-fouling genetic trait;
XX KW marine vascular plant; sulphated phenolic compound; Zostera marina;
XX KW sulfoltransferase; ST; enzyme; PCR; primer; ss.
XX XX
XX OS Zostera marina.
XX XX
XX PN WO200185971-A2.
XX PD
XX PE 15-NOV-2001.
XX PF
XX PR 10-MAY-2001; 2001WO-US015412.
XX PR 10-MAY-2000; 2000US-0202529P.
XX PA (PHYC-) PHYCOGEN INC.
XX PI Alberte RS, Smith RD;
```

```
XX XX
XX DR WPI; 2002-121947/16.
XX XX
XX PT New transgenic plants comprising a zosteric acid biosynthetic gene, a
XX PT saline resistance gene or a hypoxia resistance gene derived from Zostera
XX PT marina, useful for producing plants with antifouling traits.
XX XX
XX PS Example; Fig 3; 117pp; English.
XX XX
XX CC The present invention relates to a new transgenic plant comprising a
XX CC heterologous gene derived from the marine eelgrass Zostera marina or at
XX CC least one heterologous nucleotide sequence encoding a zosteric acid
XX CC biosynthetic function, a saline-resistance function, or a anoxia-
XX CC resistance function. The invention describes the method of producing a
XX CC transgenic plant possessing an anti-fouling genetic trait by providing a
XX CC cDNA population derived from a marine vascular plant, isolating from the
XX CC cDNA population a nucleic acid species which hybridises to a nucleic acid
XX CC that encodes a sulfoltransferase (ST), an alcohol dehydrogenase (ADH), and
XX CC phenylalanine ammonia lyase (PAL) or a cinnamate-4-hydroxylase (CH), and
XX CC transforming a target host plant with the isolated nucleic acid. The
XX CC plant is useful in the genetic engineering of plant species having
XX CC desirable genetic traits such as antifouling traits, salt and anoxia
XX CC resistance, and pathogen defence strategy. The expression of such
XX CC biosynthetic enzymes are sufficient to support the production of zosteric
XX CC acid and other sulphated phenolic compounds in a target plant. AAS20856-
XX CC AAS20862 represent degenerate or gene-specific PCR primers for cloning Z.
XX CC marina sulfoltransferase
XX XX
SQ Sequence 27 BP; 8 A; 5 C; 6 G; 8 T; 0 U; 0 Other;
XX XX
Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.2e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
XX XX
CY 20 AATAACGGTGGCGTTATTAGA 43
DB 3 AATACTTGTGGGGTTATCAGA 26
XX XX
RESULT 5
ADE85746
ID ADE85746 standard; DNA; 30 BP.
XX XX
XX ADE85746;
XX AC
XX DT 12-FEB-2004 (first entry)
XX XX
XX DE EphA2 inverted antisense oligonucleotide control SEQ ID NO:50.
XX XX
XX KW cancer; hyperproliferative cell disease; EphA2 antibody;
XX KW EphA2 agonistic antibody; cytostatic; antiasthmatic; antiproliferative;
XX KW antiinflammatory; vasotropic; respiratory; gene therapy;
XX KW metastatic cancer; asthma; psoriasis; inflammatory bowel disease;
XX KW smooth muscle restenosis; endothelial restenosis; Crohn's disease;
XX KW chronic obstructive pulmonary disease; human; control; ss.
XX XX
XX OS Synthetic.
XX XX
XX PN WO2003094859-A2.
XX PD
XX PE 20-NOV-2003.
XX PF
XX PR 12-MAY-2003; 2003WO-US015044.
XX PR 10-MAY-2002; 2002US-0379322P.
XX PR 14-OCT-2002; 2002US-0418213P.
XX PR 03-APR-2003; 2003US-0460507P.
XX PA (MEDI-) MEDIMUNE INC.
XX PI Kinch MS, Carles-Kinch K, Kiener P, Langemann S;
```

XX	WPI; 2004-012002/01.
PT	Treating cancer or a non-cancer hyperproliferative cell disease (e.g.,
PT	asthma, psoriasis, inflammatory bowel disease or restenosis) in a patient
PT	comprises administering to the patient a therapeutic amount of an EphA2
XX	antibody.
XX	
XX	Example; SEQ ID NO 50; 173bp; English.
XX	
CC	The present invention describes a method for treating cancer or a non-
CC	cancer hyperproliferative cell disease or disorder in a patient, which
CC	comprises administering to the patient a therapeutc amount of an EphA2
CC	antibody (1) that is an EphA2 agonistic antibody, an EphA2 cancer cell
CC	phenotype inhibiting antibody, an exposed EphA2 epitope antibody, or an
CC	antibody that binds EphA2 with a K-off of less than 3 x 10 ⁻³ s ⁻¹ . Also
CC	described: (1) a pharmaceutical composition comprising a therapeutic
CC	amount of (1) and a pharmaceutical carrier; (2) a cell line that produces
CC	(1); (3) a hybridoma deposited with the ATCC accession number PTA-4572,
CC	PTA-4573 or PTA-4574; (4) an isolated nucleic acid comprising a
CC	nucleotide sequence encoding a light chain variable domain or a heavy
CC	chain variable domain of the EphA2 antibody; (5) a vector comprising the
CC	nucleic acid described above; (6) a host cell comprising the vector; (7)
CC	methods of identifying the EphA2 agonistic antibody or the EphA2 antibody
CC	that inhibits a cancer cell phenotype, that kills cancer cells having a
CC	cancer cell phenotype or that preferentially binds an EphA2 epitope
CC	exposed on cancer cells; and (8) a method of diagnosing, prognosing or
CC	monitoring the efficacy of therapy for cancer in a patient known to or
CC	suspected to have cancer. (1) has cytostatic, antiasthmatic,
CC	antiapoptotic, antiinflammatory, vasotropic and respiratory activities,
CC	and can be used in gene therapy. The composition and methods are useful
CC	in managing, diagnosing, preventing or treating hyperproliferative cell
CC	diseases (I.e. metastatic cancer) or non-cancer hyperproliferative cell
CC	diseases or disorders, such as asthma, psoriasis, inflammatory bowel
CC	disease, smooth muscle restenosis, endothelial restenosis, Crohn's
CC	disease, or chronic obstructive pulmonary disease. They may also be used
CC	for monitoring the efficacy of therapy for cancer in a patient known to
CC	or suspected to have cancer, and in screening for anti-cancer drugs. The
CC	present sequence is used in the exemplification of the present invention.
SO	
XX	Sequence 30 BP; 4 A; 14 C; 6 G; 6 T; 0 U; 0 Other;
Query Match	36.4%; Score 16; DB 12; Length 30;
Best Local Similarity	79.2%; Pred. No. 5.3e+03;
Matches 19; Conservative	0; Mismatches 5; Indels 0; Gaps 0
Dy	2 CGGGTCCCGTTCTCTTAATAC 25
Dd	3 CGGTCGCCGTCTCTCACCATGAC 26
RESULT 6	
ID	ADL27336/c
ID	ADL27336 standard; DNA; 33 BP.
XX	
AC	ADL27336;
DT	03-JUN-2004 (first entry)
XX	
XX	Forward primer for amplifying prethrombin for cloning into pSecTag2A.
KW	adzyme; catalytic domain; allergic disease; inflammatory disease;
KW	inflammatory disorder; allergic disorder; inflammatory cytokine; PCR;
KW	primer; ss.
OS	Synthetic.
PN	WO2004019878-A2.
PD	11-MAR-2004.
PF	27-AUG-2003; 2003WO-US026937.
PR	27-AUG-2002; 2002US-0406517P.

XX	PR	05-NOV-2002; 2002US-0433754P.
XX	PR	27-NOV-2002; 2002US-0430001P.
XX	PA	(COMP-) COMPOUND THERAPEUTICS INC.
XX	PA	(AFET/) AFEYAN N B.
XX	P1	Afeyan NB, Baynes B, Daagupta R, Lee FD, Wong GG;
XX	DR	WPI; 2004-239110/22.
XX	PT	New adzyme for enzymatically altering a substrate, useful for preparing a
XX	PT	composition for treating diseases associated with a soluble or membrane
XX	PT	bound molecule, e.g. allergic or inflammatory diseases.
XX	PS	Example 2; Page 143; 202pp; English.
CC	CC	The specification describes an adzyme for enzymatically altering a
CC	CC	substrate. The adzyme comprises a catalytic domain that catalyzes a
CC	CC	chemical reaction converting the substrate to one or more products, and a
CC	CC	tageting group that reversibly binds with an address site on the
CC	CC	substrate or with an address site on a second molecule that occurs in
CC	CC	functional proximity to the substrate (the targeting moiety and the
CC	CC	catalytic domain are heterologous with respect to each other). The adzyme
CC	CC	is useful for preparing a composition for treating diseases associated
CC	CC	with a soluble or membrane bound molecule, e.g., allergic or inflammatory
CC	CC	diseases. Adzymes of the invention can be used to treat an inflammatory or
CC	CC	allergic disorder, where the substrate of the adzyme is an inflammatory
CC	CC	cytokine. PCR primers ADL27334-ADL27941 were used in overlap/recombinant
CC	CC	PCR to assemble prethrombin(GAS)3scFvAlphahA and scHA(GAS)3prethrombin,
XX	XX	which are adzymes of the invention.
SQ	SQ	Sequence 33 BP; 9 A; 11 C; 8 G; 5 T; 0 U; 0 Other;
Qy	Qy	Query Match 36.4%; Score 16; DB 12; Length 33;
Db	Db	Best Local Similarity 79.2%; Pred. No. 5.4e+03;
		Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0
		19 TAATRACCGGTCCGGCTTATTAG 42
		32 TACTCCTGTTGGCGGTCATTAAAG 9
RESULT 7		
AA087806/C		
ID AA087806 standard; DNA; 45 BP.		
XX AC AA087806;		
XX DT 25-MAR-2003 (revised)		
XX DT 14-NOV-1995 (first entry)		
DE Primer used to amplify IGE receptor gene mRNA.		
KM Probe; immunoglobulin; IGE; receptor; beta; allergic disease; detection;		
KW screening; diagnosis; se.		
OS Synthetic.		
FN EP649910-A1.		
PD 26-APR-1995.		
PF 21-OCT-1994; 94EP-00307751.		
PR 22-OCT-1993; 93JP-00265144.		
PA (SUME) SUMITOMO ELECTRIC IND CO.		
PI Osoegawa M, Miyabe Y, Nakata M, Ra C, Suzuki K;		
DR WPI; 1995-156760/21.		
PT Probes for mutation(s) in beta chain gene of a high affinity IGE receptor		

PT - for the diagnosis of allergic disease, esp. in neonate(s).
XX
PS Example 3; Page 9, 17pp; English.
XX
CC DNA probes (See AAQ87799-803) having sequences identical or complementary
CC to parts of the immunoglobulin E (IgE) receptor, are used to detect genes
CC associated with allergic disease (diseases involving mutations in the
CC beta chain gene). They may be used in neonatal screening, prenatal
CC diagnosis etc. Two primers (AAQ87805, AAQ87806) were used to amplify mRNA
CC in blood samples transcribed from the IGE receptor gene to produce cDNA.
CC The cDNA is then conjugated with a probe and an IGE ligand (See AAQ87804)
CC which is immobilised on a support is then used to bind to probe/IgE
CC receptor gene conjugates. The probe is then eluted by a gradual rise in
CC temperature. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 45 BP; 13 A; 11 C; 11 G; 10 T; 0 U; 0 Other;
Query Match 35.9%; Score 15.8; DB 2; Length 45;
Best Local Similarity 74.1%; Pred. No. 6.9e+03;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
OY 6 TCCGCTCTCTTATACCGGTGCG 32
Db 31 TCCATTGATTATTATAGCGCGCCG 5
RESULT 8
ID ABK89998 standard; DNA; 33 BP.
XX
AC ABK89998;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human heavy chain CDR3 variable region, PCR primer eUT.
XX
KW Human; immune response; chronic B-lymphoproliferative disorder; CDR3;
KW complementarity determining region 3; hypervariable region; B-cell;
KW immunoglobulin heavy chain; VH-CDR3; idiotypic immunoglobulin;
KW cytosolic; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200255559-A1.
XX
PD 18-JUL-2002.
XX
PF 15-JAN-2001; 2001WO-IT000014.
XX
PR 15-JAN-2001; 2001WO-IT000014.
XX
PA (FAZI/) FAZIO V M.
PA (SAGL/) SAGLIO G.
XX
PI Fazio VM, Saglio G;
XX
DR WPI; 2002-583654/62.
XX
PT Use of DNA sequences coding for hypervariable region (VH- complementarity
PT determining region 3 (CDR3)) of idiotype immunoglobulin expressed on B-
PT cells of chronic B- lymphoproliferative disorders, as therapeutic
PT vaccine.
XX
PS Example 2; Fig 1B; 30pp; English.
XX
CC The present invention relates to a method for inducing an immune response
CC against B-lymphoproliferative disorders. The method comprises DNA
CC sequences encoding for the complementarity determining region 3 (CDR3)
CC hypervariable region of immunoglobulin heavy chain (VH-CDR3) alone or in
CC combination with at least another immunomodulating sequence. The DNA
CC sequences are useful as therapeutic vaccines for chronic B-
CC lymphoproliferative disorders in mammals, preferably humans. A
CC recombinant plasmid expression vector containing a DNA sequence of the

CC invention is useful as a therapeutic vaccine or for the manufacture of a
CC vaccine effective against chronic B-lymphoproliferative disorders
CC expressing the surface idiotype immunoglobulin on B-cells in mammals,
CC preferably humans. An efficient, safe and easily reproducible DNA-based
CC immune response against B-lymphoproliferative pathologies can be
CC achieved. The present sequence represents a PCR primer used to amplify
CC human heavy chain CDR3 variable region in the examples of the present
CC invention
XX
SQ Sequence 33 BP; 7 A; 7 C; 11 G; 8 T; 0 U; 0 Other;
Query Match 35.5%; Score 15.6; DB 6; Length 33;
Best Local Similarity 70.0%; Pred. No. 8e+03;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
OY 3 GGGTCCGCTCTTATACCGGTGCG 32
Db 33 GGTACCGCTCTCTCATATATAGCGCGCCG 4
RESULT 9
ID AAX27543 standard; DNA; 34 BP.
XX
AC AAX27543;
XX
DT 27-MAY-1999 (first entry)
XX
DE Staphylokinase (Sak) encoding DNA amplifying primer 2.
XX
KW Staphylokinase; Sak; recombinant; myocardial infarction; cerebral;
KW thrombembolia disease; arterial thrombosis; pulmonary thrombosis;
KW hydrolytic; fibrin; PCR primer; ss.
XX
OS Synthetic.
XX
OS Staphylococcus aureus.
XX
PN MO9904017-A1.
XX
PD 28-JAN-1999.
XX
PF 17-JUL-1998; 98WO-CN0000129.
XX
PR 19-JUL-1997; 97CN-00105988.
XX
PA (BAIH/) BAI H.
XX
PI Zhang Q, Zhang G, Xu G, Qu G, Bie L, Xu W, Wu Y,
XX
DR WPI; 1999-132261/11.
XX
PT Highly safe, novel recombinant staphylokinase (Sak) produced from high-
PT expression engineered strain - as plasminogen activator, with very high
PT hydrolytic activity to human fibrin, useful in treating thrombembolia
PT diseases e.g. myocardial infarction.
XX
PS Claim 12; Page 26; 51pp; Chinese.
XX
CC Sequences AAX27542-43 represent PCR primers for the amplification of the
CC DNA encoding a recombinant staphylokinase (Sak). The Sak-producing
CC Staphylococcus aureus SL1.063 is deposited as CGMCC No.0353. The
CC invention provides a method for constructing a Sak-producing engineered
CC strain which comprises (a) screening Sak-producing Staphylococcus aureus;
CC obtaining a regulated Sak gene by PCR (polymerase chain reaction)
CC amplification with chromosomal DNA of Sak-producing S. aureus as
CC template, with primers (AAX27542-43) (b) introduction of the obtained DNA
CC fragment into a plasmid selected from pUC19 and pBV220; and (c)
CC transferring the recombinant plasmid into a host cell such as E. coli of
CC DH5 alpha. Tc1 or Tc2 strains. The staphylokinase can be applied in
CC treatment of myocardial infarction, thrombembolia diseases and arterial
CC thrombosis including cerebral and pulmonary thrombi. Hydrolytic activity
CC of the staphylokinase to human fibrin is very high
XX

[illegible]

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841

MM 04-DEC-2003 (first entry)
DT

DE Human map-related biallelic marker SEQ ID NO:240.
 XX Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation; diagnosis;
 KW single nucleotide polymorphism; SNP; ds.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH variation replace(24,T)
 FT /tag=a
 FT /standard_name="single nucleotide polymorphism"
 XX
 PN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PP 21-APR-1999; 99WO-IB000822.
 XX
 XX 21-APR-1998; 98US-0082614P.
 BR 23-NOV-1998; 98US-0109732P.
 PR
 XX (GIST) GENSET.
 PA
 XX Cohen D, Blumenfeld M, Chumakov I;
 P1
 XX WPI, 2000-013267/01.
 DR
 XX Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX
 PS Claim 1; Page 281; 2745pp; English.
 XX
 CC AA65654 to AA69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AA656579 to AA677440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 CC
 CC
 XX
 SQ Sequence 47 BP; 18 A; 6 C; 7 G; 16 T; 0 U; 0 Other;
 Qy Query Match 34.5%; Score 15.2; DB 3; Length 47;
 Best Local Similarity 63.9%; Pred. No. 1.3e+04;
 Matches 23; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
 GY 9 CGTCCCTTAATACCGGCGGCTTATTAGAA 44
 DB 46 CATTTAATTTAATACATGCTGCTTTGAAAA 11
 ID AAF91472 standard; DNA; 47 BP.
 XX AAF91472;
 AC
 XX
 DT 04-MAY-2001 (first entry)
 XX
 XX N. meningitidis Nspa upstream sequence inverse PCR primer PNS4.
 DE Modified Gram-negative bacterium; outer membrane vesicle; bleb; vaccine;
 XX genetically modified; protective antigen expression; LPS detoxification;
 KW

KW LPS; lipid A; homologous recombination vector; immunisation;
 KW immunoprotective; non-toxic; paediatric; plasmid construction;
 KW modified Neisseria meningitidis; PCR primer; ss.
 XX
 OS Neisseria meningitidis.
 XX
 PN WO200109350-A2.
 XX
 PD 08-FEB-2001.
 XX
 PF 31-JUL-2000; 2000WO-EP007424.
 XX
 PR 03-AUG-1999; 99GB-00018319.
 XX
 PA (SMIX) SMITHKLINE BEECHAM BIOLOGICALS.
 XX
 PI Berthet FJ, Dalemans WLJ, Denoel P, Deguesne G, Feron C, Lobet Y;
 PI Poolman J, Thiry G, Thonnard J, Voet P;
 DR WPI, 2001-138654/14.
 XX
 PT New isolated polynucleotide useful for outer membrane vesicle preparation
 PT from Gram-negative bacterial strain for vaccination of microbial
 PT infections.
 XX
 PS Example 6; Page 47; 128pp; English.
 XX
 CC The invention relates to a genetically-engineered outer membrane vesicle
 CC (bleb) preparation from a Gram-negative bacterium for use as a vaccine.
 CC The blebs of the invention are improved with respect to their
 CC immunogenicity and toxicity by the introduction of one or more genetic
 CC changes to the chromosome of the bacterium from which the blebs are
 CC derived. The changes made include the upregulation of protective antigen
 CC expression, the downregulation of immunodominant non-protective antigen
 CC expression, and genetic changes which result in detoxification of the
 CC lipid A moiety of lipopolysaccharide (LPS). The invention also
 CC encompasses modified Gram-negative bacterial strains from which the bleb
 CC preparations are made, a vector suitable for performing recombination
 CC events (for the generation of the modified bacterial strains),
 CC bacterially-derived nucleic acid sequences used in such a vector, and an
 CC immunoprotective and non-toxic Gram-negative bleb, ghost, or killed whole
 CC cell vaccine suitable for paediatric use. The bleb preparation is useful
 CC in the manufacture of a medicament for immunising a human host against a
 CC disease caused by infection of one or more of the following: Neisseria
 CC meningitidis, Neisseria gonorrhoeae, Haemophilus influenza, Moraxella
 CC catarrhalis, Pseudomonas aeruginosa, Chlamydia trachomatis, and Chlamydia
 CC pneumoniae. The invention may also be used to provide immunisation against
 CC the influenza virus. Bacterially derived nucleotide sequences of the
 CC invention are used in the performance of homologous recombination events
 CC up to 1000 bp upstream of a bacterial chromosomal gene in order to either
 CC increase or decrease expression of that gene. Immunoprotective and non-
 CC toxic Gram-negative bleb, ghost, or killed whole cell vaccines are more
 CC immunogenic, less toxic and safer, and are particularly useful for
 CC paediatric use. The present sequence represents a PCR primer used in the
 CC production of a plasmid used in the generation of a modified Neisseria
 CC meningitidis strain
 CC
 CC
 XX
 SQ Sequence 47 BP; 15 A; 9 C; 6 G; 17 T; 0 U; 0 Other;
 Qy Query Match 34.5%; Score 15.2; DB 4; Length 47;
 Best Local Similarity 71.4%; Pred. No. 1.3e+04;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 GY 17 CTTAATACCGGCGGCTTATTAGAA 44
 DB 41 CATATTTCCGACCGCGTTAATTAAGA 14
 ID ABR37852 standard; DNA; 47 BP.
 XX ABR37852;
 AC


```

XX 08-MAY-2002 (first entry)
DT
XX pCMK(+) construction PCR primer #17.
DE
XX pCMK(+), ss; PCR; primer; antibacterial; vaccine; bleb;
XX Gram-negative bacteria; outer membrane; LPS; lipopolysaccharide;
XX meningitis; bacteraemia; otitis media; pneumonia; chronic bronchitis;
XX sinusitis.
XX
XX Neisseria meningitidis.
OS
XX WO200209746-A2.
XX
XX 07-FEB-2002.
XX
XX 31-JUL-2001; 2001WO-EP008857.
XX
XX 31-JUL-2000; 2000WO-EP007424.
XX
XX 08-FEB-2001; 2001GB-00003170.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Berthel FJ, Dalemans W, Denoel P, Dequesne G, Ferron C, Garcon N;
XX Lopet Y, Poolman J, Thiry G, Thomard J, Voet P;
XX
XX WPI; 2002-188688/24.
XX
XX New immunogenic composition comprising an antigen derived from a pathogen
XX and a blep preparation from Neisseria meningitidis, useful as a vaccine
XX for treating or preventing disease caused by the pathogen.
XX
XX Example 2; Page 49; 125pp; English.
XX
XX The invention relates to an immunogenic composition comprising an antigen
XX derived from a pathogen capable of protecting a host against the
XX pathogen, mixed with an adjuvant comprising a bleb preparation derived
XX from a Gram-negative bacterial strain. The immunogenic composition
XX consists of N. meningitidis B blebs or N. meningitidis C polysaccharide
XX antigen. The blebs (derived from the outer membrane) may also have their
XX toxic lipopolysaccharide (LPS) content reduced using heterologous down
XX regulating sequences for LPS pathway genes or by up regulating genes
XX involved in LPS synthesis suppression, by a promoter replacement
XX technique. The immunogenic preparation is useful in the manufacture of a
XX medicament for the treatment of a disease caused by the pathogen from
XX which the antigen is derived (e.g. from Neisseria, meningitis and
XX bacteraemia, from Moraxella, otitis media and pneumonia, and from H.
XX influenzae chronic bronchitis, sinusitis, pneumonia and otitis media).
XX The bleb derived from M. catarrhalis or from a non-typable H. influenzae
XX is useful as an adjuvant in an immunogenic composition comprising one or
XX more pneumococcal capsular polysaccharides or protein antigens. The
XX present sequence is a PCR primer used to construct the gene delivery
XX vector pCMK(+) for producing N. meningitidis strains producing
XX recombinant blebs
XX
XX Sequence 47 BP; 15 A; 9 C; 6 G; 17 T; 0 U; 0 Other;
SQ
XX
XX Query Match 34.5%; Score 15.2; DB 6; Length 47;
XX Best Local Similarity 71.4%; Pred. No. 1.3e+04;
XX Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
XX
XX 17 CTTAATTAACCGGTGCGGTTATTAAAGA 44
XX | | | | | | | | | | | | | | | |
XX 41 CATATTTTCGACGCGGTTAATTAAGA 14
XX
XX RESULT 15
XX AA130035/C
XX ID AA130035 standard; DNA; 31 BP.
XX
XX AA130035;
XX
XX 04-NOV-2004 (revised)
DT

```

```

DT 18-OCT-2001 (first entry)
XX
XX Human single nucleotide polymorphism (SNP) 72.
DE
XX Human; resequence; genotype; disease; forensic; paternity testing;
XX single nucleotide polymorphism; SNP; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX variation 16
XX FT /**tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200166800-A2.
XX
XX 13-SEP-2001.
XX
XX 07-MAR-2001; 2001WO-US007268.
XX
XX 07-MAR-2000; 2000US-0187510P.
XX
XX 22-MAY-2000; 2000US-0206129P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2001-522952/57.
XX
XX Nucleic acid molecules from the human genome which include polymorphic
XX sites, useful in methods for predicting the presence, absence or severity
XX of a particular phenotype or disorder (e.g. diabetes) associated with a
XX particular genotype.
XX
XX Claim 1; Page 64; 145pp; English.
XX
XX The invention relates to the identification of nucleic acid molecules
XX (AA129513-AA13134) from the human genome which include polymorphic sites
XX which can predispose individuals to disease. Various genes from a number
XX of individuals were resequenced and single nucleotide polymorphisms
XX (SNPs) in these genes were discovered. The method is useful for predicting the
XX presence, absence or severity of a particular phenotype or disorder (e.g.
XX diabetes) associated with a particular genotype. The nucleic acids
XX containing the polymorphic sites may be useful in forensics and paternity
XX testing
XX
XX Revised record issued on 04-NOV-2004 : Correction to Feature Table Key
XX
XX Sequence 31 BP; 12 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 34.1%; Score 15; DB 4; Length 31;
XX Best Local Similarity 78.3%; Pred. No. 1.4e+04;
XX Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
XX
XX 12 TCCTTCTTAATACCGGTGCGG 34
XX | | | | | | | | | | | | | | | |
XX 29 TCTTCTTAATGAGCTGCGG 7
XX
XX RESULT 16
XX AA269059
XX ID AA269059 standard; DNA; 47 BP.
XX
XX AA269059;
XX
XX 10-SEP-2001 (first entry)
XX
XX Human map-related biallelic marker SEQ ID NO:3415.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation; diagnosis;
XX single nucleotide polymorphism; SNP; ds.
XX

```



```

XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX Variation replace(24,G)
XX FT /**tag=a
XX FT /standard_name="single nucleotide polymorphism"
XX
XX PN WO954500-A2.
XX
XX PD 28-OCT-1999.
XX
XX PF 21-APR-1999; 99WO-IB000822.
XX
XX PR 21-APR-1998; 98US-0082614P.
XX PR 23-NOV-1998; 98US-0109732P.
XX
XX PA (GEST ) GENSET.
XX
XX PI Cohen D, Blumenfeld M, Chumakov I;
XX
XX DR WPI; 2000-013267/01.
XX
XX PT Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX PS Claim 3; Page 959; 2745pp; English.
XX
XX CC AAZ65654 to AAZ6578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ6579 to AAZ7740 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses; they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX CC Identification and methods of the invention can also be useful for the
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX CC pharmaceutical agents acting on a disease as well as other treatment.
XX CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX SQ Sequence 47 BP; 16 A; 13 C; 5 G; 13 T; 0 U; 0 Other;
XX
XX Query Match 34.1%; Score 15; DB 3; Length 47;
XX Best Local Similarity 67.7%; Pred. No. 1.6e+04;
XX Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
XX
XX QY 10 GTTCCTCTTAATACCGGCGGTTATTA 40
XX ||||| ||||| ||||| |||||
XX 16 GTTCATCTTAATAACCATCTCTGCTCTA 46
XX
XX RESULT 17
XX ABZ02614
XX ID ABZ02614 standard; DNA, 50 BP.
XX
XX AC ABZ02614;
XX
XX DT 09-JAN-2003 (first entry)
XX
XX DE Human leukocyte gene expression profiling probe SEQ ID NO 2605.
XX
XX XX T7; leukocyte; gene expression profiling; allograft rejection;
XX KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;
XX KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
XX ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200257414-A2.

```

```

XX PD 25-JUL-2002.
XX
XX PR 22-OCT-2001; 2001WO-US047856.
XX
XX PR 20-OCT-2000; 2000US-0241994P.
XX PR 08-JUN-2001; 2001US-0296764P.
XX
XX PA (BIOC-) BIOCARDIA INC.
XX
XX PI Wohlgemuth J, Fry K, Marcuk G, Altman P, Prentice J, Phillips J;
XX PI Ly N, Woodward R, Quartermous T, Johnson F;
XX
XX DR WPI; 2002-636525/68.
XX
XX PT New system for leukocyte expression profiling, diagnosing a disease, or
XX PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
XX or congestive heart failure, comprises diagnostic oligonucleotides.
XX
XX PS Claim 1; Page 410; 0pp; English.
XX
XX CC The invention relates to a system for detecting gene expression, which
XX CC comprises one or two isolated DNA molecules that detect expression of a
XX CC gene, where the gene corresponds to any of 8143 oligonucleotides
XX CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
XX CC for leukocyte expression profiling. It is particularly useful for
XX CC diagnosing a disease, monitoring (rate of) progression of a disease,
XX CC predicting therapeutic outcome, determining prognosis for a patient,
XX CC predicting disease complications in an individual or monitoring response
XX CC to treatment in an individual. The diseases include cardiac allograft
XX CC rejection, kidney allograft rejection, liver allograft rejection,
XX CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
XX CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
XX SQ Sequence 50 BP; 9 A; 8 C; 8 G; 25 T; 0 U; 0 Other;
XX
XX Query Match 34.1%; Score 15; DB 6; Length 50;
XX Best Local Similarity 67.7%; Pred. No. 1.6e+04;
XX Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
XX
XX QY 14 CTCTTAATAACCGGCGGTTATTAAGA 44
XX ||||| ||||| ||||| |||||
XX 2 CTGCTCATCTCTTTGCGGTTATTTGAA 32
XX
XX RESULT 18
XX ABZ07725/C
XX ID ABZ07725 standard; DNA, 50 BP.
XX
XX AC ABZ07725;
XX
XX DT 09-JAN-2003 (first entry)
XX
XX DE Human leukocyte gene expression profiling probe SEQ ID NO 7716.
XX
XX XX T7; leukocyte; gene expression profiling; allograft rejection;
XX KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;
XX KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
XX ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200257414-A2.
XX
XX PD 25-JUL-2002.
XX
XX PF 22-OCT-2001; 2001WO-US047856.
XX
XX PR 20-OCT-2000; 2000US-0241994P.
XX PR 08-JUN-2001; 2001US-0296764P.
XX
XX PA (BIOC-) BIOCARDIA INC.
XX

```

PI Wohlgenuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J,
 PI Ly N, Woodward R, Quettermous T, Johnson F,
 DR WPI; 2002-636525/68.
 XX
 PT New system for leukocyte expression profiling, diagnosing a disease, or
 PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
 PT or congestive heart failure, comprises diagnostic oligonucleotides.
 XX
 PS Claim 1, Page 576; Opp, English.
 CC The invention relates to a system for detecting gene expression, which
 CC comprises one or two isolated DNA molecules that detect expression of a
 CC gene, where the gene corresponds to any of 8143 oligonucleotides
 CC (AB200010-AB208152) each having 50 base pairs (bp). The system is useful
 CC for leukocyte expression profiling. It is particularly useful for
 CC diagnosing a disease, monitoring (rate of) progression of a disease,
 CC predicting therapeutic outcome, determining prognosis for a patient,
 CC predicting disease complications in an individual or monitoring response
 CC to treatment in an individual. The diseases include cardiac allograft
 CC rejection, kidney allograft rejection, liver allograft rejection,
 CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
 CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
 XX
 SQ Sequence 50 BP, 15 A, 9 C, 13 G, 13 T, 0 U, 0 Other;
 Query Match 34.1%; Score 15; DB 6; Length 50;
 Best Local Similarity 67.7%; Pred. No. 1.6e+04;
 Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
 12 TCCTTCTTAATACCGGTCCGGTTATTAG 42
 49 TTCTTCTTCAATAGAGTCGCTTTGAAAG 19
 OY
 Db
 RESULT 19
 ID ABR59783/c
 ID ABR59783 standard; DNA, 31 BP.
 XX
 AC ABR59783;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human CLCA1 gene enzymatic nucleic acid #4154.
 XX
 KM Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KM antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KM chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KM oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KM acetylcysteine.
 XX
 KM Homo sapiens.
 OS
 XX
 PN WO200211674-A2.
 XX
 PD 14-FEB-2002.
 XX
 PF 09-AUG-2001; 2001WO-US024970.
 XX
 PR 09-AUG-2000; 2000US-0224383P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (SYNT) SYNTX USA LLC.
 PA (THOM/) THOMPSON J.
 XX
 PI Thompson J, Mcswigen J, McKenzie T, Ayers D, Szymkowski DB;
 PI Grube A;
 XX
 DR WPI; 2002-217145/27.
 XX
 PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.

XX
 XX Claim 5, Page 105; 152pp; English.
 PS
 CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX
 SQ Sequence 31 BP, 9 A, 7 C, 11 G, 4 T, 0 U, 0 Other;
 Query Match 33.6%; Score 14.8; DB 6; Length 31;
 Best Local Similarity 73.1%; Pred. No. 1.8e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 5 GTCCCGTTCCTTAAATACCGGTC 30
 30 GTCCCGTTCGTTAGCTAGCCGCTC 5
 OY
 Db
 RESULT 20
 ID AAF81443
 ID AAF81443 standard; DNA, 36 BP.
 XX
 AC AAF81443;
 XX
 DT 08-JUN-2001 (first entry)
 XX
 DE PCR primer GSP2 for corn promoter clone #70343485.
 XX
 KM Corn; promoter; transgenic plant; herbicide resistance; PCR primer; ss.
 OS
 XX
 OS Zea mays.
 XX
 PN WO200119976-A2.
 XX
 PD 22-MAR-2001.
 XX
 PF 13-SEP-2000; 2000WO-US025078.
 XX
 PR 16-SEP-1999; 99US-0154182P.
 XX
 PA (MONS) MONSANTO CO.
 PA
 PI Anderson HM, Chay CA, Chen G, Conner TW;
 PI
 XX
 DR WPI; 2001-244796/25.
 XX
 PT Novel promoter nucleic acid sequences useful for regulating heterologous
 PT gene expression in plants, comprising regulatory sequences located
 PT upstream to plant DNA structural coding sequences.
 XX
 PS Example 3; Page 87; 101pp; English.
 CC The present invention relates to novel corn promoter sequences (see
 CC AAF81456-AAF81478). The promoter sequences are useful for conferring
 CC expression of a second polynucleotide molecule in a transgenic plant
 CC tissue. In addition, the promoter sequences are useful for providing
 CC plants with herbicide resistance. The promoter sequences are suitable for
 CC selectively modulating expression of any operatively linked gene and
 CC provide additional regulatory element diversity in a plant expression

CC vector in gene stacking approaches. The present sequence is a PCR primer
CC used in the present invention

XX Sequence 36 BP; 6 A; 11 C; 9 G; 10 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 4; Length 36;
Best Local Similarity 73.1%; Pred. No. 1.8e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATTAACCGGTCGCG 34
Db 6 CTTTCTTCTCACTCAGCGGTCGCG 31

RESULT 21.
AAD43960/C
ID AAD43960 standard; DNA; 39 BP.

XX AAD43960;
XX 14-NOV-2002 (first entry)

DE DI228 oligo used to assemble beta-amyloid gene subfragment.

XX Amyloidogenic protein; Alzheimer's disease; Huntington's disease;
XX spongiform encephalopathy; familial amyloid cardiomyopathy; amyloidosis;
XX Gerstmann-Strausler-Scheinker syndrome; spongiform encephalopathy; GSS;
XX Creutzfeldt-Jacob disease; insulinoma; diabetes; body myocytis; myeloma;
XX C_β beta-amyloid; ss.

OS Unidentified.

XX MO200242462-A2.

XX 30-MAY-2002.

XX 27-NOV-2001; 2001WO-US044581.

XX 27-NOV-2000; 2000US-0253302P.

XX 29-NOV-2000; 2000US-0250198P.

XX 20-DEC-2000; 2000US-0257186P.

XX (PRAE-) PRAECTIS PHARM INC.

XX Gafter ML, Israel DI, Joyal JL, Gosselin M;

XX WPI; 2002-636427/68.

PT Novel therapeutic agent useful for treating an amyloidogenic disorder,
PT e.g. Alzheimer's disease, comprises an immunoglobulin heavy chain
PT constant region linked to a peptide capable of binding amyloidogenic
PT protein.

XX Example 4; Fig 7A; 79pp; English.

XX The invention relates to a compound comprising an immunoglobulin (Ig)
CC heavy chain constant region or its fragment that retains the ability to
CC bind an Fc receptor linked by a linker group or a direct bond to a
CC peptide capable of binding an amyloidogenic protein. The invention is
CC useful for clearing an amyloidogenic protein such as beta-amyloid,
CC transthyretin (TTR), prion protein (PrP), islet amyloid polypeptide
CC (IAPP), atrial natriuretic factor (ANF), kappa light chain, lambda light
CC chain, amyloid A, procollagen, cystatin C, beta2-microglobulin, Apol-I,
CC gelsolin, calcitonin, fibrinogen, huntington, alpha-synuclein and
CC lysozyme from a subject and for treating an amyloidogenic disorder such
CC as Alzheimer's disease and spongiform encephalopathy. Disorders treatable
CC include those caused or characterised by deposits of TTR (eg. familial
CC amyloid cardiomyopathy), PrP (eg. spongiform encephalopathies, including
CC scrapie in sheep, bovine spongiform encephalopathy in cows and
CC Creutzfeldt-Jacob disease (CJ) and Gerstmann-Strausler-Scheinker
CC syndrome (GSS) in humans), IAPP (eg. insulinoma, adult onset diabetes),
CC ANF (eg. isolated atrial amyloid), kappa or lambda light chain (eg.
CC idiopathic amyloidosis, myeloma), amyloid A (eg. amyloidosis), Apo A-I

CC (eg. hereditary non-neuropathic systemic amyloidosis), gelsolin (eg.
CC familial amyloidosis of Finnish type), fibrinogen (eg. hereditary renal
CC amyloidosis), lysozyme (eg. hereditary systemic amyloidosis). Other
CC examples of amyloidogenic disorders include Huntington's disease and
CC inclusion body myocytis. The present sequence is an oligonucleotide used
CC to assemble beta amyloid gene subfragment

SQ Sequence 39 BP; 14 A; 10 C; 8 G; 7 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 6; Length 39;
Best Local Similarity 73.1%; Pred. No. 1.8e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATTAACCGGTCGCG 34
Db 36 CATTCTTCTTATGTTCTGTCGCG 11

RESULT 22
AAZ67378/C
ID AAZ67378 standard; DNA; 47 BP.

XX AAZ67378;
XX 10-SEP-2001 (first entry)

XX Human map-related biallelic marker SEQ ID NO:1725.
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation; diagnosis;
XX single nucleotide polymorphism; SNP; ds.

OS Homo sapiens.

XX W09954500-A2.

XX 28-OCT-1999.

XX 21-APR-1999; 99WO-IB000822.

XX 21-APR-1998; 98US-0082614P.

XX 23-NOV-1998; 98US-0109732P.

XX (GSET) GENSET.

XX Cohen D, Blumenfeld M, Chumakov I;

XX WPI; 2000-013267/01.

PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.

XX Claim 1; Page 598; 2745pp; English.

XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ65654 to AAZ69578 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and

CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX
 SO Sequence 47 BP; 18 A; 4 C; 13 G; 12 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 3; Length 47;
 Best Local Similarity 59.5%; Pred. No. 1.9e+04;
 Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 3 GGGTCCGGTCTTATTAACCGGTGCGGTTATTAGAA 44
 |||||
 Db 46 GGGTCCCATCTCTTTATTAAGTTAGCACCATTATTATA 5

RESULT 23
 AA069835/c
 ID AA069835 standard; DNA; 50 BP.
 XX
 AC AA069835;

XX 25-MAR-2003 (revised)
 DT 06-MAR-1995 (first entry)
 XX

DE Human papilloma virus type-16 E6/E7 (start site 97), target region.

XX DNA protein-binding assay; test sequence; screening sequence; promoter;
 KW target; TATA box; Herpes Simplex Virus; HSV; origin of replication; U9;
 KW transcription factor; TFIID: ds.

XX Synthetic.

XX MO9414980-A1.

XX 07-JUL-1994.

XX 20-DEC-1993; 93WO-US012388.

XX 23-DEC-1992; 92US-00996783.

XX 17-SEP-1993; 93US-00123936.

XX (GENE-) GENELABS TECHNOLOGIES INC.

XX Edwards CA, Cantor CR, Andrews BM, Turin LM, Fry KE;

XX WPI, 1994-234711/28.

PT Sequence-directed DNA-binding molecules - useful in pharmaceuticals and
 PT as molecular reagents.

PS Claim 28; Page 504; 587DP; English.

XX A DNA protein-binding assay is provided, useful for screening libraries
 CC of synthetic or biological cpds. for their ability to bind DNA test
 CC sequences. The assay is versatile in that any number of test sequences
 CC can be tested by placing the test sequence adjacent to a defined protein-
 CC binding screening sequence. Binding of mols. to these test sequences
 CC changes the binding characteristics of the protein mol. to its cognate
 CC binding sequence. When such a mol. binds the test sequence, the
 CC equilibrium of the DNA:protein complexes is disturbed, generating changes
 CC in the concentration of free DNA probe. One application of this method is
 CC to eucaryotic general transcription factors (e.g. TFIID), where the
 CC target region is typically selected from DNA sequences adjacent to the
 CC binding site for the eucaryotic transcription factor. Numerous exemplary
 CC test sequences are given: the sequences in AA069251-731 and AA069850
 CC correspond to promoter targets (typically, TATA box-contg. sites) for
 CC human genes and the sequences in AA069732-849 correspond to promoter
 CC targets for viral genes. The test sequences may also be randomly
 CC generated. DNA:protein interaction may be used for screening purposes,
 CC e.g. the Herpes Simplex Virus (HSV) origin of replication and U9 (see
 CC AA069851-52, AA069865 and AA069891). (Updated on 25-MAR-2003 to correct
 CC PN field.)
 XX
 SO Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 2; Length 50;
 Best Local Similarity 73.1%; Pred. No. 1.9e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCTTCTTAATACCGGTGCGGTT 36
 |||||
 Db 27 TGCTTTATACTACCGGTTCGTT 2

RESULT 24
 AAT64297/c
 ID AAT64297 standard; DNA; 50 BP.
 XX
 AC AAT64297;

XX 25-MAR-2003 (revised)
 DT 17-MAR-1997 (first entry)
 XX

DE HPV type 16 E6/E7 gene (start site 97) TFIID binding site.

XX Duplex DNA; target region; binding characteristic; DNA binding protein;
 KW TFIID; transcription factor; binding site; inhibition; enhance; cancer;
 KW inherited genetic disorder; ds.

XX Human papillomavirus.

XX US5578444-A.

XX 26-NOV-1996.

XX 20-DEC-1993; 93US-00171389.

XX 27-JUN-1991; 91US-00723618.

XX 23-DEC-1992; 92US-00996783.

XX 17-SEP-1993; 93US-00123936.

XX (GENE-) GENELABS TECHNOLOGIES INC.

XX Fry KE, Turin LM, Andrews BM, Cantor CR, Edwards CA;

XX WPI, 1997-020402/02.

PT Altering binding characteristics of DNA binding proteins to duplex DNA -
 PT by attaching specific small cpd. to target region close to the protein's
 PT binding site, useful in treatment of viral disease, cancer etc.

PS Claim 6; Col 399; 264pp; English.

XX The sequences given in AAT63713-4312 represent duplex DNA's which act as
 CC target regions in the method of the invention. The method for altering
 CC the binding characteristics of a DNA-binding protein to duplex DNA
 CC comprises contacting the duplex DNA with a small molecule which binds
 CC sequence-specifically to a target region, where, when the small molecule
 CC is bound to the target region, it is adjacent to, but not overlapping by
 CC more than 4 bp, a binding site for a DNA-binding protein. The small
 CC molecule is added at a concentration effective to alter the binding of
 CC the DNA binding protein, pref. TFIID, to its binding site on the duplex
 CC DNA. The binding of the small molecule may inhibit or enhance the binding
 CC of the DNA-binding protein to its binding site. The compounds isolated
 CC using this method are potentially useful as therapeutic agents for
 CC treatment of any disease which involves a specific DNA sequence, e.g.
 CC cancer, or inherited genetic disorders etc. The method is suitable for
 CC screening large biological or chemical libraries and allows determination
 CC of sequence-specific and relative affinities of known DNA-binding agents
 CC for different DNA sequences. The design of these duplex DNA's allows a
 CC single DNA:protein interaction to be used for screening sequence-
 CC specific, or preferential, DNA binding proteins that recognise almost any
 CC possible sequence (see also AAT9539-74). (Updated on 25-MAR-2003 to
 CC correct PF field.)
 XX
 SO Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 2; Length 50;
 Best Local Similarity 73.1%; Pred. No. 1.9e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

11 TTCCCTTTAATACCGGTCGGGTT 36
 27 TGCCTTTATACCAACCGGTTGCGTT 2

RESULT 25
 AAX17585/c
 ID AAX17585 standard; DNA; 50 BP.

AC AAX17585;
 DT 06-MAY-1999 (first entry)

DE Test sequence from human papilloma virus type-16 B6/E7 (start site 97).
 KW Test sequence; DNA-binding molecule; screening sequence; human;
 KM nucleic acid amplification; target; viral; ds.
 OS Human papillomavirus.
 US5869241-A.
 09-FEB-1999.
 07-JUN-1995; 95US-00475228.
 27-JUN-1991; 91US-00723618.
 23-DEC-1992; 92US-0096783.
 17-SEP-1993; 93US-00123936.
 20-DEC-1993; 93US-00171389.

(GENE-) GENELABS TECHNOLOGIES INC.
 Fry KE, Turin LM, Andrews BM, Cantor CR, Edwards CA;
 WPI; 1999-152755/13.

Determination of DNA sequence preference of a DNA-binding molecule -
 based on inhibition of binding of protein to oligonucleotide sequence
 attached to test sequence.

Claim 3; Col 399-400; 270pp; English.

Sequences AAX17001 to AAX17600 represent specifically claimed target test
 sequences that are used in the method of the invention of determining the
 DNA sequence preference of a DNA-binding molecule. The method comprises:
 (i) adding a test molecule and a DNA-binding protein to a mixture of
 duplex DNA test oligonucleotides, each of the test oligonucleotides
 having a test sequence adjacent to a screening sequence, where the
 screening sequence binds to the DNA-binding protein with a binding
 affinity that is independent of the DNA sequence of the test sequence,
 and where the mixture of duplex DNA test oligonucleotides includes
 several test sequences; (ii) incubating the test molecule, the mixture of
 duplex DNA test oligonucleotides and the DNA-binding protein for a time
 sufficient to permit binding of the test molecule to test sequences in
 the duplex DNA; (iii) separating unbound test oligonucleotides from test
 oligonucleotides bound to binding protein; (iv) amplifying the unbound
 test oligonucleotides; (v) repeating steps (ii) to (iv); (vi) isolating
 the amplified test oligonucleotides; and (vii) sequencing the isolated
 test oligonucleotides. Test sequences AAX17001-X17481 and AAX17600
 correspond to promoter targets for human genes and test sequences
 AAX17482-X17595 correspond to promoter targets for viral genes

Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 2; Length 50;
 Best Local Similarity 73.1%; Pred. No. 1.9e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

11 TTCCCTTTAATACCGGTCGGGTT 36
 27 TGCCTTTATACCAACCGGTTGCGTT 2

RESULT 26
 ABR83076/c
 ID ABR83076 standard; DNA; 50 BP.

AC ABR83076;
 DT 27-AUG-2002 (first entry)

DE DNA binding molecule screening method test sequence #585.
 KW human immunodeficiency virus; HIV; parasite; cancer; cardiovascular;
 respiratory; gastrointestinal; endocrine; metabolic; rheumatic;
 immunological; haematological; neurological; psychiatric; dermatological;
 ophthalmological; musculo-skeletal; urogenital disorder; ss.
 OS Synthetic.
 US6384208-B1.
 07-MAY-2002.
 15-JUL-1999; 99US-00354947.
 27-JUN-1991; 91US-00723618.
 23-DEC-1992; 92US-0096783.
 17-SEP-1993; 93US-00123936.
 20-DEC-1993; 93US-00171389.
 07-JUN-1995; 95US-00482080.

(GENE-) GENELABS TECHNOLOGIES INC.
 Edwards CA, Cantor CR, Andrews BM, Turin LM, Fry KE;
 WPI; 2002-442819/47.

Decreasing transcriptional activity of genes for treating infections or
 cancer, by administration of an agent that binds to two non-overlapping
 regions of the gene.

Example 15; SEQ ID NO 585; 98pp; English.

The invention relates to a method of decreasing transcriptional activity
 in a duplex deoxyribonucleic acid (DNA) template (T1) comprising
 contacting (T1) with a binding agent comprising at least one small duplex
 DNA-binding molecule (T2) coupled to at least one other small duplex-
 binding molecule that binds to a non-overlapping region of target
 sequence (TS). The method is useful for inhibiting transcription of a
 range of disease-related genes for treating infections (by viruses,
 including human immunodeficiency virus, bacteria, fungi, protozoa and
 parasites), cancer, cardiovascular, respiratory, gastrointestinal,
 endocrine/metabolic, rheumatic/immunological, haematological, musculo-
 skeletal, genetic or urogenital disorders. The method provides sequence-
 specific inhibition of transcription of pathological genes without
 affecting transcription of cellular genes regulated by the same
 transcription factor, and can be applied to regulation of any gene.
 ABR82492-ABR83155 represent DNA binding molecule test sequences used in
 the method of the invention

Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 6; Length 50;
 Best Local Similarity 73.1%; Pred. No. 1.9e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

11 TTCCCTTTAATACCGGTCGGGTT 36
 11 TTCCCTTTAATACCGGTCGGGTT 36

Db	27	TGCTTTATACTAACCGGTTCCGGT	2
RESULT 27			
ABZ02818			
ID	ABZ02818	standard; DNA; 50 BP.	
XX			
AC	ABZ02818;		
DT	09-JAN-2003	(first entry)	
XX			
DE	Human leukocyte gene expression profiling probe seq	ID NO 2809.	
XX			
KM	T7; leukocyte; gene expression profiling; allograft rejection;		
KM	atherosclerosis; congestive heart failure; systemic lupus erythematosus;		
KM	rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;		
ss.			
XX			
OS	Homo sapiens.		
XX			
PN	WO200257414-A2.		
PD	25-JUL-2002.		
XX			
PE	22-OCT-2001; 2001WO-US047856.		
XX			
PR	20-OCT-2000; 2000US-0241994P.		
PR	08-JUN-2001; 2001US-0296764P.		
PA	(BIOC-) BIOCARDIA INC.		
XX			
P1	Wohlgenuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;		
P1	Ly N, Woodward R, Quenterious T, Johnson F;		
XX			
DR	WPI; 2002-636525/68.		
XX			
PT	New system for leukocyte expression profiling, diagnosing a disease, or		
PT	monitoring (the rate of) progression of a disease, e.g. atherosclerosis		
PT	or congestive heart failure, comprises diagnostic oligonucleotides.		
XX			
PS	Claim 1; Page 417; 0pp; English.		
XX			
CC	The invention relates to a system for detecting gene expression, which		
CC	comprises one or two isolated DNA molecules that detect expression of a		
CC	gene, where the gene corresponds to any of 8143 oligonucleotides		
CC	(ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful		
CC	for leukocyte expression profiling. It is particularly useful for		
CC	diagnosing a disease, monitoring (rate of) progression of a disease,		
CC	predicting therapeutic outcome, determining prognosis for a patient,		
CC	predicting disease complications in an individual or monitoring response		
CC	to treatment in an individual. The diseases include cardiac allograft		
CC	rejection, kidney allograft rejection, liver allograft rejection,		
CC	atherosclerosis, congestive heart failure, systemic lupus erythematosus,		
CC	rheumatoid arthritis, osteoarthritis or cytomegalovirus infection		
XX			
SQ	Sequence 50 BP; 19 A; 6 C; 9 G; 16 T; 0 U; 0 Other;		
Query Match	33.6%;	Score 14.8;	DB 6;
Best Local Similarity	64.7%;	Pred No.1.9e+04;	
Matches 22;	Conservative 0;	Mismatches 12;	Indels 0;
	Gaps 0;		
QY	11 TTCCCTTCTTAATACCGGTCGGGCTTATTAGAA 44		
Db	10 TTTCTGCAGCATTAAAGCTGGCGCTTAATAGAA 43		
RESULT 28			
ADE80615/C			
ID	ADE80615	standard; DNA; 50 BP.	
XX			
AC	ADE80615;		
XX			
DT	29-JAN-2004	(first entry)	

XX	Duplex oligonucleotide for DNA protein binding assay seq id 585.
DE	
XX	DNA-binding; duplex DNA test oligonucleotide; DNA protein binding;
KM	library screening; promoter target; virus; ds.
XX	
OS	Human papillomavirus.
PM	US2003124530-A1.
XX	
PD	03-JUL-2003.
XX	
PF	13-NOV-2001; 2001US-00993346.
XX	
PR	27-JUN-1991; 91US-00723618.
PR	23-DEC-1992; 92US-0096783.
PR	17-SEP-1993; 93US-00123936.
PR	20-DEC-1993; 93US-00171389.
PR	07-JUN-1993; 95US-00482080.
PR	15-JUL-1999; 99US-00354947.
PA	(GENE-) GENELABS TECHNOLOGIES INC.
XX	
PI	Edwards CA, Cantor CR, Andrews BM, Turin LM, Fry KE;
XX	WPL; 2004-031270/03.
DR	
PT	Screening for sequence-directed DNA-binding molecules comprises adding a
PT	test molecule to a test system composed of a DNA-binding protein and a
PT	duplex DNA test oligonucleotide having adjacent screening and test
PT	sequences.
XX	
PS	Claim 2; SEQ ID NO 585; 283bp; English.
XX	
CC	The invention describes a method for screening for molecules capable of
CC	binding to a selected test sequence in a duplex DNA. The above method
CC	comprises: constructing a duplex DNA test oligonucleotide having a
CC	screening sequence adjacent to a selected test sequence, where a DNA-
CC	binding protein is effective to bind to the screening sequence with a
CC	binding affinity that is substantially independent of such test sequence,
CC	but where DNA protein binding to the screening sequence is sensitive to
CC	binding of test molecules to such test sequence; adding a test molecule
CC	to be screened to a test system composed of the DNA-binding protein and
CC	the duplex DNA test oligonucleotide having the screening and test
CC	sequences adjacent one another; incubating the molecule in the test
CC	system for a period sufficient to permit binding of the molecule being
CC	tested to the test sequence in the duplex DNA; and comparing the amount
CC	of binding protein bound to the duplex DNA before and after the adding.
CC	The method is useful in screening libraries of synthetic or biological
CC	compounds for their ability to bind DNA test sequences. The method may
CC	also be used in characterizing the preferred binding sequences of any
CC	selected DNA-binding molecule. This sequence represents a test sequence
CC	corresponding to a promoter target of a viral gene.
XX	
XX	
SO	Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;
QY	
Query Match	33.6%; Score 14.8; DB 12; Length 50;
Best Local Similarity	73.1%; Pred.No. 1.9e+04;
Matches	19; Conservative 0; Mismatches 7; Indels 0;
Db	
11	TTCCCTTCTTAATACCGGTCGGGTT 36
1	
27	TGCTTTTACTAACCAGGTTTCGGTT 2
RESULT 29	
ADS91869/C	
ID	ADS91869 standard; DNA; 50 BP.
XX	
AC	ADS91869;
XX	
DT	02-DEC-2004 (first entry)
XX	

DE Nematode LNA-modified oligo capture probe #212.
XX locked nucleic acid; LNA; biostability; cancer; cytostatic;
XX diagnostic microarray; ss; probe; nematode.
XX
OS Caenorhabditis elegans.
OS Synthetic.
XX
XX Key
FH modified_base
FT 1
FT /mod_base= a
FT /note= OTHER
FT /note= OTHER= Locked nucleic acid (LNA). All LNA
FT modified_base
FT 2...49
FT /tag= b
FT /mod_base= OTHER
FT /note= OTHER= Locked nucleic acid (LNA) exists at every
FT third position (LNA-3). All LNA cytosines are methyl
FT cytosines."
XX
XX WO2004035819-A2.
XX
XX 29-APR-2004.
XX
XX 21-OCT-2003; 2003WO-DK000715.
XX
XX 21-OCT-2002; 2002US-0420278P.
XX 19-MAY-2003; 2003DK-00000752.
XX
XX (EXIQ-) EXIQON AS.
XX (MORK/) MORK S.
XX
XX Kauppien S, Alabo C, Nielsen PS, Jeffares DC, Mourier T;
PI Arcander P, Tommerup N, Tolstrup N, Vissing H;
PI WPI; 2004-357224/33.
XX
XX New non-naturally-occurring nucleic acid having a melting temperature and
PT capture efficiency higher than a control nucleic acid, useful for
PT detecting and amplifying target nucleic acid, for alternative mRNA splice
PT variant detection.
XX
XX Example 8; Page 102; 400pp; English.
XX
XX This invention relates to novel non-naturally occurring nucleic acids
CC that exhibit enhanced biostability and capture efficiency i.e.
CC hybridisation. Specifically, it refers to locked nucleic acid (LNA)
CC oligos that have restricted flexibility in the ribofuranose ring of the
CC nucleoside due to the presence of a 2'-O, 4'-C methylene bridge. The
CC present invention describes these oligos as useful for detecting target
CC nucleic acids and in particular for profiling mRNA splice variants,
CC detecting mutations, deletions or duplications that may be associated
CC with onset or increased risk of diseases such as cancer. Accordingly,
CC such oligos exhibit cytostatic activities. Furthermore, these LNA
CC containing oligos can be used as fluorescent in situ hybridisation (FISH)
CC probes or on diagnostic microarrays to detect splice isoform signatures,
CC as well as antisense oligos that can modulate or silence sense nucleic
CC acid agents. This oligonucleotide sequence is a nematode LNA-modified
CC oligo capture probe of the invention.
XX
SQ Sequence 50 BP; 13 A; 13 C; 13 G; 11 T; 0 U; 0 Other;
Query Match 33.6%; Score 14.8; DB 13; Length 50;
Best Local Similarity 59.5%; Pred. No. 1.9e+04;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;
QY 1 GCGGGTCCCGTCTTCTTAATACCGGTCGCGGTTATTAAG 42
DB 42 GCGTCCACGTTCTGTATCCTTAAGGACGCGTTTGAAG 1
RESULT 30

ACT97514
ID AC197514 standard; DNA; 25 BP.
XX
XX AC197514;
AC AC197514;
XX
XX 14-OCT-2003 (first entry)
XX
XX Human microarray DNA oligonucleotide SEQ ID NO 97505.
XX
XX EST; ss; probe; expressed sequence tag; microarray; gene expression;
XX genetic variation; biallelic marker; polymorphism; human;
XX cross-species comparison.
XX
XX Homo sapiens.
XX
XX US2003104410-A1.
XX
XX 05-JUN-2003.
XX
XX 15-MAR-2002; 2002US-00098263.
XX
XX 16-MAR-2001; 2001US-0276759P.
XX
XX (AFPY-) APFYMATRIX INC.
XX
XX Mittermann MP;
XX
XX WPI; 2003-567953/53.
XX
XX New array of nucleic acid probes, useful for in situ hybridization, in
PT Southern, Northern or dot-blot hybridization to identify or detect the
PT sequence or specific mutations of any gene.
XX
XX Claim 1; SEQ ID NO 97505; 9pp; English.
XX
XX The invention discloses a microarray comprising a plurality of nucleic
CC acid probes including one of 2,018,500 fully defined sequences, or its
CC perfect match, perfect mismatch, antisense match or antisense mismatch.
CC Also disclosed is a method of gene expression analysis. The array is used
CC in monitoring gene expression levels by hybridisation to a DNA library,
CC in analysis of genetic variation or in hybridisation of tag-labelled
CC compounds. The nucleic acid probes are specifically designed for analysis
CC of at least one target sequence. The method of analysis comprises
CC hybridising at least one or more nucleic acids to at least two or more
CC nucleic acid probes and detecting the hybridisation. The nucleic acid
CC probes are attached to a solid support. The analysis comprises monitoring
CC gene expression levels, identifying biallelic markers or polymorphisms,
CC or family members of a gene and a cross-species comparison. Each of the
CC nucleic acids further comprises a tag sequence. The array of nucleic acid
CC probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC blot hybridisation to identify or detect the sequence or specific
CC mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC primer extensions or in screening cDNA or genomic libraries or subclones
CC for additional subclones containing segments of DNA that have been
CC isolated and previously sequenced. The sequence presented is one of the
CC nucleic acid probes incorporated in the microarray. Note: The sequence
CC data for this patent can also be obtained in electronic format directly
CC from USPTO at seqdata.uspto.gov/sequence.html
XX
SQ Sequence 25 BP; 2 A; 9 C; 5 G; 9 T; 0 U; 0 Other;
Query Match 33.2%; Score 14.6; DB 9; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.1e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 2 GCGGTCCCGTCTTCTTAAT 22
DB 3 GCGGTCCCGTCTTCTTAAT 23
RESULT 31
AAQ10823/C
ID AAQ10823 standard; DNA; 34 BP.


```
XX AAQ10823;
AC
XX 09-MAY-1991 (first entry)
DT
XX Pneumocystis carinii 18S rRNA-targeted probe, 1485.
DE
XX Hybridisation assay; pneumonia; AIDS; ss.
XX
XX Synthetic.
OS
XX W09102092-A.
PN
XX 21-FEB-1991.
PD
XX 11-AUG-1989; 89US-00392679.
PF
XX 11-AUG-1989; 89US-00392679.
PR
XX 11-AUG-1989; 89US-00392679.
XX
XX (GENE-) GENE-TRAK SYST.
PA
XX Shah JS, Buharin A, Lane DJ;
PI
XX WPI; 1991-073563/10.
XX
XX Nucleic acid fragment - capable of hybridising to r RNA or r DNA of
PT pneumocystis carinii, useful as probes for detection of P carinii.
XX
XX Disclosure; Page 11; 36pp; English.
XX
XX This oligonucleotide has a sequence specific for a region of the rDNA of
CC Pneumocystis carinii, the causative agent of pneumonia. It can be used as
CC a probe in hybridisation assays to detect P. carinii in clinical samples.
CC This probe detects human but not most non-human P. carinii isolates. See
CC also AAQ10820-22 and AAQ10824-33
XX
XX Sequence 34 BP; 12 A; 7 C; 11 G; 4 T; 0 U; 0 Other;
SQ
Query Match 33.2%; Score 14.6; DB 2; Length 34;
Best Local Similarity 81.0%; Pred. No. 2.2e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 9 CGTTCCTTCTTAATACCGGT 29
Db 31 CCTTCCTTCTGATTAACCGGT 11
RESULT 32
AAT42447/c
ID AAT42447 standard; DNA; 34 BP.
XX
XX AAT42447;
AC
XX 25-MAR-2003 (revised)
DT 08-JAN-1997 (first entry)
XX
XX Probe 1485 for P. carinii 18S rRNA.
DE
XX
XX Probe; pneumocystis carinii; 18S rRNA; human; mammal; immunodeficiency;
KM pneumonia; ferret; rat; ss.
XX
XX Synthetic.
OS
XX US5519127-A.
PN
XX 21-MAY-1996.
PD
XX 21-JAN-1992; 92US-00826657.
PF
XX 11-AUG-1989; 89US-00392679.
PR
XX (STAD ) AMOCO CORP.
XX
```

```
PI Lane DJ, Buharin A, Shah J;
XX
XX WPI; 1996-259122/26.
DR
XX
XX Nucleic acid probes specific for human Pneumocystis carinii - provide
PT sensitive, accurate and rapid diagnosis of infection.
XX
XX Claim 1; Col 13-14; 15pp; English.
XX
XX AAT42443-142456 represent probes for human Pneumocystis carinii (Pc) 18S
CC rRNA. Pc infects humans and most mammalian hosts, but rarely cause
CC illness in normal individuals. However, in certain conditions of
CC immunodeficiency, Pc does give rise to life threatening pneumonia. This
CC sequence hybridises to the 18S rRNA at positions 641-652, and is capable
CC of hybridisation to human Pc. These probes can be used as a probe set for
CC Pc assay. The 1485 (this sequence), 1487 (see AAT42452) and 1159 (see
CC AAT42448) probes are reactive with all human Pc isolates. The probes 1485
CC and 1487 hybridise to rRNA and rDNA of human Pc, but not to other fungi
CC or bacteria. The 1485 and 1487 probes can therefore be used to detect Pc
CC in clinical samples. The rest of these probe sequences are reactive
CC mainly with ferret Pc and non-human strains of Pc. By using these probe
CC sequences, a more sensitive, accurate and rapid diagnosis can be
CC performed, with reduced expense, in comparison to current technology.
CC rRNA is present in the cell at high concentration, and is not likely to
CC undergo lateral transfer. (Updated on 25-MAR-2003 to correct PF field.)
XX
XX Sequence 34 BP; 12 A; 7 C; 11 G; 4 T; 0 U; 0 Other;
SQ
Query Match 33.2%; Score 14.6; DB 2; Length 34;
Best Local Similarity 81.0%; Pred. No. 2.2e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 9 CGTTCCTTCTTAATACCGGT 29
Db 31 CCTTCCTTCTGATTAACCGGT 11
RESULT 33
AD135720/c
ID AD135720 standard; DNA; 35 BP.
XX
XX AD135720;
AC
XX 15-APR-2004 (first entry)
DT
XX
XX Human tyrosine kinase receptor TrkB1g26H1s reverse PCR primer.
DE
XX
XX tyrosine kinase receptor; biosensor; human; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
PN
XX W02003025016-A2.
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-GB004214.
PF
XX
XX 17-SEP-2001; 2001GB-00022400.
PR
XX (UYBR-) UNIV BRISTOL.
XX
XX Dawbarn D, Allen SJ, Robertson AGS;
PI
XX
XX WPI; 2003-371797/35.
XX
XX Producing tyrosine kinase receptor-related polypeptides useful as
PT biosensors, comprises expressing a tyrosine kinase receptor-related
XX polypeptide in a recombinant expression system.
XX
XX Disclosure; Page 15; 54pp; English.
XX
XX The present invention describes a method for producing tyrosine kinase
CC
```



```
CC receptor-related polypeptides comprising expressing a tyrosine kinase
CC receptor-related polypeptide in a recombinant expression system.
CC separating the expressed monomeric tyrosine kinase receptor-related
CC polypeptide from multimeric form(s) of the expressed polypeptide, and
CC allowing refolding of the expressed tyrosine kinase receptor-related
CC polypeptide into a biologically active form. Also described: (1)
CC purifying recombinant TrkA1g2, TrkA1g2.6, TrkB1g4, or TrkC1g4 from
CC inclusion bodies in a bacterial expression system in which monomeric
CC TrkA1g2, TrkA1g2.6, TrkB1g4, or TrkC1g4 is separated from a mixture
CC including monomeric, and multimeric TrkA1g2, TrkA1g2.6, TrkB1g4, or
CC TrkC1g4 by a gel filtration step, and allowed to refold into an active
CC form; (2) preparations of TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2 obtained
CC by a method above comprising less than 20% TrkA1g2, TrkA1g2.6, TrkB1g2 or
CC TrkC1g2 dimer or dimer aggregate; and (3) preparations of TrkA1g2,
CC TrkA1g2.6, TrkB1g2 or TrkC1g2 obtained by a method above comprising more
CC than 80-99% TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2, or comprising 100%
CC TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2 monomer. The method is useful for
CC producing tyrosine kinase receptor-related polypeptides which can be used
CC as biosensors. Compared with previous methods, the present method
CC provides improved yields, has improved stability, does not require a
CC separate dialysis-based refolding step, is much quicker than processes
CC involving dialysis, produces product at higher concentrations without
CC strand swap dimers, and since product is not in contact with urea for the
CC length periods required during a dialysis procedure, it is less likely to
CC be amidated. The present sequence represents a PCR primer for
CC TrkB1g26His, which is used in the exemplification of the present
CC invention.
XX
SQ Sequence 35 BP; 6 A; 10 C; 7 G; 10 T; 0 U; 2 Other;
Query Match 33.2%; Score 14.6; DB 10; Length 35;
Best Local Similarity 73.9%; Pred. No. 2.2e+04;
Matches 17; Conservative 1; Mismatches 5; Indels 0; Gaps 0;
OY 21 ATAACCGGTGGCGTATTAGA 43
Db 32 AAAACGGGTGGCGTATTAGA 10
RESULT 34
AAV06323/c
ID AAV06323 standard; DNA; 38 BP.
XX
AC AAV06323;
XX
DT 06-MAY-1998 (first entry)
XX
DE Human Col III gene 3' end synthesising 3' primer.
XX
KW Collagen; Col III; recombinant; post-translational enzyme; human;
KW procollagen; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN MO9738710-A1.
XX
PD 23-OCT-1997.
XX
PE 11-APR-1997; 97WO-US007300.
XX
PR 12-APR-1996; 96US-00631336.
XX
PA (F1BR-) FIBROGEN INC.
PA (F1FI-) ACAD FINLAND.
XX
PI Kivirikki KI, Pihlajaniemi T;
XX
DR WPI, 1997-526203/48.
XX
PT Recombinant production of (pro)collagen having correct folding - using
PT vectors encoding collagen subunit and collagen post-translational enzyme
PT respectively.
```

```
XX
PS Example 11; Page 67; 90pp; English.
XX
CC This primer is used to synthesise the 3' end of the human Col III gene by
CC PCR amplification. This is used in the construction of recombinant
CC vectors containing collagen genes. A novel method for producing a
CC (pro)collagen polypeptide comprises culturing a host cell, where the host
CC cell has been infected, transfected or transformed with a first
CC expression vector comprising a polynucleotide molecule having a nucleic
CC acid sequence which encodes a (pro)collagen subunit and a second
CC expression vector comprising a polynucleotide molecule having a nucleic
CC acid sequence which encodes at least one (pro)collagen post-translational
CC enzyme or enzyme subunit. The (pro)collagen polypeptide is then purified
CC from the cultured cell. The (pro)collagen polypeptide is selected from
CC collagen types IV, V, VI, VII, VIII, IX, X, XI, XII, XIV, XV, XVI,
CC XVII, XVIII, and XIX. The methods can be used for the production of
CC collagens such as human collagens which can be used in therapeutic
CC applications. The method provides for the synthesis of correctly folded
CC proteins so that they exhibit the normal triple-helical conformation
CC characteristic of procollagens and collagens. Purification of the
CC collagens is greatly facilitated
XX
SQ Sequence 38 BP; 12 A; 10 C; 11 G; 5 T; 0 U; 0 Other;
Query Match 33.2%; Score 14.6; DB 2; Length 38;
Best Local Similarity 69.0%; Pred. No. 2.2e+04;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
OY 4 GATCCCGTTCCTTATTAACCGGTGCG 32
Db 38 GACCTGTTCCTTATTAAGCGGCGCC 10
RESULT 35
ABZ47662
ID ABZ47662 standard; DNA; 41 BP.
XX
AC ABZ47662;
XX
DT 26-JUN-2003 (first entry)
XX
DE Human ATP-binding cassette ABC7/CFTR gene polymorphic site, #4446.
XX
KW Human; drug metabolising enzyme; gene; drug metabolism; chromosome 7;
KW polymorphic site; drug evaluation; drug screening; genotyping;
KW genetic profiling; therapeutic customisation; adverse reaction;
KW clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FH variation replace(21,G)
FT /*tag=a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX
PN WO200252044-A2.
XX
PD 04-JUL-2002.
XX
PE 27-DEC-2001; 2001WO-JP011592.
XX
PR 27-DEC-2000; 2000JP-00399443.
PR 02-MAY-2001; 2001JP-00135256.
PR 27-AUG-2001; 2001JP-00256862.
XX
PA (RIKE ) RIKEN KK.
XX
PI Nakamura Y, Sekine A, Iida A, Satto S;
XX
DR WPI, 2002-583571/62.
XX
PT Identifying individuals having a polymorphism, useful for determining the
PT effectiveness or side effect of a drug or treatment protocol, comprises
```

PT detecting at least one polymorphism in the drug metabolizing enzyme
PT nucleic acid.
PS Claim 23; Page 147; 2785pp; English.
XX
CC Sequences AB243217-AB250887 represent polymorphic sites within genes
CC encoding enzymes associated with drug metabolism. The invention relates
CC to methods and compositions for identifying individuals who have at least
CC one polymorphism in such drug metabolizing enzyme-encoding genes. The
CC polymorphisms may be identified in a nucleic acid sample using probes or
CC primers specific for a sequence selected from AB243217-AB250887 using a
CC variety of detection assays, including hybridisation assays, nucleic acid
CC arrays and PCR-based methods. The invention also encompasses methods of
CC evaluating and screening drugs using genetic polymorphism data. Genetic
CC polymorphism data, particularly that relating to single nucleotide
CC polymorphisms (SNPs), may be used in studying the relationship between
CC DNA sequence variations and human diseases, conditions, and responses to
CC drugs. SNPs are also useful as polymorphism markers for discovering genes
CC that cause or exacerbate certain diseases. SNPs are particularly useful
CC in the above respects as they are stable in populations, occur
CC frequently, and have lower mutation rates than other genome variations
CC such as repeating sequences. The detection and analysis of polymorphisms
CC in genes encoding drug metabolizing enzymes allows the customisation of
CC drug therapies based upon the genetic profile of individual patients.
CC This would not only take the guesswork out of selecting the drug with the
CC greatest therapeutic effect for a particular patient, but would also
CC reduce the likelihood of adverse reactions, thereby increasing safety.
CC Methods of the invention are also useful in the drug discovery and
CC approval processes. For example, individuals could be selected for
CC clinical trials only if their genetic profiles indicate that they are
CC capable of responding to a particular drug or drug class, and previously
CC failed drug candidates could be revived if they were matched with more
CC appropriate patient populations. The methods, data and compositions of
CC the invention may therefore lead to an increase in the range of
CC possible drug targets and decreases in the number of adverse drug
CC reactions, failed drug trials, the time taken for a drug to be approved,
CC the length of time patients are on medication and the number of different
CC medications a patient needs to take before finding an effective therapy
CC
XX
SQ Sequence 41 BP; 8 A; 15 C; 2 G; 16 T; 0 U; 0 Other;
OY Query Match 33.2%; Score 14.6; DB 6; Length 41;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
Db 5 GTCCGCTCTCTTAATAC 25
16 GTCCATTCTTCAATATATC 36
RESULT 36
AB245067
ID AB245067 standard; DNA; 41 BP.
XX
AC AB245067;
XX
XX 26-JUN-2003 (first entry)
XX
DE Human ATP-binding cassette ABC7/CFTR gene polymorphic site, #1851.
XX
XX Human, drug metabolising enzyme; gene; drug metabolism; chromosome 7;
XX polymorphic site; drug evaluation; drug screening; genotyping;
XX genetic profiling; therapeutic customisation; adverse reaction;
XX clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH variation
FT /tag= a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX
FN WO200252044-A2.

XX
PD 04-JUL-2002.
XX
XX 27-DEC-2001; 2001WO-JP011592.
XX
XX 27-DEC-2000; 2000JP-00399443.
XX 02-MAY-2001; 2001JP-00135256.
XX 27-AUG-2001; 2001JP-00256862.
XX
XX (RIKEN) RIKEN KK.
XX
XX Nakamura Y, Sekine A, Iida A, Saito S;
XX WPI; 2002-583571/62.
XX
XX Identifying individuals having a polymorphism, useful for determining the
XX effectiveness or side effect of a drug or treatment protocol, comprises
XX detecting at least one polymorphism in the drug metabolizing enzyme
XX nucleic acid.
XX
XX Claim 23; Page 94; 2785pp; English.
XX
XX Sequences AB243217-AB250887 represent polymorphic sites within genes
XX encoding enzymes associated with drug metabolism. The invention relates
XX to methods and compositions for identifying individuals who have at least
XX one polymorphism in such drug metabolizing enzyme-encoding genes. The
XX polymorphisms may be identified in a nucleic acid sample using probes or
XX primers specific for a sequence selected from AB243217-AB250887 using a
XX variety of detection assays, including hybridisation assays, nucleic acid
XX arrays and PCR-based methods. The invention also encompasses methods of
XX evaluating and screening drugs using genetic polymorphism data. Genetic
XX polymorphism data, particularly that relating to single nucleotide
XX polymorphisms (SNPs), may be used in studying the relationship between
XX DNA sequence variations and human diseases, conditions, and responses to
XX drugs. SNPs are also useful as polymorphism markers for discovering genes
XX that cause or exacerbate certain diseases. SNPs are particularly useful
XX in the above respects as they are stable in populations, occur
XX frequently, and have lower mutation rates than other genome variations
XX such as repeating sequences. The detection and analysis of polymorphisms
XX in genes encoding drug metabolizing enzymes allows the customisation of
XX drug therapies based upon the genetic profile of individual patients.
XX This would not only take the guesswork out of selecting the drug with the
XX greatest therapeutic effect for a particular patient, but would also
XX reduce the likelihood of adverse reactions, thereby increasing safety.
XX Methods of the invention are also useful in the drug discovery and
XX approval processes. For example, individuals could be selected for
XX clinical trials only if their genetic profiles indicate that they are
XX capable of responding to a particular drug or drug class, and previously
XX failed drug candidates could be revived if they were matched with more
XX appropriate patient populations. The methods, data and compositions of
XX the invention may therefore lead to an increase in the range of
XX possible drug targets and decreases in the number of adverse drug
XX reactions, failed drug trials, the time taken for a drug to be approved,
XX the length of time patients are on medication and the number of different
XX medications a patient needs to take before finding an effective therapy
XX
XX
SQ Sequence 41 BP; 8 A; 15 C; 2 G; 16 T; 0 U; 0 Other;
OY Query Match 33.2%; Score 14.6; DB 6; Length 41;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
Db 5 GTCCGCTCTCTTAATAC 25
16 GTCCATTCTTCAATATATC 36
RESULT 37
ADL60971/C
ID ADL60971 standard; DNA; 41 BP.
XX
XX ADL60971;
XX
XX

DT 01-JUL-2004 (first entry)
XX Human organic anion transport protein SNP region #680.
DE
XX
XX gene therapy; human; OATP2; cMOAT; hepatic disease; metabolic disease;
KM inflammatory disease; cardiovascular disease; hyperproliferative disease;
KM neurological disease; infectious disease; liver disease;
KM high cholesterol; hypertension; congestive heart failure;
KM coronary heart disease; cancer; wound healing; ds; SNP;
KM single nucleotide polymorphism.
XX
OS Homo sapiens.
XX
XX US2004068096-A1.
XX
XX 08-APR-2004.
XX
XX 20-SEP-2002; 2002US-00252155.
XX
XX 21-SEP-2001; 2001US-0324172P.
XX 27-NOV-2001; 2001US-0333700P.
XX
XX (TSUC/) TSUCHIHASHI Z.
XX (HUI/) HUI L.
XX (KIRC/) KIRCHGESNER T.
XX
XX Tsuchihashi Z, Hui L, Kirchgessner T;
XX
XX WPI; 2004-304621/28.
XX
XX New nucleic acid encoding human OATP2 or cMOAT protein, useful in
PT diagnosing, treating or preventing diseases or disorders, e.g.
PT inflammatory, cardiovascular, hyperproliferative, neurological or
PT infectious diseases.
XX
XX Disclosures; SEQ ID NO 747; 296pp; English.
XX
XX The invention relates to an isolated nucleic acid derived from a human
CC gene encoding a protein, i.e. human OATP2 protein or human cMOAT protein,
CC where the nucleic acid comprises at least one polymorphic position. The
CC nucleic acid and the encoded protein, kits and composition are useful in
CC diagnosing, treating or preventing diseases or disorders, e.g. hepatic,
CC metabolic, inflammatory, cardiovascular, hyperproliferative,
CC neurological, infectious diseases, liver disease, high cholesterol,
CC hypertension, congestive heart failure or coronary heart disease and
CC cancer and promotes wound healing. The present sequence represents the
CC amino acid sequence of a human organic anion transport protein.
XX
SQ Sequence 41 BP; 16 A; 6 C; 14 G; 5 T; 0 U; 0 Other;
Query Match 33.2%; Score 14.6; DB 12; Length 41;
Best Local Similarity 69.0%; Pred. No. 2.3e+04;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
QY 10 GTTCCTCTTAATAACCGGCGCGGTTAT 38
Db 41 GCTCCTCTTTTAACCTCTACCGGTCAT 13
RESULT 38
ID ABN84317 standard; DNA; 45 BP.
XX
XX ABN84317;
XX
XX 29-AUG-2003 (revised)
DT 01-OCT-2002 (first entry)
XX
XX Rhinovirus specific PCR primer rhLD.R1.
DE
KM cW985; pertubagen; viral infection; virucide; human; gene therapy; PCR;
KM primer; ss.
XX

OS Human rhinovirus sp.
XX
XX WO200255697-A2.
XX
XX 18-JUL-2002.
XX
XX 16-NOV-2001; 2001WO-US043486.
XX
XX 27-NOV-2000; 2000US-0253333P.
XX 28-FEB-2001; 2001US-0272026P.
XX
XX (DELT-) DELTAGEN PROTEOMICS INC.
XX
XX Kamb CA, Poritz MA, Teng DH;
XX WPI; 2002-557822/59.
XX
XX
XX New cW985 pertubagen polypeptides and polynucleotides useful for
PT treating viral infections by the picornaviridae class, in chromosomal
PT mapping, tissue typing, forensic biology, or viral serotyping.
XX
XX Example 6; Fig 17; 117pp; English.
XX
XX The present sequence is of PCR primer rhLD.R1, which was used in an
CC example from the invention describing methods for identifying the targets
CC of viral-neutralising perturbagens. In order to construct a viral target
CC library, 10 of the polypeptides encoded by the human rhinovirus-14 genome
CC were RT-PCR amplified from viral RNA using the viral-specific
CC oligonucleotides given in ABN84310-29. These include the present primer
CC which, in addition to the viral sequence, includes a 5' restriction site.
CC PCR products were cloned into pVT725 (His+) in-frame with the LexA
CC binding domain. The polynucleotide sequence (see ABN84303) encoding novel
CC pertubagen cW985 (see ABN79541) was cloned into pVT578 such that the 53
CC amino acids of cW985 were fused in-frame with the C-terminus of the LexA
CC activating domain. The pVT578-W985 and pVT725-viral library constructs
CC were introduced into a yeast strain, and viral proteins that interacted
CC with the W985 pertubagen were identified. The invention provides host
CC cells, vectors and gene therapy vectors comprising polynucleotides
CC encoding cW985. The host cells provide for methods for producing
CC polypeptides having viral-related activity, which in turn can be used to
CC identify potential therapeutics. The invention also provides methods for
CC identifying a cellular target that interacts with the pertubagen, and
CC for using such targets to screen for viral therapeutics. (Updated on 29-
XX AUG-2003 to standardise OS field)
XX
SQ Sequence 45 BP; 11 A; 12 C; 7 G; 15 T; 0 U; 0 Other;
Query Match 33.2%; Score 14.6; DB 6; Length 45;
Best Local Similarity 62.2%; Pred. No. 2.3e+04;
Matches 23; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 4 GGTCCCGTTCCTTTTAATAACCGGCGCGGTTATTA 40
Db 37 GGTGACATTAATCTTAATTAAGCGCGCGCTGTATTGA 1
RESULT 39
ID ADO18016 standard; DNA; 47 BP.
XX
XX ADO18016;
XX
XX 01-JUL-2004 (first entry)
DT
XX
XX Primer of the invention #242.
DE
XX single nucleotide polymorphism; primer; ss.
XX
XX Synthetic.
XX
XX WO2004003220-A2.
XX
XX 08-JAN-2004.
XX

XX 26-JUN-2003; 2003WO-US020150.
XX
XX 28-JUN-2002; 2002US-0392504P.
XX
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX
XX Giles R, Baisch JM, McKeown B, Stolorow M;
XX WPI; 2004-091088/09.
XX
XX New panel of single nucleotide polymorphisms comprising two or more
XX single nucleotide polymorphisms, useful for analyzing compromised nucleic
XX acid samples.
XX
XX Claim 2; SEQ ID NO 243; 76pp; English.
XX
XX The present invention relates to a panel of two or more single nucleotide
XX polymorphisms, where each of the polymorphisms of the panel are selected
XX from single nucleotide polymorphisms that are not genetically linked with
XX respect to one another, and where each of the polymorphisms of the panel
XX are selected from single nucleotide polymorphisms that are located
XX outside tandem repeat nucleic acid sequences. The known sample and the
XX unknown sample are from the same individual. The known sample is from a
XX family member. The compromised nucleic acid sample comprises nucleic acid
XX fragments from 10-100 nucleotides in length. The identity of the one or
XX more single nucleotide polymorphisms is determined using a single base
XX primer extension reaction. The present sequence represents a primer of
XX the invention.
XX
XX Sequence 47 BP; 6 A; 12 C; 17 G; 11 T; 0 U; 1 Other;

Query Match 33.2%; Score 14.6; DB 12; Length 47;
Best Local Similarity 66.7%; Pred. No. 2.3e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 3 GGGTCCGTTCTTCTTAATACCGGTGC 32
Db 1 GGATGGGTTCCGTCCTATATCTGGGNC 30

RESULT 40

ADO18088
ID ADO18088 standard; DNA; 47 BP.
XX
XX ADO18088;
XX
XX 01-JUL-2004 (first entry)
XX
XX Primer of the invention #314.
XX
XX single nucleotide polymorphism; primer; ss.
XX
XX Synthetic.
XX
XX WO2004003220-A2.
XX
XX 08-JAN-2004.
XX
XX 26-JUN-2003; 2003WO-US020150.
XX
XX 28-JUN-2002; 2002US-0392504P.
XX
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX
XX Giles R, Baisch JM, McKeown B, Stolorow M;
XX WPI; 2004-091088/09.
XX

XX New panel of single nucleotide polymorphisms comprising two or more
XX single nucleotide polymorphisms, useful for analyzing compromised nucleic
XX acid samples.
XX

PS Claim 2; SEQ ID NO 315; 76pp; English.

XX
XX The present invention relates to a panel of two or more single nucleotide
XX polymorphisms, where each of the polymorphisms of the panel are selected
XX from single nucleotide polymorphisms that are not genetically linked with
XX respect to one another, and where each of the polymorphisms of the panel
XX are selected from single nucleotide polymorphisms that are located
XX outside tandem repeat nucleic acid sequences. The known sample and the
XX unknown sample are from the same individual. The known sample is from a
XX family member. The compromised nucleic acid sample comprises nucleic acid
XX fragments from 10-100 nucleotides in length. The identity of the one or
XX more single nucleotide polymorphisms is determined using a single base
XX primer extension reaction. The present sequence represents a primer of
XX the invention.
XX

Sequence 47 BP; 6 A; 12 C; 17 G; 11 T; 0 U; 1 Other;

Query Match 33.2%; Score 14.6; DB 12; Length 47;
Best Local Similarity 66.7%; Pred. No. 2.3e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 3 GGGTCCGTTCTTCTTAATACCGGTGC 32
Db 1 GGATGGGTTCCGTCCTATATCTGGGNC 30

Search completed: May 24, 2005, 12:14:32
Job time : 271 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 11:49:09 ; Search time 98 Seconds
(without alignments)
734.655 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943
Perfect score: 44
Sequence: 1 gcgggtccgcgtctctctta.....ccggtcgcgttattaaaga 44

Scoring table: IDENTITY NUC
Gapop 10'-0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues 1209694

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 50
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : Issued Patents NA.*
1: /cgn2_6/ptodate/1/ina/5A.COMB.seq.*
2: /cgn2_6/ptodate/1/ina/5B.COMB.seq.*
3: /cgn2_6/ptodate/1/ina/6A.COMB.seq.*
4: /cgn2_6/ptodate/1/ina/6B.COMB.seq.*
5: /cgn2_6/ptodate/1/ina/PTUS.COMB.seq.*
6: /cgn2_6/ptodate/1/ina/backfile1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	15.8	35.9	25	4	US-09-396-196G-29372
2	15.2	34.5	33	6	5519127-36
3	15.2	34.5	33	6	5519127-36
4	14.8	33.6	25	4	US-09-396-196G-29373
5	14.8	33.6	36	4	US-09-665-189A-40
6	14.8	33.6	47	4	US-09-422-978-240
7	14.8	33.6	47	4	US-09-422-978-1725
8	14.8	33.6	50	1	US-08-171-389-585
9	14.8	33.6	50	1	US-08-123-936-585
10	14.8	33.6	50	2	US-08-425-228A-585
11	14.8	33.6	50	3	US-08-482-080A-585
12	14.8	33.6	50	3	US-09-354-947-585
13	14.8	33.6	50	5	PCT-US93-12388-585
14	14.6	33.2	33	6	5519127-17
15	14.6	33.2	33	6	5519127-17
16	14.6	33.2	34	6	5519127-4
17	14.6	33.2	34	6	5519127-4
18	14.6	33.2	39	6	5519127-33
19	14.6	33.2	39	6	5519127-33
20	14.6	33.2	46	1	US-07-826-928A-30
21	14.6	33.2	47	4	US-09-422-978-415
22	14.6	33.2	49	3	US-08-889-502-34
23	14.4	32.7	47	4	US-09-422-978-2970
24	14.4	32.7	20	4	US-09-198-452A-6719
25	14.2	32.3	20	4	US-09-922-146-31
26	14.2	32.3	21	4	US-09-657-472-1129
27	14.2	32.3	36	1	US-07-956-697B-3

28	14.2	32.3	36	1	US-08-263-098-3	Sequence 3, Appli
29	14.2	32.3	38	2	US-08-857-946-83	Sequence 83, Appli
30	14.2	32.3	38	2	US-08-970-740-83	Sequence 83, Appli
31	14.2	32.3	49	3	US-09-538-709-983	Sequence 983, App
32	14	31.8	24	3	US-08-379-452-17	Sequence 17, Appli
33	14	31.8	24	3	US-09-409-670-17	Sequence 17, Appli
34	14	31.8	30	3	US-09-461-697-456	Sequence 456, App
35	14	31.8	32	4	US-09-709-103-34	Sequence 34, Appli
36	14	31.8	32	4	US-09-439-410A-34	Sequence 34, Appli
37	14	31.8	35	4	US-09-709-103-8	Sequence 8, Appli
38	14	31.8	35	4	US-09-439-410A-8	Sequence 8, Appli
39	14	31.8	41	4	US-09-060-229-117	Sequence 117, App
40	14	31.8	41	4	US-09-402-923A-117	Sequence 117, App
41	14	31.8	47	1	US-08-171-389-250	Sequence 250, App
42	14	31.8	47	1	US-08-123-936-250	Sequence 250, App
43	14	31.8	47	2	US-08-475-228A-250	Sequence 250, App
44	14	31.8	47	3	US-08-482-080A-250	Sequence 250, App
45	14	31.8	47	3	US-09-354-947-250	Sequence 250, App
46	14	31.8	47	4	US-09-422-978-250	Sequence 990, App
47	14	31.8	47	5	PCT-US93-12388-250	Sequence 990, App
48	13.8	31.4	25	4	US-09-396-196G-50594	Sequence 50594, A
49	13.8	31.4	26	1	US-08-218-933-2	Sequence 2, Appli
50	13.8	31.4	26	5	PCT-US95-03918-2	Sequence 2, Appli
51	13.8	31.4	29	3	US-08-194-560-7	Sequence 7, Appli
52	13.8	31.4	34	3	US-08-510-133A-7	Sequence 7, Appli
53	13.8	31.4	34	3	US-08-585-895-7	Sequence 7, Appli
54	13.8	31.4	34	3	US-08-601-132-7	Sequence 7, Appli
55	13.8	31.4	34	4	US-08-671-573B-7	Sequence 7, Appli
56	13.8	31.4	34	4	US-09-631-092B-7	Sequence 7, Appli
57	13.8	31.4	38	3	US-08-718-904-124	Sequence 124, App
58	13.8	31.4	38	4	US-09-449-249-124	Sequence 124, App
59	13.8	31.4	47	4	US-09-516-667-73	Sequence 73, Appli
60	13.8	31.4	48	4	US-09-516-667-35	Sequence 35, Appli
61	13.8	31.4	48	4	US-09-516-667-74	Sequence 74, Appli
62	13.8	31.4	48	4	US-09-516-667-75	Sequence 75, Appli
63	13.6	30.9	25	4	US-09-396-196G-84468	Sequence 84468, A
64	13.6	30.9	25	4	US-09-396-196G-84469	Sequence 84469, A
65	13.6	30.9	38	4	US-09-060-229-249	Sequence 249, App
66	13.6	30.9	38	4	US-09-402-923A-249	Sequence 249, App
67	13.6	30.9	40	2	US-08-628-422-25	Sequence 25, Appli
68	13.6	30.9	40	4	US-09-763-550-14	Sequence 14, Appli
69	13.6	30.9	42	4	US-09-408-020-88	Sequence 88, Appli
70	13.6	30.9	42	6	5177307-5	Sequence 88, Appli
71	13.6	30.9	42	6	5177307-5	Sequence 88, Appli
72	13.4	30.5	33	1	US-08-449-311A-5	Sequence 5, Appli
73	13.4	30.5	33	1	PCT-US95-17106A-5	Sequence 5, Appli
74	13.4	30.5	36	1	US-08-121-202-21	Sequence 21, Appli
75	13.4	30.5	36	1	US-08-121-202-22	Sequence 22, Appli
76	13.4	30.5	36	3	US-08-822-516-8	Sequence 8, Appli
77	13.4	30.5	36	3	US-09-131-684-8	Sequence 8, Appli
78	13.4	30.5	39	6	5519127-31	Sequence 8, Appli
79	13.4	30.5	39	6	5519127-31	Sequence 8, Appli
80	13.4	30.5	40	2	US-08-124-981A-20	Sequence 20, Appli
81	13.4	30.5	40	3	US-09-037-190-18	Sequence 18, Appli
82	13.4	30.5	40	3	US-09-037-192-18	Sequence 18, Appli
83	13.4	30.5	40	3	US-09-037-143-18	Sequence 18, Appli
84	13.4	30.5	40	3	US-09-049-691-18	Sequence 18, Appli
85	13.4	30.5	40	3	US-08-260-174-18	Sequence 18, Appli
86	13.4	30.5	40	3	US-09-338-128A-18	Sequence 18, Appli
87	13.4	30.5	40	3	US-09-232-346-18	Sequence 18, Appli
88	13.4	30.5	40	3	US-09-037-192-18	Sequence 18, Appli
89	13.4	30.5	45	3	US-08-358-627F-3	Sequence 18, Appli
90	13.4	30.5	45	3	US-08-465-712C-3	Sequence 18, Appli
91	13.4	30.5	45	3	US-09-552-733-3	Sequence 3, Appli
92	13.4	30.5	45	3	US-09-349-925-3	Sequence 3, Appli
93	13.4	30.5	49	3	US-08-782-480-57	Sequence 57, Appli
94	13.4	30.5	49	3	US-08-954-211-57	Sequence 57, Appli
95	13.4	30.5	49	3	US-09-005-167A-57	Sequence 57, Appli
96	13.4	30.5	49	3	US-09-176-718B-57	Sequence 57, Appli
97	13.4	30.5	50	1	US-07-750-080A-21	Sequence 21, Appli
98	13.4	30.5	50	1	US-07-750-080A-42	Sequence 42, Appli
99	13.4	30.5	50	3	US-08-651-472-21	Sequence 21, Appli
100	13.4	30.5	50	3	US-08-651-472-42	Sequence 42, Appli

ALIGNMENTS

```

RESULT 1
US-09-396-196G-29372/c
: Sequence 29372, Application US/09396196G
: Patent No. 6821724
: GENERAL INFORMATION:
: APPLICANT: Michael Miltmann
: APPLICANT: David Mack
: APPLICANT: David Lochhart
: APPLICANT: Affymetrix, Inc.
: TITLE OF INVENTION: Methods of Genetic Analysis
: FILE REFERENCE: 3101.1
: CURRENT APPLICATION NUMBER: US/09/396,196G
: CURRENT FILING DATE: 1999-09-15
: PRIOR APPLICATION NUMBER: 60/100,678
: PRIOR FILING DATE: 1998-09-17
: NUMBER OF SEQ IDS: 127806
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 29372
: LENGTH: 25
: TYPE: DNA
: ORGANISM: Mus musculus
US-09-396-196G-29372

```

Query Match	35.9%	Score 15.8;	DB 4;	Length 25;
Best Local Similarity	89.5%;	Pred. No.1.5e+03;		
Matches 17;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0

QY	26	CGTCGCGGTTATTAGAA	44
Db	19	CAGTCGCGGTAATTAGAA	1

```

RESULT 2
5519127-36
; Patent No. 5519127
; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCYSTIS CARINII
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,657
; FILING DATE: 21-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO:36:
; LENGTH: 33
5519127-36

```

Query Match	34.5%	Score 15.2;	DB 6;	Length 33;
Best Local Similarity	45.5%;	Pred. No. 3e+03;		
Matches 10;	Conservative	8;	Mismatches 4;	Indels 0;
				Gaps 0

QY 8 CCGTTCCTTCTAATAACCGT 23
:|::||::|:|:||||:
Db 3 YCCUUCCTUCUGAUAACCGU 24

RESULT 3
5519127-36
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCOCCUS CARINII
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,657
; FILING DATE: 21-JAN-1992

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO:36
; LENGTH: 33
5519127-36

```

Query Match	34.5%	Score 15.2;	DB 6;	Length 33;
Best Local Similarity	45.5%	Pred. No. 3e+03;		
Matches 10;	Conservative 8;	Mismatches 4;	Indels 0;	Gaps 0;

DY 8 CCGTTCCTTTAATAACGGT 29
:|::||::|:|::|||:
Db 3 YCCUUCCUUCUGAUUACCGR 24

RESULT 4
 US-09-396-196G-29373/c
 Sequence 29373, Application US/09396196G
 Patent NO. 6821724
 GENERAL INFORMATION:
 APPLICANT: Michael Miltmann
 APPLICANT: David Mack
 APPLICANT: David Lockhart
 APPLICANT: Affimetrix, Inc.
 TITLE OF INVENTION: Methods of Genetic Analysis
 FILE REFERENCE: 3101.1
 CURRENT APPLICATION NUMBER: US/09/396,196G
 CURRENT FILING DATE: 1999-09-15
 PRIOR APPLICATION NUMBER: 60/100,678
 PRIOR FILING DATE: 1998-09-17
 NUMBER OF SEQ ID NOS: 127806
 SOFTWARE: FastSeq for Windows Version 4.0
 SEQ ID NO 29373
 LENGTH: 25
 TYPE: DNA
 ORGANISM: Mus musculus
 US-09-396-196G-29373

Query Match	33.6%	Score 14.8	DB 4	Length 25
Best Local Similarity	88.9%	Pred. No. 4.1e+03		
Matches 16	Conservative 0	Mismatches 2	Indels 0	Gaps 0

QY 26 CGGTCGGGTTATTAGA 43
| | | | | | | | | |
Db 18 CAGTCGGGTAATTAGA 1

```

RESULT 5
US-09-665-189A-40
; Sequence 40, Application US/09665189A
; Patent No. 6645765
; GENERAL INFORMATION:
; APPLICANT: Anderson, Heather
; APPLICANT: Chay, Catherine
; APPLICANT: Chen, Guilan
; APPLICANT: Comer, Timothy
; TITLE OF INVENTION: Plant Regulatory Sequences for Control of Gene Expression
; FILE REFERENCE: 38-211 (15674)B
; CURRENT APPLICATION NUMBER: US/09/665,189A
; CURRENT FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: 09/665,189
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 40
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(36)
; OTHER INFORMATION: synthetic primer sequence

```

US-09-665-189A-40

Query Match 33.6%; Score 14.8; DB 4; Length 36;
Best Local Similarity 73.1%; Pred. No. 4.5e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTTAATACCGGTGCGG 34
Db 6 CTTTCCTTCACACGCGGTGCGG 31

RESULT 6

US-09-422-978-240/C
Sequence 240; Application US/09422978
Patent No. 6537751

GENERAL INFORMATION:

APPLICANT: Cohen, Daniel

APPLICANT: Blumenfeld, Marta

TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

FILE REFERENCE: GENSER.020CPI

CURRENT APPLICATION NUMBER: US/09/422,978

EARLIER FILING DATE: 1999-10-20

EARLIER APPLICATION NUMBER: US 09/298,850

EARLIER FILING DATE: 1999-04-21

EARLIER APPLICATION NUMBER: US 60/109,732

EARLIER FILING DATE: 1998-11-23

EARLIER APPLICATION NUMBER: US 60/082,614

EARLIER FILING DATE: 1998-04-21

NUMBER OF SEQ ID NOS: 11796

SEQ ID NO 240

LENGTH: 47

TYPE: DNA

ORGANISM: Homo Sapiens

FEATURE:

NAME/KEY: allele

LOCATION: 24

OTHER INFORMATION: 99-1368-299 : polymorphic base C or T

US-09-422-978-240

Query Match 33.6%; Score 14.8; DB 4; Length 47;
Best Local Similarity 61.1%; Pred. No. 4.8e+03;
Matches 22; Conservative 1; Mismatches 13; Indels 0; Gaps 0;

Qy 9 CGTTCCTTTAATACCGGTGCGGTATTATTAAGA 44
Db 46 CATTTAATTTAATACATGCTCTCTGTTTGAAGAA 11

RESULT 7

US-09-422-978-1725/C

Sequence 1725; Application US/09422978

Patent No. 6537751

GENERAL INFORMATION:

APPLICANT: Cohen, Daniel

APPLICANT: Blumenfeld, Marta

APPLICANT: Chumakov, Ilya

TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

FILE REFERENCE: GENSER.020CPI

CURRENT APPLICATION NUMBER: US/09/422,978

EARLIER FILING DATE: 1999-10-20

EARLIER APPLICATION NUMBER: US 09/298,850

EARLIER FILING DATE: 1999-04-21

EARLIER APPLICATION NUMBER: US 60/109,732

EARLIER FILING DATE: 1998-11-23

EARLIER APPLICATION NUMBER: US 60/082,614

EARLIER FILING DATE: 1998-04-21

NUMBER OF SEQ ID NOS: 11796

SEQ ID NO 1725

LENGTH: 47

TYPE: DNA

ORGANISM: Homo Sapiens

FEATURE:

NAME/KEY: allele

LOCATION: 24

OTHER INFORMATION: 99-5951-438 : polymorphic base C or T
US-09-422-978-1725

Query Match 33.6%; Score 14.8; DB 4; Length 47;
Best Local Similarity 59.5%; Pred. No. 4.8e+03;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 3 GGGTCCGTCCTTCTATATACCGGTGCGGTATTATTAAGA 44
Db 46 GGTCCCATCTCTCTTATTAATTAAGACCATTAATTAATA 5

RESULT 8

US-08-171-389-585/C

Sequence 585; Application US/08171389

Patent No. 5578444

GENERAL INFORMATION:

APPLICANT: Edwards, Cynthia A.

APPLICANT: Cantor, Charles R.

APPLICANT: Andrews, Beth M.

APPLICANT: Turin, Lisa M.

TITLE OF INVENTION: Sequence-Directed DNA Binding

TITLE OF INVENTION: Molecules, Compositions and Methods

NUMBER OF SEQUENCES: 641

CORRESPONDENCE ADDRESS:

ADDRESSEE: Genelabs Technologies, Inc.

STREET: 505 Penobscot Drive

CITY: Redwood City

STATE: CA

COUNTRY: USA

ZIP: 94063

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/171,389

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/123,936

FILING DATE: 17-SEP-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/996,783

FILING DATE: 23-DEC-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/723,618

FILING DATE: 27-JUN-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/081,070

FILING DATE: 22-JUN-1993

ATTORNEY/AGENT INFORMATION:

NAME: Fabian, Gary R.

REGISTRATION NUMBER: 33,875

REFERENCE/DOCKET NUMBER: 4600-0175/G19P3

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 324-0880

TELEFAX: (415) 324-0960

INFORMATION FOR SEQ ID NO: 585:

SEQUENCE CHARACTERISTICS:

LENGTH: 50 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: NO

ORIGINAL SOURCE:

INDIVIDUAL ISOLATE: Human papilloma virus type-16 E6/E7

INDIVIDUAL ISOLATE: (start site 97)

US-08-171-389-585

Query Match 33.6%; Score 14.8; DB 1; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCCTTCTTAATAACCGGTCGGGTT 36
DB 27 TGCCTTTACTAATACCGGTTTCGGTT 2

RESULT 9

US-08-123-936-585/c
Sequence 585, Application US/08123936
Patent No. 5726014
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
TITLE OF INVENTION: Screening Assay for the Detection of
TITLE OF INVENTION: DNA-Binding Molecules
NUMBER OF SEQUENCES: 640
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/123,936
FILING DATE: 27-JUN-1991
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0075.32/G19P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-08-123-936-585

Query Match 33.6%; Score 14.8; DB 1; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCCTTCTTAATAACCGGTCGGGTT 36
DB 27 TGCCTTTACTAATACCGGTTTCGGTT 2

RESULT 10
US-08-475-228A-585/c
Sequence 585, Application US/08475228A
Patent No. 5869241
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk B.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,228A
FILING DATE: 06-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Stratford, Carol A.
REGISTRATION NUMBER: 34,444
REFERENCE/DOCKET NUMBER: 4600-0175.21/G19P3D2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-08-475-228A-585

Query Match 33.6%; Score 14.8; DB 2; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCCTTCTTAATAACCGGTCGGGTT 36
DB 27 TGCCTTTACTAATACCGGTTTCGGTT 2

RESULT 11
US-08-482-080A-585/c
Sequence 585, Application US/08482080A

Patent No. 6010849
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESS: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,080A
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/171,389
FILING DATE: 20-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Brady, John F.
REGISTRATION NUMBER: 39,118
REFERENCE/DOCKET NUMBER: 4600-0175.20/G19P3D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 324-0880
TELEFAX: (650) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 E6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-08-482-080A-585
Query Match 33.6%; Score 14.8; DB 3; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 11 TTCCTTCTTAATACCGGTCGGGTT 36
Db 27 TGCCTTTACTACTACCGGTTTCGGTT 2
RESULT 12
US-09-354-947-585/C
Sequence 585, Application US/09354947
Patent No. 6384208

GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESS: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/354,947
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/482,080
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: US 08/171,389
FILING DATE: 20-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Brady, John F.
REGISTRATION NUMBER: 39,118
REFERENCE/DOCKET NUMBER: 4600-0175.20/G19P3D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 324-0880
TELEFAX: (650) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 E6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-09-354-947-585
Query Match 33.6%; Score 14.8; DB 3; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 11 TTCCTTCTTAATACCGGTCGGGTT 36
Db 27 TGCCTTTACTACTACCGGTTTCGGTT 2
RESULT 13
PCT-US93-12388-585/C
Sequence 585, Application PC/TUS9312388

GENERAL INFORMATION:
APPLICANT: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 641
CORRESPONDENCE ADDRESS:
ADDRESSEE: GeneLabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/12388
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0175.41/G19PCT2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
INDIVIDUAL ISOLATE: (start site 97)
PCT-US93-12388-585
Query Match 33.6%; Score 14.8; DB 5; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 11 TTCCTCTTAATAACCGGCGGTT 36
DB 27 TGCTTTACTACCGGTTGCGTT 2
RESULT 14
5519127-17
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCOCCUS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:17:
LENGTH: 33
5519127-17

Query Match 33.2%; Score 14.6; DB 6; Length 33;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 9 CGTTCCTCTTAATAACCGGT 29
DB 4 CCTTCCTTCGATTACCGGT 24
RESULT 15
5519127-17
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCOCCUS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:17:
LENGTH: 33
5519127-17

Query Match 33.2%; Score 14.6; DB 6; Length 33;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 9 CGTTCCTCTTAATAACCGGT 29
DB 4 CCTTCCTTCGATTACCGGT 24

RESULT 16
5519127-4/c
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCOCCUS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:4:
LENGTH: 34
5519127-4

Query Match 33.2%; Score 14.6; DB 6; Length 34;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 9 CGTTCCTCTTAATAACCGGT 29
DB 31 CCTTCCTTCGATTACCGGT 11

RESULT 17
5519127-4/c
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCOCCUS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:17:
LENGTH: 33
5519127-17

```
; FILING DATE: 11-AUG-1989
; SEQ ID NO:4
; LENGTH: 34
5519127-4

Query Match          33.2% Score 14.6; DB 6; Length 34;
Best Local Similarity 47.6%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATAACCGGT 29
    |||||
Db 31 CCTTCCTTCTGATTAACCGGT 11

RESULT 18
5519127-33
; Patent No. 5519127
; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCOCCUS CARINITI
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,657
; FILING DATE: 21-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO:33
; LENGTH: 39
5519127-33

Query Match          33.2% Score 14.6; DB 6; Length 39;
Best Local Similarity 47.6%; Pred. No. 5.6e+03;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATAACCGGT 29
    |||||
Db 5 CCUUCUUUCUGAUUACCGGU 25

RESULT 19
5519127-33
; Patent No. 5519127
; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCOCCUS CARINITI
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,657
; FILING DATE: 21-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO:33
; LENGTH: 39
5519127-33

Query Match          33.2% Score 14.6; DB 6; Length 39;
Best Local Similarity 47.6%; Pred. No. 5.6e+03;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATAACCGGT 29
    |||||
Db 5 CCUUCUUUCUGAUUACCGGU 25

RESULT 20
US-07-826-928A-30
; Sequence 30, Application US/07826928A
; Patent No. 5439829
; GENERAL INFORMATION:
; APPLICANT: Anderson, Leslie D.
; APPLICANT: Cook, James A.
```

```
; APPLICANT: David, Gary S.
; APPLICANT: Hochschwender, Susan M.
; APPLICANT: Kasher, Mary S.
; APPLICANT: Smith, Michele C.
; APPLICANT: Stemmer, Willem P.
; TITLE OF INVENTION: METHOD OF IMMOBILIZING AND CROSS LINKING
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: IN
; COUNTRY: USA
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,928A
; FILING DATE: 19920124
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy, Richard B.
; REGISTRATION NUMBER: 35,296
; REFERENCE/DOCKET NUMBER: X8180A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 317-276-3589
; TELEFAX: 317-276-1294
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 46 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-826-928A-30

Query Match          33.2% Score 14.6; DB 1; Length 46;
Best Local Similarity 69.0%; Pred. No. 5.9e+03;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 16 TCTTAATACCGCGCGGTATTATAGAA 44
    |||||
Db 9 TATTAAATAGTATCGCTATTATTAAGA 37

RESULT 21
US-09-422-978-3415
; Sequence 3415, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSER.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 3415
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
```

```
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-3812-243 : polymorphic base T or G
US-09-422-978-3415

Query Match      33.2%; Score 14.6; DB 4; Length 47;
Best Local Similarity 64.5%; Pred. No. 5.9e+03;
Matches 20; Conservative 1; Mismatches 10; Indels 0; Gaps 0;

QY      10 GTTCCTTCTAATACCGGTGCGGTTATT 40
DB      16 GTTCATCCCTAATAACCTTCTCAGCTCCTTA 46

RESULT 22
US-08-889-502-34
; Sequence 34, Application US/08889502
; Patent No. 6066726
; GENERAL INFORMATION:
; APPLICANT: Fair, David H
; APPLICANT: Ruseek, Shelley J
; TITLE OF INVENTION: GENE THERAPY VECTOR WITH TISSUE
; TITLE OF INVENTION: SPECIFICITY
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kevin M. Farrell
; STREET: P.O. Box 999
; CITY: York Harbor
; STATE: ME
; COUNTRY: USA
; ZIP: 03911
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/889,502
; FILING DATE: 08-JUL-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Farrell, Kevin M
; REGISTRATION NUMBER: 35,505
; REFERENCE/DOCKET NUMBER: 0146-2008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (207) 363-0558
; TELEFAX: (207) 363-0528
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 49 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-889-502-34

Query Match      33.2%; Score 14.6; DB 3; Length 49;
Best Local Similarity 62.2%; Pred. No. 6e+03;
Matches 23; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY      3 GGGTCCGCTTCCTTCTAATAACCGGTGCGGTTATT 39
DB      10 GGTGCTTCTCTCTTCTCACTTGTCAAGGGGCTCTTAGT 46

RESULT 23
US-09-422-978-2970
; Sequence 2970, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
```

```
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 2970
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-21307-370 : polymorphic base A or G
US-09-422-978-2970

Query Match      32.7%; Score 14.4; DB 4; Length 47;
Best Local Similarity 69.2%; Pred. No. 7.2e+03;
Matches 18; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY      1 GCGGCTCCGCTTCCTTCTAATAACG 26
DB      22 GCRCCTCCTGTTGCTTCTAATAAGC 47

RESULT 24
US-09-198-452A-6719/C
; Sequence 6719, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifols, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6719
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6719

Query Match      32.3%; Score 14.2; DB 4; Length 20;
Best Local Similarity 84.2%; Pred. No. 7.1e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      10 GTTCCTTCTAATAACCGG 28
DB      19 GTTCCTTCTGATTAACAG 1

RESULT 25
US-09-922-146-31/C
; Sequence 31, Application US/09922146
; Patent No. 6566133
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
; FILE REFERENCE: RTS-0252
; CURRENT APPLICATION NUMBER: US/09/922,146
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-31

Query Match
Best Local Similarity 32.3%; Score 14.2; DB 4; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 21 ATACCGGTCCGGTATT 39
Db 19 AGACCTGTCCGGTCTT 1

RESULT 26
US-09-657-472-1129/C
; Sequence 1129, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolik, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US/09/657,472
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1129
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-1129

Query Match
Best Local Similarity 32.3%; Score 14.2; DB 4; Length 21;
Matches 16; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 13 CTTCTTAATRACCGGTCCG 33
Db 21 CTTCTTAATRACGTGCGG 1

RESULT 27
US-07-956-697B-3
; Sequence 3, Application US/07956697B
; Patent No. 5374543
; GENERAL INFORMATION:
; APPLICANT: Murdoch, Douglas Craig
; TITLE OF INVENTION: Enhanced Indole Biosynthesis
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: Amgen Center
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word Version 5.0
```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/956,697B
; FILING DATE: 02-OCT-1992
; CLASSIFICATION: 435
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
US-07-956-697B-3

Query Match
Best Local Similarity 32.3%; Score 14.2; DB 1; Length 36;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 25 CCGGTCCGGGTATTATAGA 43
Db 11 CCGGTCCGGCGCATTAAGA 29

RESULT 28
US-08-263-098-3
; Sequence 3, Application US/08263098
; Patent No. 5494816
; GENERAL INFORMATION:
; APPLICANT: Murdoch, Douglas Craig
; TITLE OF INVENTION: Enhanced Indole Biosynthesis
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc.
; STREET: Amgen Center
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: California
; COUNTRY: USA
; ZIP: 91320-1789
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word Version 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/263,098
; FILING DATE: 21-JUN-1994
; CLASSIFICATION: 435
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 36 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: unknown
US-08-263-098-3

Query Match
Best Local Similarity 32.3%; Score 14.2; DB 1; Length 36;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 25 CCGGTCCGGGTATTATAGA 43
Db 11 CCGGTCCGGCGCATTAAGA 29

RESULT 29
US-08-857-946-83/C
; Sequence 83, Application US/08857946
; Patent No. 5994075
; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P. N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Banner & Witcoff, Inc.
STREET: 75 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109-1807
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/857,946
FILING DATE: 16-MAY-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/60/017,824
FILING DATE: 17-MAY-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kathleen M. Williams
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3529/05573
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-345-9100
TELEFAX: 617-345-9111
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:
LENGTH: 38 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
FEATURE:
NAME/KEY: primer bmm160f
US-08-857-946-83

Query Match 32.3%; Score 14.2; DB 2; Length 38;
Best Local Similarity 62.9%; Pred. No. 8.3e+03;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 4 GGTCCCGTCTTCTTAATACCGGTGCGGTTAT 38
DB 38 GGTCCAGTATGTCCTTAACGCGCGTCTTT 4

RESULT 30
US-08-970-740-83/C
Sequence 83, Application US/08970740
Patent No. 6015670
GENERAL INFORMATION:
APPLICANT: Goodfellow, P.N.
TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
NUMBER OF SEQUENCES: 162
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Inc.
STREET: 28 State Street, 28th Floor
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/970,740
FILING DATE: 14-NOV-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/857,946
FILING DATE: 16-MAY-1997
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/017,824
FILING DATE: 17-MAY-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kathleen M. Williams
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3529/59829
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-227-7111
TELEFAX: 617-227-4399
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:
LENGTH: 38 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
FEATURE:
NAME/KEY: primer bmm160f
US-08-970-740-83

Query Match 32.3%; Score 14.2; DB 3; Length 38;
Best Local Similarity 62.9%; Pred. No. 8.3e+03;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 4 GGTCCCGTCTTCTTAATACCGGTGCGGTTAT 38
DB 38 GGTCCAGTATGTCCTTAACGCGCGTCTTT 4

RESULT 31
US-09-538-709-983/C
Sequence 983, Application US/09538709
Patent No. 6468749
GENERAL INFORMATION:
APPLICANT: Ulanovsky, et al
TITLE OF INVENTION: SEQUENCE-DEPENDENT GENE SORTING TECHNIQUES
FILE REFERENCE: 540579-2006
CURRENT APPLICATION NUMBER: US/09/538,709
CURRENT FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 1311
SOFTWARE: PatentIn version 3.0
SEQ ID NO 983
LENGTH: 49
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Adaptor
US-09-538-709-983

Query Match 32.3%; Score 14.2; DB 3; Length 49;
Best Local Similarity 70.4%; Pred. No. 8.9e+03;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 9 CGTCCCTTCTTAATACCGGTGCGGCT 35
DB 44 CGTCCGTTCCGATCGCGCGCGGT 18

RESULT 32
US-08-379-452-17
Sequence 17, Application US/08379452
Patent No. 6040174
GENERAL INFORMATION:
APPLICANT: IMER, Jean-Luc
APPLICANT: MEHTALI, Majid
APPLICANT: PAVITANI, Andrea
TITLE OF INVENTION: DEFECTIVE ADENOVIRUSES AND CORRESPONDING
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: 1737 King Street, Suite 500
CITY: Alexandria

STATE: Virginia
COUNTRY: United States
ZIP: 22314-2756
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/379,452
FILING DATE: 26-JAN-1995
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: WO PCT/FR94/00624
FILING DATE: 27-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 93 06482
FILING DATE: 28-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Dadio, Susan M.
REGISTRATION NUMBER: 40,373
REFERENCE/DOCKET NUMBER: 029395-002
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Synthetic oligonucleotide (OTG5482)
US-08-379-452-17

Query Match 31.8%; Score 14; DB 3; Length 24;
Best Local Similarity 77.3%; Pred. No. 9.1e+03;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 23 AACGGTCGGCGTTATTAGAA 44
Db 2 AACTGTCACCGTGATTAAAA 23

RESULT 33
US-09-409-670-17
Sequence 17, Application US/09409670
Patent No. 6133028
GENERAL INFORMATION:
APPLICANT: IMLER, Jean-Luc
APPLICANT: MEHTALI, Majid
APPLICANT: PAVIRANT, Andrea
TITLE OF INVENTION: DEFECTIVE ADENOVIRUSES AND CORRESPONDING
TITLE OF INVENTION: COMPLEMENTATION LINES
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESSES:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: 1737 King Street, Suite 500
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22314-2756
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/409,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/379,452

FILING DATE: 26-JAN-1995
APPLICATION NUMBER: WO PCT/FR94/00624
FILING DATE: 27-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 93 06482
FILING DATE: 28-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Dadio, Susan M.
REGISTRATION NUMBER: 40,373
REFERENCE/DOCKET NUMBER: 029395-002
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Synthetic oligonucleotide (OTG5482)
US-09-409-670-17

Query Match 31.8%; Score 14; DB 3; Length 24;
Best Local Similarity 77.3%; Pred. No. 9.1e+03;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 23 AACGGTCGGCGTTATTAGAA 44
Db 2 AACTGTCACCGTGATTAAAA 23

RESULT 34
US-09-461-697-456
Sequence 456, Application US/09461697
Patent No. 6277974
GENERAL INFORMATION:
APPLICANT: COGENT NEUROSCIENCE, Inc.
APPLICANT: Lo, Donald C.
APPLICANT: Barney, Shawn
APPLICANT: Thomas, Mary Beth
APPLICANT: Portbury, Stuart D.
APPLICANT: Putnam, Kasuri L.
APPLICANT: Katz, Lawrence C.
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING
TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING
TITLE OF INVENTION: CELL DEATH
FILE REFERENCE: 10001-005-999
CURRENT APPLICATION NUMBER: US/09/461,697
CURRENT FILING DATE: 1999-12-14
NUMBER OF SEQ ID NOS: 466
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 456
LENGTH: 30
TYPE: DNA
ORGANISM: Homo sapiens
US-09-461-697-456

Query Match 31.8%; Score 14; DB 3; Length 30;
Best Local Similarity 77.3%; Pred. No. 9.6e+03;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 20 AATAACGGTCGGCGTTATTAA 41
Db 9 AACACCGGTTGGGTTGTTAA 30

RESULT 35
US-09-709-103-34
Sequence 34, Application US/09709103
Patent No. 673391
GENERAL INFORMATION:
APPLICANT: Cismowski, Mary

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/043,553
FILING DATE: 15-APR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/048,740
FILING DATE: 05-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: B.J.Sadoff
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 620-35
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)816-4091
TELEFAX: (703)816-4100
INFORMATION FOR SEQ ID NO: 117:
SEQUENCE CHARACTERISTICS:
LENGTH: 41 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-060-299-117

Query March 31.8%; Score 14; DB 4; Length 41;
Best Local Similarity 66.7%; Pred. No. 1e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATACCGGTGCGGTTAT 38
DB 39 CGTTCCTTCTTAATACCGGTGCGGTTATCAT 10

RESULT 40
US-09-402-923A-117/c
Sequence 117, Application US/09402923A
Patent No. 6555654

GENERAL INFORMATION:

APPLICANT: Todd, John A
Hess, John W
Caskey, Charles T
Cox, Roger D
Gerhold, David
Hammond, Holly
Hey, Patricia
Kawaguchi, Yoshihiko
Merriman, Tony R
Metzker, Michael L
TITLE OF INVENTION: No. 6555654e1 LDL-Receptor
NUMBER OF SEQUENCES: 455
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Nixon and Vanderhye
STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
CITY: Arlington
STATE: Virginia
COUNTRY: US
ZIP: VA 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/402,923A
FILING DATE: 14-Feb-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB98/01102
FILING DATE: 15-APR-1998
APPLICATION NUMBER: US 60/043,553
FILING DATE: 15-APR-1997
APPLICATION NUMBER: US 60/048,740
FILING DATE: 05-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: B.J.Sadoff
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 620-81

TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)816-4091
TELEFAX: (703)816-4100
INFORMATION FOR SEQ ID NO: 117:
SEQUENCE CHARACTERISTICS:
LENGTH: 41 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 117:
US-09-402-923A-117

Query Match 31.8%; Score 14; DB 4; Length 41;
Best Local Similarity 66.7%; Pred. No. 1e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATACCGGTGCGGTTAT 38
DB 39 CGTTCCTTCTTAATACCGGTGCGGTTATCAT 10

Search completed: May 24, 2005, 12:45:35
Job time : 101 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 12:10:04 ; Search time 339 Seconds
(without alignments)
795.936 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943
Perfect score: 44
Sequence: 1 gcgggtccgcctctctta.....ccggtcgcgttataaagaa 44

Scoring table:
IDENTITY NUC
Gapop 10'-0 , Gapext 1.0

Searched: 5695437 seqs, 3066160638 residues
Total number of hits satisfying chosen parameters: 5377818

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database :

Published Applications NA:*

1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq:*
12: /cgn2_6/ptodata/1/pubpna/US09C_NEW_PUB.seq:*
13: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
14: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
16: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq:*
18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq:*
19: /cgn2_6/ptodata/1/pubpna/US10F_NEW_PUB.seq:*
20: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq:*
21: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
22: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	16	36.4	27	9	US-09-854-122-8
2	16	36.4	27	9	US-09-854-122-9
3	16	36.4	30	19	US-10-823-259-45
4	16	36.4	30	19	US-10-823-254-45
5	16	36.4	33	19	US-10-792-498-20
6	15.8	35.9	25	19	US-10-809-189-29372
7	15.8	35.9	41	17	US-10-035-833A-1851
8	15.8	35.9	41	17	US-10-035-833A-4446
9	15.6	35.5	33	18	US-10-466-347-11
10	15.4	35.0	25	18	US-10-719-895-20
11	15.4	35.0	25	19	US-10-719-900-918103

C 12	15.2	34.5	47	18	US-10-343-561-98	Sequence 98, Appl
C 13	15	34.1	25	19	US-10-719-900-350576	Sequence 350576,
C 14	15	34.1	25	19	US-10-719-900-825969	Sequence 825969,
C 15	15	34.1	31	9	US-09-801-274-523	Sequence 523, App
C 16	15	34.1	50	17	US-10-131-827-2605	Sequence 2605, Ap
C 17	15	34.1	50	17	US-10-131-827-7716	Sequence 7716, Ap
C 18	14.8	33.6	25	19	US-10-719-900-81188	Sequence 81188, A
C 19	14.8	33.6	25	19	US-10-719-900-927327	Sequence 927327,
C 20	14.8	33.6	31	10	US-10-809-189-29373	Sequence 29373, A
C 21	14.8	33.6	31	10	US-09-927-046-4154	Sequence 4154, Ap
C 22	14.8	33.6	47	17	US-10-349-143-240	Sequence 240, App
C 23	14.8	33.6	47	17	US-10-349-143-1725	Sequence 1725, Ap
C 24	14.8	33.6	50	10	US-09-993-346-585	Sequence 585, App
C 25	14.8	33.6	50	17	US-10-131-827-2809	Sequence 2809, Ap
C 26	14.6	33.2	25	15	US-10-098-2638-97505	Sequence 97505, A
C 27	14.6	33.2	25	19	US-10-719-900-202404	Sequence 202404,
C 28	14.6	33.2	25	19	US-10-719-900-728815	Sequence 728815,
C 29	14.6	33.2	25	19	US-10-719-900-797256	Sequence 797256,
C 30	14.6	33.2	25	19	US-10-719-900-816976	Sequence 816976,
C 31	14.6	33.2	25	19	US-10-719-900-854921	Sequence 854921,
C 32	14.6	33.2	25	19	US-10-719-900-896407	Sequence 896407,
C 33	14.6	33.2	35	19	US-10-489-739-7	Sequence 7, Appl
C 34	14.6	33.2	41	17	US-10-252-155-747	Sequence 747, App
C 35	14.6	33.2	45	9	US-09-991-003B-16	Sequence 16, Appl
C 36	14.6	33.2	47	17	US-10-349-143-3415	Sequence 3415, Ap
C 37	14.4	32.7	25	15	US-10-098-2638-88885	Sequence 88885, A
C 38	14.4	32.7	25	19	US-10-719-900-221631	Sequence 221631,
C 39	14.4	32.7	25	19	US-10-719-900-221632	Sequence 221632,
C 40	14.4	32.7	25	19	US-10-719-900-434524	Sequence 434524,
C 41	14.4	32.7	25	19	US-10-719-900-639025	Sequence 639025,
C 42	14.4	32.7	34	14	US-10-025-222A-7	Sequence 7, Appl
C 43	14.4	32.7	41	17	US-10-252-155-747	Sequence 747, App
C 44	14.4	32.7	47	17	US-10-349-143-2970	Sequence 2970, Ap
C 45	14.4	32.7	50	17	US-10-062-188-159	Sequence 159, App
C 46	14.4	32.7	50	17	US-10-062-188-159	Sequence 159, App
C 47	14.2	32.3	20	10	US-09-922-146-31	Sequence 31, Appl
C 48	14.2	32.3	20	17	US-10-289-762-6719	Sequence 6719, Ap
C 49	14.2	32.3	21	18	US-10-786-720-7147	Sequence 7147, Ap
C 50	14.2	32.3	21	18	US-10-786-720-9415	Sequence 9415, Ap
C 51	14.2	32.3	21	19	US-10-848-755A-25	Sequence 25, Appl
C 52	14.2	32.3	32	17	US-10-371-771-16	Sequence 16, Appl
C 53	14.2	32.3	33	18	US-10-799-372-2	Sequence 2, Appl
C 54	14.2	32.3	39	17	US-10-423-828-54	Sequence 54, Appl
C 55	14.2	32.3	50	17	US-10-175-689-10	Sequence 10, Appl
C 56	14.2	32.3	50	17	US-10-131-827-4778	Sequence 4778, Ap
C 57	14	31.8	24	9	US-09-725-720-17	Sequence 17, Appl
C 58	14	31.8	24	10	US-09-739-007-17	Sequence 17, Appl
C 59	14	31.8	25	19	US-10-169-900-1	Sequence 1, Appl
C 60	14	31.8	25	19	US-10-719-900-118945	Sequence 118945,
C 61	14	31.8	25	19	US-10-719-900-118965	Sequence 118965,
C 62	14	31.8	25	19	US-10-719-900-328268	Sequence 328268,
C 63	14	31.8	25	19	US-10-719-900-328269	Sequence 328269,
C 64	14	31.8	25	19	US-10-719-900-328269	Sequence 328269,
C 65	14	31.8	25	19	US-10-719-900-349040	Sequence 349040,
C 66	14	31.8	25	19	US-10-719-900-349041	Sequence 349041,
C 67	14	31.8	25	19	US-10-719-900-350580	Sequence 350580,
C 68	14	31.8	25	19	US-10-719-900-572728	Sequence 572728,
C 69	14	31.8	25	19	US-10-719-900-804828	Sequence 804828,
C 70	14	31.8	25	19	US-10-719-900-818986	Sequence 818986,
C 71	14	31.8	30	9	US-09-922-261-456	Sequence 456, App
C 72	14	31.8	32	18	US-10-804-491-34	Sequence 34, Appl
C 73	14	31.8	35	18	US-10-804-491-8	Sequence 8, Appl
C 74	14	31.8	38	15	US-10-282-287-29	Sequence 29, Appl
C 75	14	31.8	41	16	US-10-331-907-117	Sequence 117, App
C 76	14	31.8	42	18	US-10-804-408-96	Sequence 96, Appl
C 77	14	31.8	45	14	US-10-294-171-5	Sequence 5, Appl
C 78	14	31.8	47	17	US-09-993-346-250	Sequence 250, App
C 79	13.8	31.4	21	18	US-10-349-143-990	Sequence 990, App
C 80	13.8	31.4	21	18	US-10-786-720-7148	Sequence 7148, Ap
C 81	13.8	31.4	21	18	US-10-786-720-7149	Sequence 7149, Ap
C 82	13.8	31.4	21	18	US-10-786-720-9416	Sequence 9416, Ap
C 83	13.8	31.4	21	18	US-10-786-720-9417	Sequence 9417, Ap
C 84	13.8	31.4	24	10	US-09-940-185-1982	Sequence 1982, Ap
C 85	13.8	31.4	25	14	US-10-215-112-12954	Sequence 12954, A

```
C 85 13.8 31.4 25 15 US-10-098-263B-71257 Sequence 71257, A
C 86 13.8 31.4 25 15 US-10-098-263B-71258 Sequence 71258, A
C 87 13.8 31.4 25 15 US-10-098-263B-87670 Sequence 87670, A
C 88 13.8 31.4 25 15 US-10-098-263B-124443 Sequence 124443, A
C 89 13.8 31.4 25 15 US-10-098-263B-130243 Sequence 130243, A
C 90 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 91 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 92 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 93 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 94 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 95 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 96 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 97 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 98 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 99 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
C 100 13.8 31.4 25 19 US-10-098-263B-130243 Sequence 130243, A
```

ALIGNMENTS

```
RESULT 1
US-09-854-122-8/c
; Sequence 8, Application US/09854122
; Patent No. US20020016980A1
; GENERAL INFORMATION:
; APPLICANT: ALBERTE, RANDALL S.
; TITLE OF INVENTION: TRANSGENIC PLANTS INCORPORATING TRAIT OF ZOSTERA MARINA
; FILE REFERENCE: PHA-007.01
; CURRENT APPLICATION NUMBER: US/09/854,122
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/202,529
; PRIOR FILING DATE: 2000-05-10
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-854-122-8
Query Match 36.4%; Score 16; DB 9; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.8e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Cy 20 AATAACCGGTGCGGTTATTAGA 43
Db 25 AATACTTGTCGGGTATATCAGA 2

RESULT 2
US-09-854-122-9
; Sequence 9, Application US/09854122
; Patent No. US20020016980A1
; GENERAL INFORMATION:
; APPLICANT: ALBERTE, RANDALL S.
; TITLE OF INVENTION: TRANSGENIC PLANTS INCORPORATING TRAIT OF ZOSTERA MARINA
; FILE REFERENCE: PHA-007.01
; CURRENT APPLICATION NUMBER: US/09/854,122
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/202,529
; PRIOR FILING DATE: 2000-05-10
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-854-122-9
Query Match 36.4%; Score 16; DB 9; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.8e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Cy 20 AATAACCGGTGCGGTTATTAGA 43
Db 25 AATACTTGTCGGGTATATCAGA 2
```

```
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-854-122-9
Query Match 36.4%; Score 16; DB 9; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.8e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
Cy 20 AATAACCGGTGCGGTTATTAGA 43
Db 3 AATACTTGTCGGGTATATCAGA 26
```

```
RESULT 3
US-10-823-259-45
; Sequence 45, Application US/10823259
; Publication No. US20050049176A1
; GENERAL INFORMATION:
; APPLICANT: Kiener, Peter
; APPLICANT: Langermann, Solomon
; TITLE OF INVENTION: EphA2 and Hyperproliferative Cell Disorders and Epithelial and
; FILE REFERENCE: 10271-058-999
; CURRENT APPLICATION NUMBER: US/10/823,259
; CURRENT FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: 60/462,009
; PRIOR FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: phosphorothioate-modified an
US-10-823-259-45
Query Match 36.4%; Score 16; DB 19; Length 30;
Best Local Similarity 79.2%; Pred. No. 6e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
Cy 2 CGGTCGCGGTCTTCTTAATAC 25
Db 3 CGGTCGCGGTCTTCTTACATGAC 26
```

```
RESULT 4
US-10-823-254-45
; Sequence 45, Application US/10823254
; Publication No. US20050059592A1
; GENERAL INFORMATION:
; APPLICANT: Kiener, Peter
; APPLICANT: Langermann, Solomon
; TITLE OF INVENTION: EphA2 and Hyperproliferative Cell Disorders
; FILE REFERENCE: 10271-060-999
; CURRENT APPLICATION NUMBER: US/10/823,254
; CURRENT FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: 60/462,024
; PRIOR FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: phosphorothioate-modified an
US-10-823-254-45
Query Match 36.4%; Score 16; DB 19; Length 30;
```

Best Local Similarity 79.2%; Pred. No. 6e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2 CGGGTCCGGTCTCTTAAATAC 25
|||:|||||:|||||
Db 3 CGGTCGGTCTCTTACCATGAC 26

RESULT 5

US-10-792-498-20/c
; Sequence 20, Application US/10792498
; Publication No. US20050074865A1

GENERAL INFORMATION:
; APPLICANT: Afeyan, Noubar B.
; APPLICANT: Lee, Frank D.
; APPLICANT: Wong, Gordon G.
; APPLICANT: Das Gupta, Ruchira
; APPLICANT: Baynes, Brian
; TITLE OF INVENTION: ADZYMES AND USES THEREOF
; FILE REFERENCE: COTR-P03-001
; CURRENT APPLICATION NUMBER: US/10/792,498
; PRIOR FILING DATE: 2004-03-02
; PRIOR APPLICATION NUMBER: US 10/650,592
; PRIOR FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 60/406,517
; PRIOR FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: US 60/423,754
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/430,001
; PRIOR FILING DATE: 2002-11-27
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligo prethrombinfwdH3
US-10-792-498-20

Query Match 36.4%; Score 16; DB 19; Length 33;
Best Local Similarity 79.2%; Pred. No. 6.1e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 19 TAATAACGGTCCGGTATTAAAG 42
|||:|||||:|||||
Db 32 TACTCACTGTCGGCGTCATTAAAG 9

RESULT 6

US-10-809-189-29372/c
; Sequence 29372, Application US/10809189
; Publication No. US20050048531A1

GENERAL INFORMATION:
; APPLICANT: Michael Mittemann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29372
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-29372

Query Match 35.9%; Score 15.8; DB 19; Length 25;
Best Local Similarity 89.5%; Pred. No. 7e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CGGTCCGGTCTTAAAGAA 44
|||:|||||:|||||
Db 19 CAGTCCGGTAAATTAAGA 1

RESULT 7

US-10-035-833A-1851
; Sequence 1851, Application US/10035833A
; Publication No. US20040072156A1

GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035,833A
; PRIOR FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1851
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-1851

Query Match 35.9%; Score 15.8; DB 17; Length 41;
Best Local Similarity 81.0%; Pred. No. 7.9e+03;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GTCCCGTCTCTTAAATAC 25
|||:|||||:|||||
Db 16 GTCCCTTCCTTCAATATAC 36

RESULT 8

US-10-035-833A-4446
; Sequence 4446, Application US/10035833A
; Publication No. US20040072156A1

GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035,833A
; PRIOR FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4446
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-4446

Query Match 35.9%; Score 15.8; DB 17; Length 41;
Best Local Similarity 81.0%; Pred. No. 7.9e+03;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GTCCCGTCTCTTAAATAC 25
|||:|||||:|||||
Db 16 GTCCCTTCCTTCAATATAC 36

RESULT 9

US-10-466-347-11/c
; Sequence 11, Application US/10466347

```
; Publication No. US20040109849A1
; GENERAL INFORMATION:
; APPLICANT: Fazio, Vito M.
; TITLE OF INVENTION: DNA VACCINES EXPRESSING HYPERVARIABLE VH-CDR3 IDIOTYPIC DETERMINA
; FILE REFERENCE: 02901/000028-US00
; CURRENT APPLICATION NUMBER: US/10/466,347
; PRIOR APPLICATION NUMBER: PCT/IT01/00014
; PRIOR FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-466-347-11

Query Match          35.5%; Score 15.6; DB 18; Length 33;
Best Local Similarity 70.0%; Pred. No. 9.1e+03;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Cy      3 GGGTCCCGCTCTCTTATTAACCGGTGGC 32
Db      33 GGTACCGCTCTCTCATATTAAGCGCGCGC 4

RESULT 10
US-10-719-895-20/c
; Sequence 20, Application US/10719895
; Publication No. US20040213805A1
; GENERAL INFORMATION:
; APPLICANT: Verheijde, Monique H.
; TITLE OF INVENTION: Deletions in Arterivirus replicons
; FILE REFERENCE: P55434US
; CURRENT APPLICATION NUMBER: US/10/719,895
; PRIOR FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: EP 01201921.2
; PRIOR FILING DATE: 2001-05-21
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer LV266
US-10-719-895-20

Query Match          35.0%; Score 15.4; DB 18; Length 25;
Best Local Similarity 76.0%; Pred. No. 1e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Cy      6 TCCGCTTCCTTCTTATAACCGGTC 30
Db      25 TCGCGTGACTTCTTATTAACAGTC 1

RESULT 11
US-10-719-900-918103/c
; Sequence 918103, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

```
; SEQ ID NO 918103
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-918103

Query Match          35.0%; Score 15.4; DB 19; Length 25;
Best Local Similarity 76.0%; Pred. No. 1e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Cy      17 CTTATTAACCGGTGCGGTATTAA 41
Db      25 CTGAAGATCTGTAGCTTTATTAA 1

RESULT 12
US-10-343-561-98/c
; Sequence 98, Application US/10343561
; Publication No. US20040126389A1
; GENERAL INFORMATION:
; APPLICANT: Berthet, Francois-Xavier Jacques
; APPLICANT: Dalemans, Wilfried
; APPLICANT: Denoel, Philippe
; APPLICANT: Dequeane, Guy
; APPLICANT: Feron, Christiane
; APPLICANT: Garcon, Nathalie
; APPLICANT: Lobet, Yves
; APPLICANT: Poolman, Jan
; APPLICANT: Thiry, Georges
; APPLICANT: Thonnard, Joelle
; APPLICANT: Voet, Pierre
; TITLE OF INVENTION: Vaccines Comprising Outer Membrane
; TITLE OF INVENTION: Vesicles from Gram Negative Bacteria
; FILE REFERENCE: B45260
; CURRENT APPLICATION NUMBER: US/10/343,561
; PRIOR FILING DATE: 2003-01-31
; PRIOR APPLICATION NUMBER: PCT/EP01/08857
; PRIOR FILING DATE: 2001-07-31
; PRIOR APPLICATION NUMBER: EP 00956369.3
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: GB 0103170.7
; PRIOR FILING DATE: 2001-02-08
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: EMS4 primer
US-10-343-561-98

Query Match          34.5%; Score 15.2; DB 18; Length 47;
Best Local Similarity 71.4%; Pred. No. 1.5e+04;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Cy      17 CTTATTAACCGGTGCGGTATTAA 44
Db      41 CATATTTCCGAGCGGTTAATTAAGA 14

RESULT 13
US-10-719-900-350576/c
; Sequence 350576, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
```

NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 350576
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-350576

Query Match 34.1%; Score 15; DB 19; Length 25;
Best Local Similarity 78.3%; Pred. No. 1.5e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 12 TCCTTCTTAATACCGGTGCGG 34
Db 23 TCTGCTTAATACCTGCTCCGG 1

RESULT 14
US-10-719-900-825969
Sequence 825969, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
CURRENT FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002.11.20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 825969
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-825969

Query Match 34.1%; Score 15; DB 19; Length 25;
Best Local Similarity 78.3%; Pred. No. 1.5e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 GCGGTCGCCGTTCTTCTTATA 23
Db 3 GTGGTTCAGTTGATCTTATA 25

RESULT 15
US-09-801-274-523/C
Sequence 523, Application US/09801274
Patent No. US20020032319A1
GENERAL INFORMATION:
APPLICANT: Cargill, Michele
APPLICANT: Ireland, James S.
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
FILE REFERENCE: 2825.2009-001
CURRENT APPLICATION NUMBER: US/09/801,274
CURRENT FILING DATE: 2001-03-07
PRIOR APPLICATION NUMBER: US 60/187,510
PRIOR FILING DATE: 2000-03-07
PRIOR APPLICATION NUMBER: US 60/206,129
PRIOR FILING DATE: 2000-05-22
NUMBER OF SEQ ID NOS: 1802
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 523
LENGTH: 31
TYPE: DNA
ORGANISM: Homo sapiens
US-09-801-274-523

Query Match 34.1%; Score 15; DB 9; Length 31;
Best Local Similarity 78.3%; Pred. No. 1.6e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 12 TCCTTCTTAATACCGGTGCGG 34
Db 29 TCTTCTTAATGACTGTGCGG 7

RESULT 16
US-10-131-827-2605
Sequence 2605, Application US/10131827
Publication No. US20040009479A1
GENERAL INFORMATION:
APPLICANT: Wohlgenuth, Jay
APPLICANT: Fry, Kirk
APPLICANT: Woodward, Robert
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
FILE REFERENCE: 506612000120
CURRENT APPLICATION NUMBER: US/10/131,827
CURRENT FILING DATE: 2002-09-06
PRIOR APPLICATION NUMBER: US 10/006,290
PRIOR FILING DATE: 2001-10-22
PRIOR APPLICATION NUMBER: US 60/296,764
PRIOR FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 9090
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2605
LENGTH: 50
TYPE: DNA
ORGANISM: Homo sapiens
US-10-131-827-2605

Query Match 34.1%; Score 15; DB 17; Length 50;
Best Local Similarity 67.7%; Pred. No. 1.8e+04;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 14 CTTCTTAATACCGGTGCGGTTTAAAGAA 44
Db 2 CTGCTCATCTCTTTGCGGCTTATTGAA 32

RESULT 17
US-10-131-827-7716/C
Sequence 7716, Application US/10131827
Publication No. US20040009479A1
GENERAL INFORMATION:
APPLICANT: Wohlgenuth, Jay
APPLICANT: Fry, Kirk
APPLICANT: Woodward, Robert
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
FILE REFERENCE: 506612000120
CURRENT APPLICATION NUMBER: US/10/131,827
CURRENT FILING DATE: 2002-09-06
PRIOR APPLICATION NUMBER: US 10/006,290
PRIOR FILING DATE: 2001-10-22
PRIOR APPLICATION NUMBER: US 60/296,764
PRIOR FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 9090
SOFTWARE: PatentIn version 3.1
SEQ ID NO 7716
LENGTH: 50
TYPE: DNA
ORGANISM: Homo sapiens
US-10-131-827-7716

Query Match 34.1%; Score 15; DB 17; Length 50;
Best Local Similarity 67.7%; Pred. No. 1.8e+04;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 12 TCCTTCTTAATACCGGTGCGGTTTAAAG 42

```
Db      49  TTCTTCTTCAATGAGTGGCTTTTGAAAAG 19

RESULT 18
; US-10-719-900-81188
; Sequence 81188, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 81188
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-10-719-900-81188

Query Match      33.6%; Score 14.8; DB 19; Length 25;
Best Local Similarity 88.9%; Pred. No. 1.9e+04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      6  TCCGTCCTCTTCTTATA 23
Db      8  TCCTGTACTTCTTATA 25

RESULT 19
; US-10-719-900-927327/c
; Sequence 927327, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 927327
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-10-719-900-927327

Query Match      33.6%; Score 14.8; DB 19; Length 25;
Best Local Similarity 88.9%; Pred. No. 1.9e+04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      24  ACCGTCGCGGTATTAA 41
Db      22  ACCTGTGCGGATATTAA 5

RESULT 20
; US-10-809-189-29373/c
; Sequence 29373, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affimetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189

Db      49  TTCTTCTTCAATGAGTGGCTTTTGAAAAG 19

CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29373
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-10-809-189-29373

Query Match      33.6%; Score 14.8; DB 19; Length 25;
Best Local Similarity 88.9%; Pred. No. 1.9e+04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      26  CGTCGCGGTATTAGA 43
Db      18  CAGTCGCGGTATTAGA 1

RESULT 21
; US-09-927-046-4154/c
; Sequence 4154, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4154
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic Acid
; US-09-927-046-4154

Query Match      33.6%; Score 14.8; DB 10; Length 31;
Best Local Similarity 73.1%; Pred. No. 2e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

OY      5  GTCCCGTCTCTTATTAACCGGTC 30
Db      30  GTCCCGTCTGTGACTAGCCCGTC 5

RESULT 22
; US-10-349-143-240/c
; Sequence 240, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
```


PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 240
LENGTH: 47
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: allele
LOCATION: 24
OTHER INFORMATION: 99-1368-299 : polymorphic base C or T
US-10-349-143-240

Query Match 33.6% Score 14.8; DB 17; Length 47;
Best Local Similarity 61.1%; Pred. No. 2.2e+04;
Matches 22; Conservative 1; Mismatches 13; Indels 0; Gaps 0;

Qy 9 GGTTCCTCTTATATACCGGTGCGGTATTATTAAGA 44
Db 46 CATTATATTTATATACATGCTCTCTTTTGA 11

RESULT 23
US-10-349-143-1725/C
Sequence 1725, Application US/10349143
Publication No. US20040005584A1
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Ballelic markers for use in constructing a high density...
FILE REFERENCE: GEMSET 020CPI
CURRENT APPLICATION NUMBER: US/10/349,143
PRIOR FILING DATE: 2003-01-21
PRIOR APPLICATION NUMBER: US/09/422,978
PRIOR FILING DATE: 1999-10-20
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 1725
LENGTH: 47
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: allele
LOCATION: 24
OTHER INFORMATION: 99-5951-438 : polymorphic base C or T
US-10-349-143-1725

Query Match 33.6% Score 14.8; DB 17; Length 47;
Best Local Similarity 59.5%; Pred. No. 2.2e+04;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 3 GGGTCCCGTTCCTCTTATATACCGGTGCGGTATTATTAAGA 44
Db 46 GGGTCCCGATCTCTCTTATATATAGACCATTAATATATA 5

RESULT 24
US-09-993-346-585/C
Sequence 585, Application US/0993346
Publication No. US20030124530A1
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.

Turin, Lisa M.
Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/993,346
FILING DATE: 13-NO. US20030124530A1-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/354,947
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/171,389
FILING DATE: 20-DEC-1993
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Brady, John F.
REGISTRATION NUMBER: 39,118
REFERENCE/DOCKET NUMBER: 4600-0175.20/G19P3D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 324-0880
TELEFAX: (650) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 E6/E7
(start site 97)
US-09-993-346-585

Query Match 33.6% Score 14.8; DB 10; Length 50;
Best Local Similarity 73.1%; Pred. No. 2.2e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTTATATACCGGTGCGGTT 36
Db 27 TGCCTTATATACCGGTTCGGTT 2

RESULT 25
US-10-131-827-2809
Sequence 2809, Application US/10131827
Publication No. US20040009479A1
GENERAL INFORMATION:
APPLICANT: Wohlgenuth, Jay
APPLICANT: Fry, Kirk
APPLICANT: Woodward, Robert
APPLICANT: Ly, Ngoc
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE

```

; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2809
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-2809

Query Match          33.2%; Score 14.6; DB 17; Length 50;
Best Local Similarity 64.7%; Pred. No. 2.2e+04;
Matches 22; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy      11 TTCCTTTTAATTAACCGGTCGGCTTATTAGAA 44
      ||||| ||||| ||||| ||||| |||||
Db      10 TTTCGACAGCATTAAGCTGGCGCTTATTAGAA 43

RESULT 26
US-10-098-263B-97505
; Sequence 97505, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
; APPLICANT: Miltman, Michael
; TITLE OF INVENTION: Human Microarray
; FILE REFERENCE: 3118.1
; CURRENT APPLICATION NUMBER: US/10/098,263B
; CURRENT FILING DATE: 2003-01-08
; PRIOR APPLICATION NUMBER: 60/276,759
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 131066
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 97505
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-098-263B-97505

Query Match          33.2%; Score 14.6; DB 15; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      2 CGGGTCCGCTTCCTTCTTAAT 22
      ||||| ||||| ||||| |||||
Db      3 CGGGTCCGCTTCCTTCTTAAT 23

RESULT 27
US-10-719-900-202404
; Sequence 202404, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 202404
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-202404
```

```

Query Match          33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      4 GGTCCGCTTCCTTCTTAATA 24
      ||||| ||||| ||||| |||||
Db      2 GGTCACTCTCTTCTTCTTA 22

RESULT 28
US-10-719-900-728815
; Sequence 728815, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 728815
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-728815

Query Match          33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      10 GTTCCTTCTTAATTAACCGGTC 30
      ||||| ||||| ||||| |||||
Db      1 GTTCCTTCTCACTTACCAAGTC 21

RESULT 29
US-10-719-900-797256
; Sequence 797256, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 797256
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-797256

Query Match          33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      4 GGTCCGCTTCCTTCTTAATA 24
      ||||| ||||| ||||| |||||
Db      5 GGTCCCTTACTGCTTATAA 25

RESULT 30
US-10-719-900-816976
; Sequence 816976, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT FILING DATE: 2003-11-20
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 816976
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-816976

Query Match 33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 6 TCCCGTCTCTTATTAATACC 26
Db 1 TCCCTTCTCTTATTAATCC 21

RESULT 31
US-10-719-900-854921
Sequence 854921, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT FILING DATE: 2003-11-20
PRIOR FILING DATE: 2002-11-20
PRIOR APPLICATION NUMBER: 60/427,808
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 854921
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-854921

Query Match 33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 GCGGCTCCGCTTCTTTTAA 21
Db 5 GCGGCTCCGCTTCTTCACTTAA 25

RESULT 32
US-10-719-900-896407
Sequence 896407, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT FILING DATE: 2003-11-20
PRIOR FILING DATE: 2002-11-20
PRIOR APPLICATION NUMBER: 60/427,808
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 896407
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-896407

Query Match 33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 10 GTTCCTCTTAATACCGGTC 30
Db 3 GTTCCTACGTAAATCGGGTC 23

RESULT 33
US-10-489-739-7/c
Sequence 7, Application US/10489739
Publication No. US20050070690A1
GENERAL INFORMATION:
APPLICANT: The University of Bristol
APPLICANT: Dawbarn, David
APPLICANT: Allen, Shelley Jane
APPLICANT: Robertson, Alan George Simpson
TITLE OF INVENTION: Polypeptide Purification Method
FILE REFERENCE: 62637.000006
CURRENT FILING DATE: 2004-03-16
PRIOR FILING DATE: 2004-03-16
PRIOR APPLICATION NUMBER: GB0122400.5
PRIOR FILING DATE: 2001-09-17
PRIOR APPLICATION NUMBER: PCT/GB02/04214
PRIOR FILING DATE: 2002-09-17
NUMBER OF SEQ ID NOS: 44
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 35
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: TrkBtg2 6His Reverse Primer
US-10-489-739-7

Query Match 33.2%; Score 14.6; DB 19; Length 35;
Best Local Similarity 73.9%; Pred. No. 2.5e+04;
Matches 17; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 21 ATAAACCGGTCCGGTTATTAAGA 43
Db 32 AAAACCGGTCCGGYCATTTAATA 10

RESULT 34
US-10-252-155-747/c
Sequence 747, Application US/10252155
Publication No. US20040068096A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS IN ORGANIC ANION TRANSPORT
FILE REFERENCE: D0152 NP
CURRENT FILING DATE: 2002-09-20
PRIOR FILING DATE: 2001-09-21
PRIOR APPLICATION NUMBER: US 60/324,172
PRIOR FILING DATE: 2001-09-21
PRIOR APPLICATION NUMBER: US 60/333,700
NUMBER OF SEQ ID NOS: 783
SOFTWARE: PatentIn version 3.1
SEQ ID NO 747
LENGTH: 41
TYPE: DNA
ORGANISM: Homo sapiens
US-10-252-155-747

Query Match 33.2%; Score 14.6; DB 17; Length 41;
Best Local Similarity 69.0%; Pred. No. 2.6e+04;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 10 GTTCCTCTTAATACCGGTTCGGTTAT 38

Db 41 GCTCCTCTCTTTTAACCTTACCGGTCAAT 13

RESULT 35

US-09-991-003B-16/c
 ; Sequence 16, Application US/09991003B
 ; Patent No. US20020177125A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KAMB, Carl Alexander
 ; APPLICANT: PORITZ, Mark Aaron
 ; APPLICANT: TENG, David Heng-Fai
 ; TITLE OF INVENTION: Human Rhinovirus Assays, and Compositions Therefrom
 ; FILE REFERENCE: 29345/36971A
 ; CURRENT APPLICATION NUMBER: US/09/991,003B
 ; CURRENT FILING DATE: 2002-11-16
 ; NUMBER OF SEQ ID NOS: 28
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 16
 ; LENGTH: 45
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: rh1D.R2 primer
 US-09-991-003B-16

Query Match 33.2%; Score 14.6; DB 9; Length 45;
 Best Local Similarity 62.2%; Pred. No. 2.6e+04;
 Matches 23; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 4 GGTCCGCTCTCTTAATACCGGTGGGTATTA 40

Db 37 GGTGACATTAACTCTATTAAAGCGCGCTGTATTGA 1

RESULT 36

US-10-349-143-3415
 ; Sequence 3415, Application US/10349143
 ; Publication No. US20040005584A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Cohen, Daniel
 ; APPLICANT: Blumenfeld, Marta
 ; APPLICANT: Chumakov, Ilya
 ; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
 ; FILE REFERENCE: GENSET.020CPI
 ; CURRENT APPLICATION NUMBER: US/10/349,143
 ; CURRENT FILING DATE: 2003-01-21
 ; PRIOR APPLICATION NUMBER: US/09/422,978
 ; PRIOR FILING DATE: 1999-10-20
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
 ; NUMBER OF SEQ ID NOS: 11796
 ; SEQ ID NO 3415
 ; LENGTH: 47
 ; TYPE: DNA
 ; ORGANISM: Homo Sapiens
 ; FEATURE:
 ; NAME/KEY: allele
 ; LOCATION: 24
 ; OTHER INFORMATION: 99-3812-243 : polymorphic base T or G
 US-10-349-143-3415

Query Match 33.2%; Score 14.6; DB 17; Length 47;
 Best Local Similarity 64.5%; Pred. No. 2.7e+04;
 Matches 20; Conservative 1; Mismatches 10; Indels 0; Gaps 0;

Qy 10 GTTCTCTTAATACCGGTGGGTATTA 40

Db 16 GTTCATCCKTAAACCAATTCACGCTCCTA 46

RESULT 37

US-10-098-263B-88885/c
 ; Sequence 88885, Application US/10098263B
 ; Publication No. US20030104410A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Miltman, Michael
 ; TITLE OF INVENTION: Human Microarray
 ; FILE REFERENCE: 3118.1
 ; CURRENT APPLICATION NUMBER: US/10/098,263B
 ; CURRENT FILING DATE: 2003-01-08
 ; PRIOR APPLICATION NUMBER: 60/276,759
 ; PRIOR FILING DATE: 2001-03-16
 ; NUMBER OF SEQ ID NOS: 131066
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
 ; SEQ ID NO 88885
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: Homo sapien
 US-10-098-263B-88885

Query Match 33.7%; Score 14.4; DB 15; Length 25;
 Best Local Similarity 75.0%; Pred. No. 2.8e+04;
 Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3 GGTCCGCTCTCTTAATACCGGTGGGTATTA 26

Db 25 GAGTACCGGTCTCTCTGATTAATTAAC 2

RESULT 38

US-10-719-900-221631
 ; Sequence 221631, Application US/10719900
 ; Publication No. US20050026164A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Xue Wei Zhou
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
 ; FILE REFERENCE: 3528.1
 ; CURRENT APPLICATION NUMBER: US/10/719,900
 ; CURRENT FILING DATE: 2003-11-20
 ; PRIOR APPLICATION NUMBER: 60/427,808
 ; PRIOR FILING DATE: 2002-11-20
 ; NUMBER OF SEQ ID NOS: 982914
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
 ; SEQ ID NO 221631
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: Mus musculus
 US-10-719-900-221631

Query Match 32.7%; Score 14.4; DB 19; Length 25;
 Best Local Similarity 75.0%; Pred. No. 2.8e+04;
 Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 10 GTTCTCTTAATACCGGTGGGTATTA 33

Db 2 GTTCTTGCTACTAACAAGTCACG 25

RESULT 39

US-10-719-900-221632
 ; Sequence 221632, Application US/10719900
 ; Publication No. US20050026164A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Xue Wei Zhou
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
 ; FILE REFERENCE: 3528.1
 ; CURRENT APPLICATION NUMBER: US/10/719,900
 ; CURRENT FILING DATE: 2003-11-20
 ; PRIOR APPLICATION NUMBER: 60/427,808
 ; PRIOR FILING DATE: 2002-11-20
 ; NUMBER OF SEQ ID NOS: 982914

```
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 221632
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-221632
```

```
Query Match          32.7%; Score 14.4; DB 19; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
```

```
QY      10 GTTCCTCTTATACCGGTGCG 33
          ||||| ||||| |||||
DB       2 GTCTTGTCTAGTACCGATCAG 25
```

RESULT 40

```
US-10-719-900-434524/C
; Sequence 434524, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 434524
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-434524
```

```
Query Match          32.7%; Score 14.4; DB 19; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
```

```
QY      16 TCTTATATACCGGTGCGGTATAT 39
          ||||| ||||| |||||
DB       25 TCTTACGACGAGTCTGGGTATAT 2
```

Search completed: May 24, 2005, 13:22:14
Job time : 340 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 11:54:00 ; Search time 1848 Seconds
(without alignments)
906.292 Million cell updates/sec

Title: us-10-673-063-3_COPY_900_943

Perfect score: 44
Sequence: 1 gcggggtccgcgttcctctta.....ccggtcgcggtattaaagaa 44

Scoring table:
IDENTITY NUC
Gapop 10-0, Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 159776

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 100 summaries

Database :

EST: *
1: gb_est1: *
2: gb_est2: *
3: gb_hic: *
4: gb_est3: *
5: gb_est4: *
6: gb_est5: *
7: gb_est6: *
8: gb_g881: *
9: gb_g882: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	* Query Match Length DB ID	Description
1	16	36.4	35 8 BZ763244 SALK_1156
2	15.8	35.9	50 9 CR191751 Forward s
3	15.4	35.0	50 9 AL754601 Arabidops
4	15.2	34.5	46 8 AZ438384 IM0228024
5	15.2	34.5	50 1 AU104874 AU104874
6	15.2	34.5	50 1 AU106701 AU106701
7	15	34.1	49 8 AZ808932 2M0072809
8	14.8	33.6	46 4 BU049506 BU049506
9	14.6	33.2	41 8 AZ795288 2M0049M22
10	14.6	33.2	50 9 CR147596 Forward s
11	14.4	32.7	32 8 BH811169 Forward s
12	14.4	32.7	45 8 BH636447 1008011D0
13	14.4	32.7	46 8 BH904918 SALK_1053
14	14.4	32.7	49 6 CB190523 PI27G03.Y
15	14.4	32.7	50 8 BH791926 SALK_0620
16	14.4	32.7	50 9 CR147596 Forward s
17	14.2	32.3	50 1 AU102908 AU102908
18	14	31.8	41 9 TAI92A120 T. brucei
19	14	31.8	48 8 AZ801189 2M0059K02
20	14	31.8	50 9 BH863023 SALK_0929
21	14	31.8	50 9 CR222513 Forward s
22	13.8	31.4	45 8 BH636447 1008011D0
23	13.8	31.4	46 8 BZ292212 SALK_1236
24	13.8	31.4	48 8 AZ831243 2M010F20

25	13.8	31.4	50 1 AU104153 AU104153
26	13.6	31.4	50 1 AU106910 AU106910
27	13.6	30.9	37 9 AL771100 Arabidops
28	13.6	30.9	38 1 AJ803928 AJ803928
29	13.6	30.9	44 9 AG204200 Pan trogl
30	13.6	30.9	45 4 BU035009 BU035009
31	13.6	30.9	48 9 CR405537 Arabidops
32	13.6	30.9	50 1 AU102726 AU102726
33	13.6	30.9	50 1 AU106009 AU106009
34	13.4	30.5	33 9 CG724001 119079B0
35	13.4	30.5	35 9 CL436566 PST3252-N
36	13.4	30.5	38 8 AZ642621 IM0505B13
37	13.4	30.5	39 1 AU010606 AU010606
38	13.4	30.5	39 1 AU011134 AU011134
39	13.4	30.5	39 1 AU012105 AU012105
40	13.4	30.5	39 1 AU012381 AU012381
41	13.4	30.5	39 1 AU012382 AU012382
42	13.4	30.5	40 8 BH796426 T. brucei
43	13.4	30.5	45 9 TA3G04P TA3G04P
44	13.4	30.5	48 7 DI8810 MUSGS00961
45	13.4	30.5	50 1 AU107655 AU107655
46	13.4	30.5	50 9 CR236244 Forward s
47	13.2	30.0	29 1 AU256798 AU256798
48	13.2	30.0	38 8 BH910864 SALK_0629
49	13.2	30.0	38 9 TA360D04P TA360D04P
50	13.2	30.0	40 8 AZ310280 IM0025K10
51	13.2	30.0	42 8 AZ665709 IM0547K13
52	13.2	30.0	43 1 A1765730 A1765730
53	13.2	30.0	44 1 AA196741 ZQ09402.B
54	13.2	30.0	44 9 CL528318 ASV14B08.
55	13.2	30.0	46 1 A1669689 wc12d11.x
56	13.2	30.0	46 4 BU049506 BU049506
57	13.2	30.0	46 7 W58703 ZG23804.r1
58	13.2	30.0	47 8 AZ783792 2M0025N23
59	13.2	30.0	47 8 BH848002 SALK_0673
60	13.2	30.0	48 1 AU266867 AU266867
61	13.2	30.0	48 9 AG204400 Pan trogl
62	13.2	30.0	49 1 AU265180 AU265180
63	13.2	30.0	49 8 AU034111 AU034111
64	13.2	30.0	50 1 AU102858 AU102858
65	13.2	30.0	50 1 AU104031 AU104031
66	13.2	30.0	50 1 AU104033 AU104033
67	13.2	30.0	50 1 AU104035 AU104035
68	13.2	30.0	50 1 AU104036 AU104036
69	13.2	30.0	50 1 AU104037 AU104037
70	13.2	30.0	50 1 AU104038 AU104038
71	13.2	30.0	50 1 AU104039 AU104039
72	13.2	30.0	50 1 AU104254 AU104254
73	13	29.5	28 6 CA795703 Cae BL 27
74	13	29.5	31 1 AU789302 AU789302
75	13	29.5	32 7 D21043 HMG502027
76	13	29.5	35 4 BU047401 BU047401
77	13	29.5	37 1 AU666664 AU666664
78	13	29.5	37 8 AZ592382 IM0403G13
79	13	29.5	42 9 AL757728 Arabidops
80	13	29.5	44 7 T17569 mps v3 The
81	13	29.5	45 1 AA676774 ZJ71F12.S
82	13	29.5	48 6 CA968570 CGL02807
83	13	29.5	49 1 AL643698 AL643698
84	13	29.5	49 9 CG719534 111905B8A1
85	13	29.5	50 1 CG101193 AU010193
86	13	29.5	50 1 AU105429 AU105429
87	13	29.5	50 1 AU105439 AU105439
88	13	29.5	50 1 AU105441 AU105441
89	13	29.5	50 1 AU105446 AU105446
90	13	29.5	50 1 AU107549 AU107549
91	12.8	29.1	23 8 BH811030 SALK_0571
92	12.8	29.1	23 9 AJ587643 Arabidops
93	12.8	29.1	28 4 BM395440 50072-2-9
94	12.8	29.1	32 1 AU104466 AU104466
95	12.8	29.1	36 8 AZ604700 IM0425T10
96	12.8	29.1	38 8 BZ660720 SALK_0241
97	12.8	29.1	38 8 BZ660721 SALK_0241

ALIGNMENTS									
RESULT 1									
B2763244			35 bp	DNA			linear	GSS 13-MAR-2003	
LOCUS									
DEFINITION	B2763244								
	SALK_115680.48.40.x Arabidopsis thaliana TDNA insertion lines								
	Arabidopsis thaliana genomic clone SALK_115680.48.40.x, genomic								
	survey sequence.								
ACCESSION	B2763244								
VERSION	B2763244.1								
KEYWORDS	GI:28935797								
SOURCE	GSS.								
ORGANISM	Arabidopsis thaliana (chale cress)								
	Arabidopsis thaliana								
	Eukaryota, Viridiplantae, Streptophyta, Embryophyta, Tracheophyta;								
	Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;								
	rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.								
REFERENCE	1 (bases 1 to 35)								
AUTHORS	Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R.,								
	Gadriab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,								
	Shinn,P., Zimmerman,J. and Ecker,J.R.								
	A Sequence-Indexed Library of Insertion Mutations in the								
	Arabidopsis Genome								
JOURNAL	Unpublished (2001)								
COMMENT	Contact: Joseph R. Ecker								
	The Salk Institute Genomic Analysis Laboratory (SIGAL)								
	10010 N. Torrey Pines Road, La Jolla, CA 92037, USA								
	Tel: 858 453 4100 x1752								
	Fax: 858 558 6379								
	Email: ecker@salk.edu								
	This is single pass sequence recovered from the left border of								
	TDNA.								
FEATURES	Class: TDNA tagged.								
source	Location/Qualifiers								
	1..35								
	/organism="Arabidopsis thaliana"								
	/mol_type="genomic DNA"								
	/ecotype="Col-0"								
	/db_xref="taxon:3702"								
	/clone="SALK_115680.48.40.x"								
	/clone.lib="Arabidopsis thaliana TDNA insertion lines"								
	/note="PCR was performed on Arabidopsis thaliana lines								
	each of which contains one or more TDNA insertion								
	elements. The resultant fragment for each line was								
	directly sequenced to determine the genomic sequence at								
	the site of insertion. Details of the protocols used can								
	be found at http://signal.salk.edu/tdna_protocols.html								
ORIGIN									
	Query Match 36.4%; Score 16; DB 8; Length 35;								
	Best Local Similarity 68.8%; Pred. No.5.2e+04;								
	Matches 22; Conservative 0; Mismatches 10; Indels 0; Gaps 0;								
QY	9 CGTTCCTCTTAATACCGCTGCGCGTATTATTA 40								
Db	1 CGTTTTCTCTACTAATGTCGAGAGTGTATA 32								
RESULT 2									
LOCUS	CR191751		50 bp	DNA			linear	GSS 06-JUL-2004	
DEFINITION	Forward strand read from insert in 5'HPRT insertion targeting and								
	chromosome engineering clone MHPN57019, genomic survey sequence.								
ACCESSION	CR191751								
VERSION	CR191751.1								
KEYWORDS	GSS; genome survey sequence; MICEP.								
SOURCE	Mus musculus (house mouse)								

ORGANISM	Mus musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 50) Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weyden,L., Jonkers,J., Smith,J., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y., Rogers,J. and Bradley,A.
TITLE	Direct Submission
JOURNAL	Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK. http://www.sanger.ac.uk/MICRR
FEATURES	Location/Qualifiers 1..50 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090" /cname="MHFNS7019" /clone_1fb="MHFN"
ORIGIN	
Query Match	35.9%; Score 15.8; DB 9; Length 50;
Best local similarity	65.7%; Pred. No. 6.e+04;
Matches	23; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
Dn	16 CGGGCCCCCTTCCCTTAATACCGGTGCGGTT 36 2 CGGGTCCCCTTCCTTTAATAACCGGTGCGGTT 36 16 CGGGCCCCCTTCCCTTAATAAACGGAGAGGGCT 50
RESULT 3	
AL754601/c	50 bp DNA linear GSS 01-APR-2004
LOCUS	Arabidopsis thaliana T-DNA flanking sequence GK-054H09-012427,
DEFINITION	genomic survey sequence.
ACCESSION	AL754601
VERSION	AL754601.1 GI:21487099
KEYWORDS	GSS.
SOURCE	Arabidopsis thaliana (thale cress)
ORGANISM	Arabidopsis thaliana Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosoids; eurosids II; Brassicales; Brassicaceae; Arabidopsi. 1 Li,Y., Rosso,M.G., Strizhov,N., Viehoever,P. and Weishaar,B. GABI-Kat SimpleSearch: a flanking sequence tag (PST) database for the identification of T-DNA insertion mutants in Arabidopsis thaliana Bioinformatics 19 (11), 1441-1442 (2003) JOURNAL MEDLINS 22755829 PUBMED 12874060 2 Rosso,M.G., Li,Y., Strizhov,N., Reis,B., Dekker,K. and Weishaar,B. An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for flanking sequence tag-based reverse genetics Plant Mol. Biol. 53 (1-2), 247-259 (2003) JOURNAL MEDLINS 23117147 PUBMED 14756321 3 Strizhov,N., Li,Y., Rosso,M.G., Viehoever,P., Dekker,K.A. and Weishaar,B. High-throughput generation of sequence indexes from T-DNA mutagenized Arabidopsis thaliana lines Biotechniques 35 (6), 1164-1168 (2003) JOURNAL PUBMED 14682050 4 (bases 1 to 50) Rosso,M.G., Li,Y., Strizhov,N. and Weishaar,B. Direct Submission Submitted (31-MAR-2004) Weishaar B., Max-Planck-Institut fuer Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany This sequence has been recovered from the left border of the T-DNA. It indicates an insertion close to or within gene At3g52160. Details on the protocols used for generation of the sequence are described in References 1-3 The sequences are generated at the MPI
COMMENT	

for Plant Breeding Research in the context of the GABI-Kat project.
GABI-Kat is part of the German Plant Genomics program designated
'GABI'. Information on line availability can be found at:
<http://www.mpiz-koeln.mpg.de/GABI-Kat/>.

FEATURES

source

1..50
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="GK-054H09-012427"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/ecotype="Col-0"
/note="PCR was performed on DNA from Arabidopsis thaliana
plants (T1) which were transformed with the T-DNA from
vector PAC161 (Genbank accession number: AJ537514). The
lines contain one or more T-DNA insertions. The DNA
fragment(s) resulting from the PCR were directly sequenced
to determine the genomic sequence flanking the insertion.
T-DNA derived sequences were removed."

ORIGIN

Query Match 35.0%; Score 15.4; DB 9; Length 50;
Best Local Similarity 76.0%; Pred. No. 9.8e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 11 TTCCCTTTAATACCGGTCCGGGT 35
|||
29 TTCCTTCTATCAATCGCTCATGT 5

RESULT 4

AZ438384

LOCUS

46 bp DNA linear GSS 03-OCT-2000
IM0228024F Mouse 10kb plasmid UUC1M library Mus musculus genomic
clone UUC1M0228024 F, genomic survey sequence.

ACCESSION

AZ438384

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Mus;
1 (bases 1 to 46)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenan, E., Pedersen, T.,
Rellly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
unpublished (2000)

TITLE

JOURNAL

COMMENT

Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0228 row: 0 column: 24
Seq primer: CGTTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 46.
Location/Qualifiers
1..46

FEATURES

source

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUC1M0228024"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUC1M library"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male); Purified genomic DNA from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g14732114[g14732114], a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

ORIGIN

Query Match 34.5%; Score 15.2; DB 8; Length 46;
Best Local Similarity 85.0%; Pred. No. 1.2e+05;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 7 CCCGTCCTCTTAATACC 26
|||
3 CCTTTCCTCTTAATACC 22

RESULT 5

AU104874

LOCUS

50 bp mRNA linear EST 28-JAN-2004
AU104874 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
HEP03014, mRNA sequence.

ACCESSION

AU104874

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 50)
Suzuki, Y., Taira, H., Tanoda, T., Mizushima-Sugano, J., Sese, J.,
Hara, H., Ota, T., Isegai, T., Tanaka, T., Morishita, S., Okubo, K.,
Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.
Diverse transcriptional initiation revealed by fine, large-scale
mapping of mRNA start sites
EMBO Rep. 2 (5), 388-393 (2001)

TITLE

JOURNAL

COMMENT

Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: yusuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
Sugano, S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
Location/Qualifiers
1..50

FEATURES

source

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP03014"
/clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN

Query Match 34.5%; Score 15.2; DB 1; Length 50;
Best Local Similarity 63.9%; Pred. No. 1.2e+05;
Matches 23; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 5 GTCCCGTTCCTTAAATACCGGTCGGCTTATTA 40
 Db 13 GTCCGTTCCTTGTATACACCGCCGTCGCTACTA 48

RESULT 6
 AUI06701
 LOCUS AUI06701
 DEFINITION AUI06701 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
 XAT09190, mRNA sequence.
 ACCESSION AUI06701
 VERSION AUI06701.1 GI:13556222
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 50)
 Suzuki,Y., Taira,H., Teunoda,T., Mizushima-Sugano,J., Sese,J., Hara,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.
 Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites
 EMBO Rep. 2 (5), 388-393 (2001)
 21270072
 11375929
 CONTACT: Yutaka Suzuki
 Department of Virology
 Institute of Medical Science, University of Tokyo
 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
 Email: yusuzuki@ims.u-tokyo.ac.jp
 Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S.
 Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).
 Location/Qualifiers
 1..50
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="XAT09190"
 /clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN
 Query Match 34.5%; Score 15.2; DB 1; Length 50;
 Best Local Similarity 71.4%; Pred. No. 1.2e+05;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 10 GTTCCTTCTTAATAACCGGTCGGCTTA 37
 Db 13 GTCCGTTCCTTGTATACACCGCCGTCGCTACTA 40

RESULT 7
 A2808932
 LOCUS A2808932
 DEFINITION A2808932 Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC2M0072N09 R, genomic survey sequence.
 ACCESSION A2808932
 VERSION A2808932.1 GI:12974784
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 49)
 Dunn,D., Aoyagi,A., Barber,M., Beacom,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weis,R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

TITLE
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL
 COMMENT Unpublished (2000)
 Contact: Robert B. Weis
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., StC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0072 row: N column: 09
 Seq primer: CACACAGAAACAGCTATGAC
 Class: plasmid ends
 High quality sequence stop: 49.
 Location/Qualifiers
 1..49
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0072N09"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g1|4732114|gbl|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN
 Query Match 34.1%; Score 15; DB 8; Length 49;
 Best Local Similarity 67.7%; Pred. No. 1.4e+05;
 Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 7 CCCGTTCTTCTTAATAACCGGTCGGCTTA 37
 Db 18 CCCGACCTTCTTAAGTATAGAGACTA 48

RESULT 8
 B0049506
 LOCUS B0049506
 DEFINITION B0049506 NIBB Mochii normalized Xenopus neurula library Xenopus laevis cDNA clone X1026f15 3', mRNA sequence.
 ACCESSION B0049506
 VERSION B0049506.1 GI:17378905
 KEYWORDS EST.
 SOURCE Xenopus laevis (African clawed frog)
 ORGANISM Xenopus laevis
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae; Xenopodinae; Xenopus; Xenopus.
 1 (bases 1 to 46)
 Kitayama,A., Terasaka,C., Mochii,M., Ueno,N., Shin-i,T. and Kohara,Y.
 Expressed genes in X. laevis embryo
 Unpublished (2001)
 Contact: Tadasu Shin-i

TITLE
 Expressed genes in X. laevis embryo
 Unpublished (2001)
 Contact: Tadasu Shin-i

VERSION BH61169.1 GI:20389052
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosid II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1 (bases 1 to 32)
Alonso,J.M., Leisner,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadriab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shim,P., Zimmerman,J. and Ecker,J.R.
A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.
Location/Qualifiers
1..32
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Col-0"
/db_xref="taxon:3702"
/clone_lib="SALK_057363"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"

ORIGIN
Query Match 32.7%; Score 14.4; DB 8; Length 32;
Best Local Similarity 65.6%; Pred. No. 2.4e+05;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 11 TTCTTCTTAATACCGGTGCGGTTATTAG 42
||||| ||||| ||||| |||||
1 TTCCTTAATATTTCGGTAAAGGTTGTTATG 32

DB
1 TTCCTTAAATACCGGTGCGGTTATTAG 42
||||| ||||| ||||| |||||
1 TTCCTTAATATTTCGGTAAAGGTTGTTATG 32

RESULT 12
BH636447 45 bp DNA linear GSS 14-FEB-2002
LOCUS 1008011D08.1BL x1 1008 - RescueMu Grid I Zea mays genomic, genomic
DEFINITION survey sequence.
ACCESSION BH636447
KEYWORDS BH636447.1 GI:18658684
GSS.
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Zea.
REFERENCE 1 (bases 1 to 45)
Walbot,V.
Maize genomic sequences found using engineered RescueMu transposon
JOURNAL Unpublished (2001)
COMMENT Contact: Walbot V
Department of Biological Sciences
Stanford University
855 California Ave, Palo Alto, CA 94304, USA
Tel: 650 723 2227
Fax: 650 725 8221
Email: walbot@stanford.edu

Very probable ligation site of ends cut by single endonuclease.
Reverse complemented post-ligation sequence from source sequence.
Plate: 1008011 row: 35
Class: transposon-caged.
Location/Qualifiers
1..45
/organism="Zea mays"
/mol_type="genomic DNA"
/cultivar="mixed background W23/Al8/B73"
/db_xref="taxon:4577"
/tissue_type="leaf"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="1008 - RescueMu Grid I"
/note="Organ: leaf; Vector: RescueMu (engineered from
pBluescript backbone); Site 1: BamHI; Site 2: BglII;
RescueMu is a 4.9 kb, modified maize Mu transposon
designed to allow plasmid rescue from total genomic DNA.
Mu elements insert preferentially into transcription
units. For more information on RescueMu, go to the web
site www.zmdb.iastate.edu and follow the links for
'RescueMu.' Grid I was grown at Berkeley in 2001. DNA was
extracted from leaf punches, double digested using BamHI
and BglII, and ligated to form circular plasmids. DH10B
cells were transformed and then screened on LB plates with
ampicillin."

ORIGIN
Query Match 32.7%; Score 14.4; DB 8; Length 45;
Best Local Similarity 75.0%; Pred. No. 2.5e+05;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 21 ATAAACCGGTGCGGTTATTAGAA 44
||||| ||||| ||||| |||||
DB 12 ATAACTGTACGGGTTTTCGAA 35

RESULT 13
BH904918 46 bp DNA linear GSS 04-SEP-2002
LOCUS SALK_105328.44.50.x Arabidopsis thaliana TDNA insertion lines
DEFINITION Arabidopsis thaliana genomic clone SALK_105328.44.50.x, genomic
survey sequence.
ACCESSION BH904918
KEYWORDS BH904918.1 GI:22717592
GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosid II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1 (bases 1 to 46)
Alonso,J.M., Leisner,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadriab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shim,P., Zimmerman,J. and Ecker,J.R.
A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA. This sequence lies within 300 bases of the 3' end of
At1g25570.
Class: TDNA tagged.
Location/Qualifiers
1..46
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"

/ecotype="Col-0"
 /db_xref="taxon:3702"
 /clone="SALK_105328.44.50.x"
 /clone_lib="Arabidopsis thaliana TDNA insertion lines"
 /note="PCR was performed on Arabidopsis thaliana lines
 each of which contains one or more TDNA insertion
 elements. The resultant fragment for each line was
 directly sequenced to determine the genomic sequence at
 the site of insertion. Details of the protocols used can
 be found at http://signal.salk.edu/tDNA_protocols.html"

Query	5	GTCCCGTCCTCTTAATACCGCGCGCGCTTATTACGA	44
Db	5	GTCAAATCTCTTCATTTCCTCTCGGCATTGCGAA	44
Matches	24;	Conservative	0; Mismatches 16; Indels 0; Gaps 0;
Query Match	32.7%	Score 14.4;	DB 8; Length 46;
Best Local Similarity	60.0%	Pred. No. 2.5e+05;	

LOCUS	49 bp	mRNA	linear	EST 05-FEB-2003
CB190523				
DEFINITION	p127933.v1	Ancylostoma ceylanicum adult	Ancylostoma ceylanicum cDNA	
	5'	similar to contains element MMR28	repetitive element ;	mRNA
		sequence.		

ACCESSION	CB190523	GI:28253915
VERSION	CB190523.1	
KEYWORDS	EST.	
SOURCE	Ancyllostoma ceylanicum	
ORGANISM	Ancyllostoma ceylanicum	

REFERENCE
AUTHORS

1 (bases 1 to 49)
McCarer, J., Clifton, S., Chiapelli, B., Pape, D., Martin, J.,

TITLE	JOURNAL	COMMENT
The Washington Univ. Nematode EST Project, 1999	Unpublished (1999)	Contact: McCarter JP

The Washington Univ. Nematode EST Project, 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Library donated by John Hawdon of The George Washington University,
Washington DC (mrjmh@gwumc.edu). Claire Murphy and Dr. James
McCarver of Washington University, GSC, St. Louis, MO mass excised
the pluscscript phagemid from the lambda ZAP II library.

FEATURES

SOURCE

```
1. .49
/organism="Ancylostoma ceylanicum"
/mol_type="mRNA"
/seq_id="1"
/seq_len="1000"
```

```

/ad_xref="taxon:53356"
/dev stage="adult"
/lab host="SOLR (Stratagene)"
/clone_lib="Ancylostroma ceylanicum adult"
/notes="Vector: pBluescript SK+ excised from Lambda ZAP II
(Stratagene); Site_1: XhoI; Site_2: BcoRI; Lambda ZAP II
library (99% recombinants, average insert size 1500bp,
amplified one time (1066 pfu) donated by John Hawdon of
The George Washington University, Washington
DC (mtm@gwumc.edu). Claire Murphy and Dr. James McGett
of Washington University GSC, St. Louis, MO mass excised
the pBluescript phagemid from the Lambda ZAP II library."

```

ORIGIN

Query Match	32.7%	Score 14.4	DB 6	length 49
Best Local Similarity	65.6%	Pred. No. 2.66+05		
Matches	21	Conservative	0	Mismatches 11
				Indels 0
				Gaps 0
Q7	2	CGGGTCCCGTTCCTTTAATACCGGCGG	33	
Db	49	CGGGTCCGAACTTATTCCTTACGCGGTACG	18	

[illegible]

REFERENCE	1 (pages 1 to 50)
AUTHORS	Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Chaik,R., Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shim,P., Zimmerman,J. and Ecker,J.R.
TITLE	A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
JOURNAL	Unpublished (2001)
COMMENT	Contact: Joseph R. Ecker

Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel.: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu

This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.

FEATURES
BOL

/organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /ecotype="Col-0"
 /db_xref="taxon:3702"
 /clone="SALK_062026.27.05.x"
 /clone_lib="Arabidopsis thaliana TDNA insertion lines"
 /note="PCR was performed on Arabidopsis thaliana lines
 each of which contains one or more TDNA insertion
 elements. The resultant fragment for each line was
 directly sequenced to determine the genomic sequence at
 the site of insertion. Details of the protocols used can
 be found at http://signal.salk.edu/tdna_protocols.htm"

ORIGIN

Query Match	32.7%;	Score 14.4;	DB 8;	Length 50;
Best Local Similarity	65.6%;	Pred. No. 2.6e+05;		
Matches 21; Conservative	0;	Mismatches 11;	Indels 0;	Gaps 0

QY 7 CCGGTCCTTCTAATAACCGGTGGCGTTAT 38
 ||| ||| ||| ||| ||| ||| |||
DB 11 CCACTCCTATGAATATCTGCGTGAT 42

RESULT 16			
CR147596/c			
LOCUS			
CR147596	50 bp	DNA	linear
			GSS 06-JUL-2004

DEFINITION	Forward strand read from insect in 5'HPT insertion targeting and chromosome engineering clone MHPV78d19, genomic survey sequence.
ACCESSION	CR147596
VERSION	CR147596.1
KEYWORDS	GI:49906067
GSS	GSS: genome survey sequence; MICE.

KEYWORDS

```

SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
REFERENCE   1 (bases 1 to 50)
AUTHORS     Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weyden,L.,
            Jonkers,J., Smith,D., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y.,
            Rogers,J. and Bradley,A.
TITLE       Direct Submission
JOURNAL     Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire,
            CB10 1SA, UK. http://www.sanger.ac.uk/MICER
FEATURES    source
            1..50
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
            /clone="MH078d19"
            /clone_lib="MHPN"

ORIGIN
Query Match      32.7%; Score 14.4; DB 9; Length 50;
Best Local Similarity 75.0%; Pred. No. 2.6e+05;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Oy      20 AATAACCGTCGCGGTATTAGA 43
         ||||| | | |||||
Db      40 AATAACCTCTTAAAGATTATAGA 17

RESULT 17
LOCUS    AU102908      50 bp      mRNA      linear      EST 28-JAN-2004
DEFINITION AU102908 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
            HEP13140, mRNA sequence.
ACCESSION AU102908
VERSION   AU102908.1 GI:13552429
KEYWORDS  EST.
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 50)
AUTHORS   Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Seese,J.,
            Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K.,
            Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.
            Diverse transcriptional initiation revealed by fine, large-scale
            mapping of mRNA start sites
JOURNAL   EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE   21270072
PUBMED    11375929
COMMENT   Contact: Yutaka Suzuki
            Department of Virology
            Institute of Medical Science, University of Tokyo
            4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
            Email: yusuzuki@ims.u-tokyo.ac.jp
            Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and
            Sugano,S. Construction and characterization of a full
            length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
            143-156 (1997)

FEATURES    source
            1..50
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /clone="HEP13140"
            /clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN
Query Match      32.3%; Score 14.2; DB 1; Length 50;
Best Local Similarity 70.4%; Pred. No. 3.1e+05;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Oy      16 TCTTAATAACCGTCGCGGTATTAGA 42

```

```

Db      30 TCTGACAAACCGTCGCGCATTAACGAG 4

RESULT 18
LOCUS     TA192A12Q      41 bp      DNA      linear      GSS 13-DEC-2000
DEFINITION T. brucei sheared genomic DNA clone 192a12, reverse sequence,
            genomic survey sequence.
ACCESSION AL478202
VERSION   AL478202.1 GI:11842012
KEYWORDS  GSS.
SOURCE    Trypanosoma brucei
            Trypanosoma brucei
            Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;
            Trypanosoma.
REFERENCE 1 (bases 1 to 41)
AUTHORS   Hall,N., Bowman,S., Leonard,N.J., Doggett,J., Atkin,R.,
            Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
            Melville,S.B., Rajandream,M.A. and Barrell,B.G.
            Wellcome Trust Genome Campus, Hinxton,
            Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
            nh@sanger.ac.uk
            Constructed at the Institute for Genomic Research (TIGR),
            Rockville, MD. Genomic DNA isolated from a cloned population of
            trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
            to give a tight size distribution (
            4 kb). The v + i method used for the library construction is
            described in detail in Smith, H. and Venter, J.C. (Making small
            insert libraries for whole genome shotgun sequencing projects. In
            Genome Sequencing: A Practical Approach, eds. M. Vaubin and B.
            Barrell, Oxford University Press, 1999).
            Email: nelsayed@tigr.org
            Details of T. brucei sequencing at the Sanger Centre are available
            at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES    source
            1..41
            /organism="Trypanosoma brucei"
            /mol_type="genomic DNA"
            /strain="TREU927"
            /db_xref="taxon:5691"
            /clone="192a12"

ORIGIN
Query Match      31.8%; Score 14; DB 9; Length 41;
Best Local Similarity 64.5%; Pred. No. 3.7e+05;
Matches 20; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Oy      8 CCGTCTCTTTAATAACCGTCGCGGTAT 38
         ||||| | | |||||
Db      10 CAGGTCTTCTTTTAAGCTGNGCAGGTTT 40

RESULT 19
LOCUS     AZ801189      48 bp      DNA      linear      GSS 16-FEB-2001
DEFINITION ZMO059K02R Mouse 10kb plasmid U06C1M library Mus musculus genomic
            clone U06C2M005K02 R, genomic survey sequence.
ACCESSION AZ801189
VERSION   AZ801189.1 GI:12953512
KEYWORDS  GSS.
SOURCE    Mus musculus (house mouse)
            Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 48)
AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,B., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D., Weise,R.
            Mouse whole genome scaffolding with paired end reads from 10kb

```

JOURNAL
COMMENT
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddum@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0059 row: K column: 02
Seq primer: CACACAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 48.
Location/Qualifiers

FEATURES
source
1..48
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U082M0059K02"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10Kb plasmid U082M0059 library"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN
Query Match 31.8%; Score 14; DB 8; Length 48;
Best Local Similarity 66.7%; Pred. No. 3.8e+05;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
1 GCAGGATCCGCTTCTTATTAACCGGTC 30
2 ||||| ||||| ||||| ||||| |||||
3 7 GCAGGATCTGTTACTTAAGAAAACCTGCC 36

Db
1 GCAGGATCCGCTTCTTATTAACCGGTC 30
2 ||||| ||||| ||||| ||||| |||||
3 7 GCAGGATCTGTTACTTAAGAAAACCTGCC 36

RESULT 20
BH863023/c
LOCUS
DEFINITION
SALK_092995 Arabidopsis thaliana TDNA insertion lines Arabidopsis
thaliana genomic clone SALK_092995, genomic survey sequence.
ACCESSION
BH863023
VERSION
BH863023.1 GI:22098352
KEYWORDS
GSS.
SOURCE
Arabidopsis thaliana (chale crese)
ORGANISM
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 50)
Alonso, J.M., Leisner, T.J., Barajas, P., Chen, H., Chouk, R.,
Garinab, C., Jeeke, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L.,
Shim, P., Zimmerman, J., and Becker, J.R.
A Sequence-Indexed Library of Insertion Mutations in the

JOURNAL
COMMENT
Arabidopsis Genome
Unpublished (2001)
Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: eckers@salk.edu
This is single pass sequence recovered from the left border of
TDNA. This sequence lies within an annotated intron of At3g16380.
Class: TDNA tagged.
Location/Qualifiers

FEATURES
source
1..50
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Col-0"
/db_xref="taxon:13702"
/clone="SALK_092995"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/cdna_protocols.html

ORIGIN
Query Match 31.8%; Score 14; DB 8; Length 50;
Best Local Similarity 66.7%; Pred. No. 3.8e+05;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
15 TTCTTAATTAACCGGTCGCGTTATTAAGAA 44
16 ||||| ||||| ||||| ||||| |||||
17 39 TTCTTAATTAACCGAAGTAATGATGATGAA 10

Db
15 TTCTTAATTAACCGGTCGCGTTATTAAGAA 44
16 ||||| ||||| ||||| ||||| |||||
17 39 TTCTTAATTAACCGAAGTAATGATGATGAA 10

RESULT 21
CR222513
LOCUS
DEFINITION
Forward strand read from insert in 5'HPRT insertion targeting and
chromosome engineering clone MHPN255103, genomic survey sequence.
ACCESSION
CR222513
VERSION
CR222513.1 GI:50001362
KEYWORDS
GSS; genome survey sequence; MICER.
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 50)
Adams, D.J., Biggs, P.J., Cox, A.V., Davies, R.M., van der Weyden, L.,
Jokers, J., Smith, J., Plumb, R.W., Taylor, R.G., Nishijima, I., Yu, Y.,
Rogers, J., and Bradley, A.
Direct Submision
Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. <http://www.sanger.ac.uk/MICER>

FEATURES
source
1..50
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/clone="MHPN255103"
/clone_lib="MHPN"

ORIGIN
Query Match 31.8%; Score 14; DB 9; Length 50;
Best Local Similarity 77.3%; Pred. No. 3.8e+05;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
11 TTCCTTATTAACCGGTCGC 32
12 ||||| ||||| ||||| ||||| |||||
13 3 TTCCTTATTAACCACTGCGCC 24

Db
11 TTCCTTATTAACCGGTCGC 32
12 ||||| ||||| ||||| ||||| |||||
13 3 TTCCTTATTAACCACTGCGCC 24

RESULT 22	BH636447/c	45 bp	DNA	linear	GSS 14-FEB-2002
LOCUS	BH636447				
DEFINITION	100801D08.1EL.x1 1008 - Rescuemu Grid I Zea mays genomic, genomic survey sequence.				
ACCESSION	BH636447				
VERSION	BH636447.1				
KEYWORDS	GI:18658684				
SOURCE	GSS.				
ORGANISM	Zea mays				
REFERENCE	Eukaryota, Viridiplantae, Streptophyta, Embryophyta, Tracheophyta, Spermatophyta, Magnoliophyta, Liliopsida, Poales, Poaceae, PACCAD clade, Panicoidae, Andropogoneae; Zea.				
AUTHORS	1 (bases 1 to 45)				
TITLE	Walbot.V.				
JOURNAL	Maize genomic sequences found using engineered Rescuemu transposon unpublished (2001)				
COMMENT	Contact: Walbot V Department of Biological Sciences Stanford University 855 California Ave, Palo Alto, CA 94304, USA Tel: 650 723 2227 Fax: 650 725 8221 Email: walbot@stanford.edu Very probable ligation site of ends cut by single endonuclease. Reverse complemented post-ligation sequence from source sequence. Plate: 1008011 row: 35 Class: transposon-tagged. Location/Qualifiers				
FEATURES	source				
	1..45				
	/organism="Zea mays"				
	/mol_type="genomic DNA"				
	/cultivar="mixed background W23/A188/B73"				
	/db_xref="taxon:4577"				
	/tissue_type="leaf"				
	/dev_stage="adult"				
	/lab_host="DH10B"				
	/clone_lib="1008 - Rescuemu Grid I"				
	/note="Organ: leaf; Vector: Rescuemu (engineered from pBluescript backbone); Site_1: BamHI; Site_2: BglII; Rescuemu is a 4.9 kb, modified maize Mu transposon designed to allow plasmid rescue from total genomic DNA. Mu elements insert preferentially into transcription units. For more information on Rescuemu, go to the web site www.zmmb.iasrate.edu and follow the links for 'Rescuemu.' Grid I was grown at Berkeley in 2001. DNA was extracted from leaf punches, double digested using BamHI and BglII, and ligated to form circular plasmids. DH10B cells were transformed and then screened on LB plates with ampicillin."				
ORIGIN					
Query Match	31.4%;	Score 13.8;	DB 8;	Length 45;	
Best Local Similarity	63.6%;	Pred. No. 4.5e+05;			
Matches	21;	Conservative 0;	Mismatches 12;	Indels 0;	Gaps 0;
QY	6 TCCCGTTCCTTATAATACCGGTGCGGTAT 38				
Db	44 TCCACTAGCTTCGAAACCCGCTACAGGTAT 12				
RESULT 23	BZ292212	46 bp	DNA	linear	GSS 24-OCT-2002
LOCUS	BZ292212				
DEFINITION	SAUK_123631.34.00.x Arabidopsis thaliana TDNA insertion lines				
ACCESSION	BZ292212				
VERSION	BZ292212.1				
KEYWORDS	GSS.				
SOURCE	Arabidopsis thaliana (thale cress)				
ORGANISM	Arabidopsis thaliana				

REFERENCE	AUTHORS				Eukaryota: Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons: core eudicots: rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis. 1 (bases 1 to 46)			
REFERENCE	Alonso, J.M., Leisner, T.J., Barajas, P., Chen, H., Cheuk, R., Gadrinab, C., Jeske, A., Karnes, M., Kim, C.U., Parker, H., Prednig, L., Shih, P., Zimmerman, J. and Ecker, J.R.				A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome			
JOURNAL	COMMENT				Unpublished (2001) Contact: Joseph R. Ecker Salk Institute Genomic Analysis Laboratory (SIGNAL) The Salk Institute for Biological Studies 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA Tel.: 858 453 4100 x1752 Fax: 858 558 6379 Email: ecker@salk.edu This is single pass sequence recovered from the left border of TDNA.			
FEATURES	source				Class: TDNA tagged. Location/Qualifiers 1..46 /organism="Arabidopsis thaliana" /mol_type="genomic DNA" /ecotype="Col-0" /db_xref="taxon:3702" /clone="SALK_123631.34.00.x" /note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html "			
ORIGIN	Query Match				31.4%; Score 13.8; DB 8; Length 46;			
	Best Local Similarity				72.0%; Pred. No. 4.5e+05;			
	Matches				18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;			
Db	4 GGTCCTGCTCTTAATATACCGG 28							
	5 GTCCCATCTCTCTACTACTAGG 29							
RESULT 24	AZ831243				48 bp DNA linear GSS 20-FEB-2001			
LOCUS	2M0110P20R Mouse 10kb plasmid U0CCIM library Mus musculus genomic clone U0GC2M0110P20 R, genomic survey sequence.							
ACCESSION	AZ831243							
VERSION	AZ831243.1 GI:13001151							
KEYWORDS	GSS.							
SOURCE	Mus musculus (house mouse)							
ORGANISM	Mus musculus							
	Euteleostomi; Euteleostomi; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 48)							
REFERENCE	Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, P.B., Hamil, C., Isajima, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Niederhauser, A. and Wright, D., Weiss, R.							
AUTHORS	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts							
	Unpublished (2000)							
JOURNAL	COMMENT				Contact: Robert B. Weiss University of Utah Genome Center Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLc, UT 84112, USA Tel.: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu			

ACCESSION AL771100
 VERSION AL771100.1 GI:21533302
 KEYWORDS
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Brakaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1
 REFERENCE
 AUTHORS Li, Y., Rosso, M.G., Strizhov, N., Viehoveer, P. and Weisshaar, B.
 TITLE GABI-Kat Simplesearch: a flanking sequence tag (FST) database for
 the identification of T-DNA insertion mutants in Arabidopsis
 thaliana
 JOURNAL Bioinformatics 19 (11), 1441-1442 (2003)
 MEDLINE 22755829
 PUBMED 12874060
 REFERENCE
 AUTHORS 2
 Rosso, M.G., Li, Y., Strizhov, N., Reiss, B., Dekker, K. and
 Weisshaar, B.
 TITLE An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for
 flanking sequence tag-based reverse genetics
 JOURNAL Plant Mol. Biol. 53 (1-2), 247-259 (2003)
 MEDLINE 23117147
 PUBMED 14756321
 REFERENCE
 AUTHORS 3
 Strizhov, N., Li, Y., Rosso, M.G., Viehoveer, P., Dekker, K.A. and
 Weisshaar, B.
 TITLE High-throughput generation of sequence indexes from T-DNA
 mutagenized Arabidopsis thaliana lines
 Biotechniques 35 (6), 1164-1168 (2003)
 14682050
 4 (bases 1 to 37)
 Li, Y., Strizhov, N., Rosso, M.G. and Weisshaar, B.
 TITLE Direct Submission
 Submitted (31-MAR-2004) Weisshaar, B., Max-Planck-Institut fuer
 Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
 This sequence has been recovered from the left border of the T-DNA.
 It indicates an insertion within the locus defined by BAC clone
 T2X10. Details on the protocols used for generation of the sequence
 are described in References 1-3. The sequences are generated at the
 MPI fuer Plant Breeding Research in the context of the GABI-Kat
 project. GABI-Kat is part of the German Plant Genomics program
 designated 'GABI'. Information on line availability can be found
 at: <http://www.mpiz-koeln.mpg.de/GABI-Kat/>.
 Location/Qualifiers
 1..37
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="GK-177C09-013534"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 /ecotype="Col-0"
 /note="PCR was performed on DNA from Arabidopsis thaliana
 plants (T1) which were transformed with the T-DNA from
 vector PAC161 (GenBank accession number: AJ337514). The
 lines contain one or more T-DNA insertions. The DNA
 fragment(s) resulting from the PCR were directly sequenced
 to determine the genomic sequence flanking the insertion.
 T-DNA derived sequences were removed."
 ORIGIN
 Query Match 30.9%; Score 13.6; DB 9; Length 37;
 Best Local Similarity 67.9%; Pred. No. 5.3e+05;
 Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
 QY 3 GGGTCCCGTTCCTTAAATACCGGTC 30
 |||||
 Db 37 GGATCCCATAGTCTTAATGACGGTC 10
 |||||

LOCUS AJ803928 38 bp mRNA linear EST 11-AUG-2004
 DEFINITION AJ803928 Antirrhinum majus whole plant Antirrhinum majus cDNA clone
 018_5_08_107, mRNA sequence.
 ACCESSION AJ803928
 VERSION AJ803928.1 GI:51119256
 KEYWORDS EST.
 SOURCE Antirrhinum majus (snapdragon)
 ORGANISM Antirrhinum majus
 Brakaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 asterids; lamiales; Lamiales; Plantaginaceae; Antirrhineae;
 Antirrhinum.
 1 (bases 1 to 38)
 Zacho, S., Stueber, K., Saedler, H., Sommer, H. and Schwarz-Sommer, Z.
 TITLE Antirrhinum EST collection
 JOURNAL Unpublished (2003)
 COMMENT Contact: Schwarz-Sommer Z
 Molekulare Pflanzen-genetik
 MPI fuer Zuechtungsforchung
 Carl-von-Linne Weg 10, D-50829, Germany.
 Location/Qualifiers
 1..38
 /organism="Antirrhinum majus"
 /mol_type="mRNA"
 /db_xref="taxon:4151"
 /clone="018_5_08_107"
 /tissue_type="whole plant"
 /clone_lib="Antirrhinum majus whole plant"
 ORIGIN
 Query Match 30.9%; Score 13.6; DB 1; Length 38;
 Best Local Similarity 80.0%; Pred. No. 5.4e+05;
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 6 TCCCGTCTCTTAAATAC 25
 |||||
 Db 4 TCCCATTCGTCATTAATAC 23
 |||||

RESULT 29
 AG204200 44 bp DNA linear GSS 06-MAR-2004
 LOCUS Pan troglodytes DNA, clone: RP43-089110.T7, genomic survey
 DEFINITION
 ACCESSION AG204200
 VERSION AG204200.1 GI:45236375
 KEYWORDS GSS.
 SOURCE Pan troglodytes (chimpanzee)
 ORGANISM Pan troglodytes
 Brakaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.
 1
 REFERENCE
 AUTHORS Park, H., Kim, Y., Kim, S., Han, Y., Woo, T., Park, K., Eun, C.J.,
 Hoon, S.T., Chu, M., Kim, H., Joo, S., Kim, C., Song, W. and Yoo, H.
 TITLE BAC end sequences of library RP-43
 JOURNAL Unpublished
 2 (bases 1 to 44)
 Park, H., Kim, Y., Kim, S., Han, Y., Woo, T., Park, K., Eun, C.J.,
 Hoon, S.T., Chu, M., Kim, H., Joo, S., Kim, C., Song, W. and Yoo, H.
 TITLE Direct Submission
 Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of
 Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC);
 52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
 (E-mail: redstone@mail.krrib.re.kr, URL: <http://phs.grc.krrib.re.kr/>,
 Tel: 82-42-866-7181, Fax: 82-42-860-4409)
 Clones are derived from the chimpanzee BAC library RP-43 This BAC
 end was generated during the K&D process and may have higher chance
 of clone tracking errors.
 PRIMERS
 Sequencing: T7
 LIBRARY
 Vector : pBAC3.6
 R.Site 1 : EcoRI

[illegible]

FEATURES	source
<p>Location/Qualifiers</p> <p>1. .50</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="mRNA"</p> <p>/db_xref="taxon:9606"</p> <p>/clone="HEP22332"</p> <p>/clone_lib="Sugano Homo sapiens cDNA library"</p>	
<p>Query Match</p> <p>Best Local Similarity 30.9%; Score 13.6; DB 1; Length 50;</p> <p>Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;</p>	
<p>Db</p> <p>15 CGCTCTTCGAGTACCTGTCGGGCTT 42</p>	
<p>9 CGTCCCTTCTTAATACCGGCGCGGCTT 36</p> <p> </p>	
<p>RESULT 34</p> <p>CG724001/c</p>	
<p>LOCUS</p> <p>CG724001 33 bp DNA linear GSS 20-OCT-2003</p>	
<p>DEFINITION</p> <p>1119079B05.2EL_x1 1119 - RescuenMu Grid AA Zea mays genomic, genomic</p>	
<p>ACCESSION</p> <p>CG724001</p>	
<p>VERSION</p> <p>CG724001.1 GI:37760402</p>	
<p>KEYWORDS</p> <p>GSS.</p>	
<p>SOURCE</p> <p>Zea mays</p>	
<p>ORGANISM</p> <p>Zea mays</p>	
<p>REFERENCE</p> <p>1 (bases 1 to 33)</p>	
<p>AUTHORS</p> <p>Walbot, V.</p>	
<p>TITLE</p> <p>Maize genomic sequences found using engineered RescuenMu transposon</p>	
<p>JOURNAL</p> <p>Unpublished (2001)</p>	
<p>COMMENT</p> <p>Contact: Walbot V</p> <p>Department of Biological Sciences</p> <p>Stanford University</p> <p>855 California Ave, Palo Alto, CA 94304, USA</p> <p>Tel: 650 723 2227</p> <p>Fax: 650 725 8221</p> <p>Email: walbot@stanford.edu</p> <p>Possible ligation site of ends cut by 2 different endonucleases.</p> <p>Reverse complemented post-ligation sequence from source sequence.</p> <p>Plate: 1119079 row: B column: 05</p> <p>Class: transposon-tagged.</p> <p>Location/Qualifiers</p> <p>1. .33</p> <p>/organism="Zea mays"</p> <p>/mol_type="genomic DNA"</p> <p>/cultivar="mixed background W23/A188/B73/K55"</p> <p>/db_xref="taxon:4577"</p> <p>/tissue_type="leaf"</p> <p>/dev_stage="adult"</p> <p>/lab_host="MDH10B"</p> <p>/clone_lib="1119 - RescuenMu Grid AA"</p> <p>/note="Organ: leaf; Vector: RescuenMu (engineered from pBluescript backbone); Site 1: BamHI; Site 2: BglII; RescuenMu is a 4.9 kb, modified maize Mu transposon designed to allow plasmid rescue from total genomic DNA. Mu elements insert preferentially into transcription units. For more information on RescuenMu, go to the web site 'www.zmdb.iastate.edu' and follow the links for 'RescuenMu'. Grid AA was grown at UC San Diego in 2002. DNA was extracted from leaf strips, double digested using BamI and BglII, and ligated to form circular plasmids. DH10B cells were transformed and then screened on LB plates with ampicillin."</p>	

ORIGIN

Query Match 30.5%; Score 13.4; DB 9; Length 33;
Best Local Similarity 73.9%; Pred. No. 6.4e+05;
Matches 17; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4 GGTCCTTCTTAATACCGGTG 26
|||||
Db 33 GATCCGCTCTTACTATCC 11

RESULT 35
CL436566 35 bp DNA linear GSS 18-MAR-2004
LOCUS PS13252-NR.Seg MICH1 Mus musculus genomic clone PS13252-NR.Seg
DEFINITION similar to Gpi1p1, genomic survey sequence.
ACCESSION CL436566
VERSION CL436566.1 GI:45571487
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 35)
AUTHORS Hicks, G.G.
TITLES www.Bscells.ca
JOURNAL Unpublished (2002)
COMMENT Contact: Hicks GG
Mammalian Functional Genomics Centre
Manitoba Institute of Cell Biology, University of Manitoba
ONS029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
Tel: 204 787 2133
Fax: 204 787 2190
Email: hicks@gsc.umanitoba.ca
UNNEOSV1 gene trap. Tag generated by plasmid rescue. Additional
sequence information and target gene cloning can be generated. ES
cell line harboring insertion mutation of target gene is available.
Sequence analysis available from
http://140.193.242.7/esdb/public_search_frame.php?PST=PS13252-NR.Se
g
Class: Gene Trap.
Location/Qualifiers
1..35
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="129 sv"
/db_xref="taxon:10090"
/clone="PS13252-NR.Seg"
/sex="Male"
/cell_type="Embryonic stem cell"
/cell_line="D3H (J1 subclone)"
/clone_id="MICH1"
/note="Vector: UNNEOSV1"

ORIGIN

Query Match 30.5%; Score 13.4; DB 9; Length 35;
Best Local Similarity 73.9%; Pred. No. 6.4e+05;
Matches 17; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATACCGGTG 31
|||||
Db 4 CTTTCTTCTTAATCTGGGTG 26

RESULT 36
AZ642621 38 bp DNA linear GSS 14-DEC-2000
LOCUS IM0505B13R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0505B13 R, genomic survey sequence.
ACCESSION AZ642621
VERSION AZ642621.1 GI:11769410
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 38)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, B., Pedersen, T.,
Rellay, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von
Niederhausen, A. and Wright, D., Weiss, R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0505 row: B column: 13
Seq primer: CACACAGCAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 38.
Location/Qualifiers
1..38
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0505B13"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_id="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (gil4732114|gb|AF129072.1) a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

ORIGIN

Query Match 30.5%; Score 13.4; DB 8; Length 38;
Best Local Similarity 64.5%; Pred. No. 6.5e+05;
Matches 20; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1 GCGGCTCCGCTTCTTAAATACCGGTG 31
|||||
Db 5 GTGGCTCCCATTCATGATGATCACCCCTG 35

RESULT 37
AU010606/c 39 bp mRNA linear EST 31-JUL-1998
LOCUS AU010606 Schizosaccharomyces pombe late log phase cDNA
DEFINITION Schizosaccharomyces pombe cDNA clone spc10127, mRNA sequence.
ACCESSION AU010606
VERSION AU010606.1 GI:3347286
KEYWORDS EST.
SOURCE Schizosaccharomyces pombe (fission yeast)

SOURCE ORGANISM	Schizosaccharomyces pombe (fission yeast)	Schizosaccharomyces pombe
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
Schizosaccharomycetales; Schizosaccharomycetaceae;

REFERENCE 1 (b) (5) DPP, 1 to 39

AUTHORS: Morimyo, M. and Milta, K.

TITLE Identification of expressed sequence tags of *Schizosaccharomyces pombe*

JOURNAL Unpublished (1998)

COMMENT Contact: Mitsuoki Morimyo

Genome Research Group

National Institute of Radiological Sciences

9-1, Anagawa-4-chome, Inage-ku, Chiba, Chiba 263-8555, Japan

Email: morimyo@n1rb.go.jp

Source	Location/Qualifiers	Features
1	30	

BOURCE

/organ

/organism="Schizosaccharomyces pombe"

/mol_type="mRNA"

```

/strain="972"

```

```
/db_xref="taxon:4896"
```

```
/clone="spc06701"
```

```
/beX="n minus"
```

```
/clone_11d="Schizosaccharomyces pombe late log phase cDNA"
```

/home=vector; M13mp19; the cDNA library on

Schizosaccharomyces pombe was prepared by cloning cDNA

into the small size of M13mp19 DNA and the direction of DNA experiences was not always from 5' to 3'. The cDNA data of

Schizosaccharomyces pombe are available for searching on frequencies was not always 1:1000. The cDNA data of

the World Wide Web: (URL: <http://www.nirs.gov>)"

www.ck12.org

ORIGIN

Query Match 30.5%; Score 13.4; DB 1; Length 39;

Best Local Similarity 64.5%; Pred. No. 6.5e+05;

Matches	20;	Conservative	0;	Mismatches	11;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	-----	--------	----	------	----

14 CTTCCTTAATACCGGTCGGCGTTATTAGAA 44

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

Search completed: May 24, 2005, 13:16:40
Job time : 1861 secs

This Page Blank (uspto)